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Abstract 
Abstract 
During the last one and a half centuries, our basic understanding of leukemia has 
expanded greatly, from the first description as "white blood" in the year of 1845 to 
the recognition of leukemia as disorders of hematopoietic cell differentiation and 
apoptosis. Nevertheless, there is still an urgent need for developing novel approaches 
for leukemia therapy since conventional methods of leukemia treatment, including 
chemotherapy and radiotherapy, have a number of limitations and are often 
accompanied with many adverse side effects. Natural products, especially traditional 
Chinese medicine (TCM), as an important resource for discoveries of drugs against 
cancer, have extensively caught the sight of many scientists. 
Kushen, the dried roots of Sophora flavescens Aiton, is a TCM herb commonly 
used to treat gastrointestinal disorders, skin ulcers, inflammatory diseases and cancer. 
Previous studies from our laboratory had found that Sophoraflavanone G, a flavanone 
isolated from Kushen, exhibited potent anti-tumor effect on human hepatoma cells 
via induction of apoptosis. However, the modulatory effects of this compound on 
human myeloid leukemia cells and its possible anti-leukemic mechanisms remain 
• poorly understood. 
In the present study, Sophoraflavanone G was examined for its modulatory 
effects on the proliferation, apoptosis and differentiation of human acute 
promyelocytic leukemia HL-60 cells. Our in vitro studies showed that 
Sophoraflavanone G could suppress the proliferation of HL-60 cells in a dose- and 
time-dependent manner, with an estimated IC50 of 20 |j.M at 48 hours of incubation. 
On the other hand, Sophoraflavanone G showed no significant direct cytotoxicity 
towards the human peripheral blood leukocytes and murine bone marrow cells at its 
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growth-inhibitory concentrations for HL-60 cells. The suppressive effect of 
Sophoraflavanone G on the tumorigenicity of the HL-60 cells in BALB/c nude mice 
was also examined. The results show that pretreatment of HL-60 cells with 
Sophoraflavanone G in vitro could significantly inhibit the in vivo growth of 
leukemia cells in nude mice. Moreover, as suggested by Western blotting analysis 
and cell cycle analysis, Sophoraflavanone G was capable of down-regulating the 
protein expression of CDK-6 and triggering cell cycle arrest at the GQ/GI phase in the 
HL-60 cells after 24 hours of treatment. Furthermore, Sophoraflavanone G was also 
shown to inhibit the proliferation of the multidrug-resistant (MDR) leukemia 
HL-60/MX2 cells and induce cell cycle arrest at the GQ/GI phase. Apart from 
suppressing the proliferation of the HL-60 cells by cell cycle arrest, we found that 
Sophoraflavanone G could also induce cell death through triggering apoptosis in the 
HL-60 cells. DNA fragmentation, which is a hallmark of apoptosis, was induced in 
Sophoraflavanone G-treated HL-60 cells in a dose-dependent manner. This apoptosis 
inducing effect was further confirmed by PI/Annexin V-GFP double staining. The 
results of activation of caspase-3 and caspase-9, as well as induction of 
mitochondrial membrane depolarization, suggest that the mitochondria-mediated 
“ apoptotic pathway, also known as intrinsic apoptotic pathway, may be involved in the 
Sophoraflavanone G-induced apoptosis. Western blotting experiments also indicated 
that Sophoraflavanone G might activate the intrinsic apoptotic pathway by 
up-regulating the pro-apoptotic Bcl-2 family members Bax and Bak proteins, and 
down-regulating the anti-apoptotic member Bcl-2 protein. Interestingly, our 
preliminary results show that Sophoraflavanone G failed to trigger terminal 
differentiation of HL-60 cells under the prescribed experimental conditions, as 
judged by morphological analysis on cytospin preparations of Sophoraflavanone 
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G-treated HL-60 cells and functional assessment of differentiation by the nitroblue 
tetrazolium reduction assay. Our results, when taken together, suggest that 
Sophoraflavanone G may exert its anti-leukemic effect through induction of cell 
cycle arrest as well as triggering apoptosis of the leukemia cells. More in-depth 
investigations are needed to reveal the molecular and signaling mechanisms 
underlying the anti-tumor activities of Sophoraflavanone G before it can be exploited 
for the therapeutic treatment of some forms of human myeloid leukemia. 
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Chapter One 
General Introduction 
Chapter 1 General Introduction 
1.1 Hematopoiesis and Leukemia 
1.1.1 An Overview on Hematopoiesis 
Blood participates in many important biological processes of human life, ranging 
from the transport of oxygen to the production of antibodies. Everyday the human 
body produces up to 5x10^^ blood cells in normal tissue turnover and for body 
defense against foreign invasion (Leung et al, 2005). The term "hematopoiesis" is 
used to describe this highly dynamic and coordinated process of blood cell formation 
and development (Smith, 2003). Hematopoiesis obtains its name from the ancient 
Greek words haima and poiesis, meaning "blood" and "forming", respectively. In 
this section, several aspects of hematopoiesis in humans, including the site switching 
of hematopoiesis, the process of hematopoiesis, and the regulation of this life process 
by various hematopoietic cytokines, will be discussed. 
In humans, blood development system involves multiple switching in the sites of 
hematopoiesis. Generally, it can be divided into two phases: the transient embryonic 
("primitive") phase and the definitive ("adult") phase (Orkin and Zon, 2002). During 
early embryogenesis, hematopoiesis has already begun to take place in the mesoderm 
. and two waves of hematopoietic stem cell generation occur in the first month of 
human gestation. The first one occurs in the yolk sac, generating myeloid precursor 
cells devoid of lymphoid potential. On the other hand, the second wave started from 
the 27th day of gestation, taking place on the ventral endothelium of the dorsal aorta 
and vitelline artery of the embryo, producing the first multipotent, lympho-myeloid 
progenitor cells in human ontogeny (Peault and Tavian, 2003). The site of 
hematopoiesis is then migrated and this blood development system continues in the 
liver and spleen at mid-gestation. Finally, from the sixth to seventh month of fetal 
life and thereafter, the red bone marrow gradually becomes the major organ for the 
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production and development of all peripheral blood hematopoietic cells (Leung et al., 
2005; Hoffbrand et al, 2006). 
Human blood contains many types of mature blood cells, e.g. T and B 
lymphocytes, erythrocytes, monocytes and granulocytes, with very different 
morphologies and functions. All blood cells, however, generated ultimately from a 
common "ancestor" - the so called hematopoietic stem cells (HSC) (Leung et al., 
2005). The pluripotent HSC are capable of self-renewal and of producing all cell 
lineages found in the hematopoietic system through a series of downstream 
hematopoietic progenitors (Jones et al, 1996). HSC proliferate and generate 
common myeloid and lymphoid progenitors, which differentiate into immature 
progenitor cells of the various blood cell lineages and further lead to accomplish the 
process of hematopoiesis. As depicted in Figure 1.1, the common myeloid progenitor 
is the precursor of four distinct cell lineages: erythrocytic and megakaryocytic, 
monocytic and granulocytic lineages. The erythrocytic and megakaryocytic lineages 
generate red blood cells and blood platelets, respectively. In addition, the monocytic 
lineage gives rise to monocytes in the circulation and macrophages in the tissues. 
Furthermore, the granulocytic lineage produces granulocytes, including basophils, 
eosinophils, and neutrophils. On the contrary, the common lymphoid progenitor is 
responsible for generation of B and T lymphocytes through B and T cells 
development pathways, respectively (Leung et al., 2005). Therefore, hematopoiesis 
involves the irreversible differentiation commitment of the progenitor cells to one or 
another lineage and the progressive maturation of cells within that lineage (Metcalf, 
1998). 
Hematopoietic cell development is tightly regulated by a number of cytokines, 
collectively known as the hematopoietic cytokines. The hematopoietic cytokines, 
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including the colony-stimulating factors (CSF) and interleukins (IL), is a broad 
family of proteins or glycoproteins. In addition, these hematopoietic cytokines, 
produced by a wide variety of hematopoietic and non-hematopoietic cells, function 
as mediators both positively and negatively signaling the hematopoietic cell to 
undergo differentiation, proliferation, quiescence, and apoptosis (Leung et al, 2005). 
Generally speaking, hematopoietic cytokines function by binding to their specific 
receptors and this binding further triggers a variety of signaling pathways, including 
the protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways 
(Vitale et al, 2002; Lentzsch et al., 2004). The inducing signals then initiate a 
sequential genetic program of transcriptional activation, resulting in production of 
specific cell types. So far four CSF have been characterized, including macrophage 
colony-stimulating factor (M-CSF)，granulocyte macrophage colony-stimulating 
factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and the 
multi-colony-stimulating factor [multi-CSF, also known as interleukin-3 (IL-3)] 
(Metcalf, 1988; Crosier and Clark, 1992). These four CSF can induce proliferation 
and differentiation of normal myeloid precursor cells to form colonies. For example, 
GM-CSF promotes non-lymphoid cells formation at the early developmental stage. 
M-CSF and G-CSF, relatively lineage-specific, trigger formation of monocytes and 
granulocytes, respectively (Comalada et al., 2005). On the other hand, IL-7 induces 
the lymphoid progenitors to differentiate into B cell progenitors and T cell 
progenitors (Fry and Mackall, 2005). Furthermore, instead of having limited effects 
on a specific cell lineage，most of hematopoietic cytokines are involved in the 
development of different cell types and in various developmental stages. 
Nevertheless, each hematopoietic cytokine has unique functions that cannot be 
completely compensated by other cytokines. It appears that immature myeloid 
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progeny responds mainly to stimulation by multiple cytokines whereas more mature 
myeloid progenitor cells respond to stimulation by single cytokine (Leung et al, 
2005). 
To conclude, hematopoiesis is a complex network and highly coordinated 
process. In normal hematopoiesis, there is a subtle balance between cell proliferation 
and differentiation on one hand and apoptosis and cell senescence on the other hand. 
Catastrophes will be resulted when the "balance" is broken down in abnormal 
hematopoiesis. The disorders include aplastic anemia, neutropenia, 
thrombocytopenia, myelodysplasia, and hematologic malignancies like lymphoma 
and leukemia (Smith, 2003; Leung et al., 2005). Among all these disorders, leukemia 
will be discussed in detail in the next section. 
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Hematopoietic Stem Cell (pluripotent and capable of extensive self-renewal) 
Myeloid Lymphoid 
Progenitor Cell Progenitor Cell 
Early Early Myeloblast Pre-B Cell Pre-T Cell 





Monocyte / \ IB Cell I IT Cell 
Reticulocyte / N^ 
Basophil Eosinophil 
Red Blood Cell] | Platelet | Neutrophil 
Fig. 1.1 Diagrammatic representation of hematopoiesis. The hematopoietic 
network begins with pluripotent hematopoietic stem cells (HSC), through 
intermediate progenitors, all cell lineages found in the hematopoietic system. HSC 
proliferate and generate the common myeloid and lymphoid progenitors, which then 
differentiate into immature progenitor cells of the various blood cell lineages. 
Generally speaking, throughout the whole development process, the proliferative 
‘ potential of the hematopoietic cells decreases with increasing degree of 
differentiation. (Leung et al，2005) 
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1.1.2 Leukemia 
As discussed in Section 1.1.1，in normal hematopoiesis, hematopoietic 
progenitor cells can successfully differentiate into functional blood cells. In leukemia, 
a disease of abnormal hematopoiesis, these progenitor cells continue to proliferate 
but fail to differentiate into functional mature blood cells. Leukemia may result from 
disturbance or abnormalities in any stages of hematopoietic cell development (Figure 
1.1). In this section, the classification, the current and novel treatments for leukemia 
will be discussed. 
1.1.2.1 An Overview of Leukemia 
Leukemia was first described in 1845 by the British pathologist John Hughes 
Bennett and the German pathologist Rudolf Virchow and later leukemia was named 
by Virchow (Stone et al, 2003). Virchow described leukemia as "white blood" 
because he observed that the number of red blood cells was very few compared to the 
"colorless" corpuscles or the white blood cells (leukocytes) under microscope 
(Leung et al, 2005). In fact, apart from leukocyte leukemia, leukemia also involves 
erythrocyte leukemia and megakaryocyte leukemia though they are quite rare. 
Leukemia can be regarded as a cancer of the blood cells, representing a large 
proportion of hematological malignancies (Tsiftsoglou et al., 2003). In leukemia, 
early hematopoietic progenitor cells are irresponsive to the external stimuli within 
the bone marrow microenvironment and fail to differentiate into discrete types of 
blood cells (Tsiftsoglou et al, 2003). These cells acquire immortality, self-perpetuate, 
grow in high numbers in the bone marrow at the expense of other cells and then spill 
into the blood circulation, eventually reach the secondary lymphoid organs such as 
lymph nodes and spleen, and the central nervous system, as well as to other organs 
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including liver, lungs, testicles，ovaries and kidneys (Tsiftsoglou et al., 2003; Leung 
era/., 2005). 
Leukemia produces specific symptoms corresponding to the type of leukemia 
and organs involved as well as the condition of the patient. However, leukemia 
patients do have generalized symptoms such as fatigue, loss of appetite, unexplained 
weight loss, bone and back pain, and easy bruising. Moreover, anemia, neutropenia 
and thrombocytopenia are usually the consequences of bone marrow failure, which 
can lead to infection and hemorrhage (Leung et al., 2005). Certain diagnostic tests, 
including blood cell counts and bone marrow tests through bone marrow aspiration 
or biopsy, are generally used to find out if leukemia is present, what type of leukemia 
it is, and how well the disease is responding to the treatments. Furthermore, more and 
more precise laboratory tests have been developed and applied to diagnose and 
classify leukemia, and these include cytochemistry, immunocytochemistry, 
cytogenetics and molecular genetic studies, and flow cytometry (American Cancer 
Society, 2008). 
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1.1.2.2 Classification and Epidemiology of Leukemia 
There are two basic criteria to consider in classifying leukemia, one is the degree 
of maturity of the leukemia cells together with their onset rate, and the other factor is 
developmental lineage of the leukemia cells. Therefore, leukemia can be classified 
by the first criterion into acute leukemia or chronic leukemia. In acute leukemia, the 
leukemia cells stop differentiation in an earlier stage of hematopoiesis and begin to 
proliferate rapidly. Therefore, this type of leukemia has a sudden onset with rapid 
progression, leading to accumulation of immature and fimctionless cells in the 
marrow and blood. On the other hand, the cells of chronic leukemia appear more 
mature but they usually have abnormal functions. However, the lifespan of chronic 
leukemia cells is much longer than that of normal leukocytes and result in 
over-infiltration of mature granulocytes or lymphocytes in bone marrow. The chronic 
leukemia usually progresses slower than the acute one and with a prolonged clinical 
course (Leung et al, 2005). 
Leukemia can also be classified into myeloid or lymphoid, according to the 
second criterion. Myeloid leukemia develops from precursor cells of the granulocytic, 
monocytic, erythrocytic or megakaryocytic lineage while lymphocytic leukemia 
develops from precursor cells of the lymphocytic lineage (Leung et al, 2005). 
Therefore, taking the two criteria together, most cases of leukemia can be briefly 
classified into one of the four major types: acute myeloid leukemia (AML), acute 
lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic 
lymphoblastic leukemia (CLL). However, classifying leukemia is difficult and 
controversial when the morphology of the leukemia cells is not so clear cut. To have 
a better classification, the French-American-British (FAB) system was developed to 
classify the subtypes of different acute leukemia. The subtypes of different acute 
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leukemia are summarized in Table 1.1. 
According to the statistical data and information from the American. Cancer 
Society (2008)，the key statistics and the risk factors for the four major types of 
leukemia are summarized in Table 1.2. In the United States, leukemia accounts for 
approximately 3% of all cancer diagnoses with the death rate around 4% (American 
Cancer Society, 2008). In China, the occurrence of leukemia is high, which is around 
4 in 100,000 and leukemia ranks as No.6 high incidence in all cancer diagnoses 
(Chen et al, 2005). In Hong Kong, childhood cancer is the second leading cause of 
death among children. Among different types of childhood malignancy, leukemia has 
the highest incidence in Hong Kong, accounting for approximately 36% of total 
cancer diagnoses as reported in the most recent ten-year (1990-2000) review 
(Children's Cancer Foundation, Hong Kong, 2008). 
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Table 1.1 The French-American-British (FAB) system for 
classification of acute leukemia 
TVpe Subtype 
• MO: undifferentiated myeloblastic 
• Ml : myeloblastic with minimal maturation 
• M2: myeloblastic with granulocytic maturation 
• M3: promyelocytic with many granules 
Acute myeloid leukemia • myelomonocytic with eosinophilia 
(AML) • m 5 a : monoblastic 
• M5B: promonoblastic 
• M6: erythroblastic 
• M7: megakaryoblastic 
• LI: T cell or pre-B cell; homogeneous small 
blasts with little cytoplasm 
Acute lymphoblastic • 丁 cell or pre-B cell; heterogeneous large 
I A"! 1 p m 1 o 
blasts with variable amounts of cytoplasm 
(ALL) , L3: B cell; homogeneous large blasts with 
vacuolated basophilic cytoplasm 
(American Cancer Society, 2008) 
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Table 1.2 Key statistics and risk factors for the four major types of leukemia 
AML ALL CML CLL 
Estimated new 
cases in 2008 in 13,290 5,430 4,830 15,110 
the US alone 
Estimated no. of 
death in 2008 in 8,820 1,460 450 4,390 
the US alone 
Average age of 幻 • 67 72 
patients 
Ratio of adult to Adult: 90% Adult: 67% Adult 
children Children: 10% Children: 33% (mostly) Adult only 
* Five-year 
relat 二 二 2O.40/0 65.2% 42.3% 74.2� /� 
rate (1996-2002, 
in the US) 
Male Male 
Sex prevalence ^^^ghtly higher) (slightly higher) _ “ 
• Smoking • High-dose • High-dose • Herbicides 
• Long-term radiation radiation (e.g. Agent 
exposure to • Viral infection Orange) 




• Viral infection 
(e.g. HTLV-1) 
* The five-year relative survival rate refers to the percentage of patients who live at 
least 5 years after their cancer is diagnosed. It varies according to the type of 
leukemia and the age of the patient. 
(American Cancer Society, 2008) 
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1.1.2.3 Conventional Approaches to Leukemia Therapy 
Nowadays, chemotherapy, radiotherapy and hematopoietic stem cell 
transplantation are the conventional methods of leukemia treatment. Treatment 
options are based on the leukemia subtypes and disease stages. 
Chemotherapy is the most common approach for leukemia therapy. In this 
approach, leukemia patients are treated with a combination of different kinds of 
cytotoxic drugs through mouth, veins, muscle, or cerebrospinal fluid (American 
Cancer Society, 2008). The dosage and the type of drugs used depend on the 
leukemia subtypes and progression. Moreover, the chemotherapeutic treatment can 
be generally divided into three stages: 1) induction therapy: using high dosage of 
drugs, such as vincristine and L-asparaginase, to rapidly kill the leukemia cells in 
blood and bone marrow; 2) intensive consolidation therapy: using more drugs, such 
as 6-mercaptopurine, vincristine, prednisone, and methotrexate, and higher dosages 
to kill the hidden leukemia cells in other organs; 3) maintenance therapy: using low 
dosage of drug, such as 6-mercaptopurine and methotrexate, to prevent the relapse of 
leukemia. The patient is commonly regarded to be completely cured if there is no 
relapse within five years. Chemotherapy has an advantage of direct and rapid 
delivery of drug to kill circulating leukemia cells (Leung et al, 2005). However, 
chemotherapy is the double-edged sword of modem medicine. Due to the low 
selectivity and high cytotoxicity, most of the chemotherapeutic drugs 
non-specifically kill all rapidly dividing cells involving not just leukemia cells but 
also normal rapidly growing cells such as the hematopoietic cells in the bone marrow, 
hair follicular cells and gastrointestinal epithelial cells (American Cancer Society, 
2008). As a result, chemotherapy can cause serious side effects in patients. Reduced 
production of blood platelets contributes to easy bruising and profuse bleeding, 
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growth inhibition of hair follicular cells and gastrointestinal epithelial cells result in 
loss of hair, diarrhea and vomiting, respectively. Apart from the side effects, 
multidrug resistance (MDR) is also a major concern in the chemotherapeutic agents 
against cancer (Ullah, 2008). Although the resistance is usually developed from a 
single chemotherapeutic substance, it will further lead to multiple resistance to 
numerous substances characterized by different mechanisms of action and by 
different chemical structures (Stavrovskaya, 2000). Many common anti-cancer drugs, 
such as doxorubicin, mitoxantrone, etoposide，vincristine, have already been reported 
to cause MDR in cancer cells (Stavrovskaya, 2000; Ullah, 2008). 
In radiotherapy, X-rays and gamma-rays are employed to kill leukemia cells. It is 
often used with chemotherapy and is an essential part of treatment before bone 
marrow transplantation. Radiotherapy is also applied when leukemia cells have 
spread to the brain and spinal fluid or to the testicles. However, radiation may also 
affect the function of the treated organs. For instance, children who receive radiation 
to the brain may cause problems in learning and coordination, and radiation to the 
testicles may develop problems in both fertility and hormone production (Leung et 
a/., 2005). 
Hematopoietic stem cell transplantation (HSCT) includes both bone marrow 
transplantation, which involves the collection of stem cells from bone marrow, and 
peripheral blood stem cell transplantation, which is the collection of stem cells from 
peripheral blood. HSCT therapy involves two major steps: 1) elimination of the 
patient's hematopoietic system by chemotherapy and/or radiotherapy; 2) replacement 
with normal hematopoietic stem cells. While in the second step, the source of normal 
hematopoietic stem cells could be either from another individual with same tissue 
type as the patient, namely allogeneic transplantation, or from the patient's own 
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hematopoietic stem cells which were frozen previously, namely autologous 
transplantation (Leung et al, 2005). Nowadays, HSCT has been developed into a 
well-established therapy not only for leukemia but also some inherited severe blood 
cell diseases. It has reported that HSCT is the most successful curative treatment for 
AML and can even cure relapsed AML (Rubnitz et al, 2008). Nevertheless, bone 
marrow transplantation has the limitations of higher cost and difficulty of finding 
human leukocyte antigen (HLA)-compatible donors for the leukemia patients. In 
addition, the hematopoietic stem cells for the donor may react against the patient's 
normal cells. This leads to graft-versus-host disease, which can make the patients 
very sick (Leung et al., 2005; American Cancer Society, 2008). 
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1.1.2.4 Novel Approaches to Leukemia Therapy 
During the last one and a half centuries, our basic understanding of leukemia has 
been greatly explored, from the first description as "white blood" in the year of 1845 
to the recognition of leukemia as disorders of hematopoietic cell differentiation and 
apoptosis (Tsiftsoglou et al, 2003). This development of understanding stepwise 
pushes the treatment of leukemia becoming more effective with fewer side effects. 
In the earlier development of leukemia therapy, the treatment mainly targeted on 
the leukemia characteristic of rapid growth since at that time leukemia was only 
recognized as diseases of uncontrolled cellular growth. The earlier treatments include 
radiotherapy and chemotherapy. The conventional chemotherapeutic agents involve 
alkylating agents, anti-metabolites, anti-tumor antibiotics, folate analogues as 
enzyme inhibitors, blockers of mitosis, cell cycle cytotoxic inhibitors, nitrosourea 
derivatives, and so on (Tsiftsoglou et al., 2003). Unequivocally, cancer 
chemotherapy has been successful in effectively curing a few malignant neoplasms 
(e.g. Burkitt's lymphoma and choriocarcinoma) and useful in treating symptoms and 
prolonging life for several years in some other cases like childhood leukemias 
(Tsiftsoglou et al, 2003). However, conventional chemotherapy has not been able to 
eradicate hematological malignancies. One report has shown that prior exposure to 
radiation and chemotherapy such as alkylating agents (cyclophosphamide) and 
intercalating topoisomerase II inhibitors (etoposide) may trigger secondary AML 
(Rubnitz et al, 2008). As summarized by Tsiftsoglou et al. (2003), the major 
problems leading to the failure of conventional cancer chemotherapy include: 1) 
enormous diversity in morphology and physiology of neoplasms; 2) extensive 
cellular heterogeneity and heterogeneity in molecular abnormalities in malignant 
tumors; 3) inadequate delivery of anti-cancer agents to the targeted tumor sites; 4) 
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lack of selective anti-tumor activity and broad-spectrum toxicity to normal tissues; 5) 
genome instability; and 6) development of MDR (Tsiftsoglou et al., 2003). 
With the development of modem biology such as molecular biology and 
molecular genetics, apart from uncontrolled cellular proliferation, leukemia has been 
recognized as disorders of differentiation and apoptosis (Tsiftsoglou et al., 2003). 
Based on this updated understanding, many novel exploitable targets for drug 
development have been revealed over the past several years. These include genes and 
unique proteins regulating apoptosis and cell differentiation in malignant cells, 
specific proteins driving the cell cycle machinery, cell lineage-specific transcription 
factors and angiogenesis factors (Tsiftsoglou et al, 2003). For instance, Genasense®, 
a clinical grade Bcl-2 antisense oligonucleotide, was advanced into clinical trials in 
patients with leukemia (Schimmer, 2008). Bcl-2 is a key intracellular anti-apoptotic 
protein. Reduced expression of Bcl-2 protein by Bcl-2 antisense oligonucleotide can 
induce apoptosis in preclinical studies (Schimmer, 2008). Apart from Bcl-2 protein, 
more key regulators involving in apoptosis signaling pathways, such as death 
receptors, caspases as well as transcription factors (e.g. nuclear factor kappa B), have 
been used as the targets of chemotherapeutic agents. In addition to inducing 
apoptosis, triggering differentiation is another novel approach to leukemia treatment. 
All-trans retinoic acid (ATRA), which is able to induce cellular differentiation, has 
been clinically used to treat acute promyelocytic leukemia (APL). APL, an unique 
subtype of AML (classified as M3 of AML), is characterized by the blockage of 
granulocytic differentiation at the promyelocytic stage and specific reciprocal 
chromosomal translocation t(15;17)(q22;ql2). This chromosomal translocation 
produces a fusion gene, resulting in the formation of fusion protein PML-RARa 
(promyelocytic leukemia-retinoic acid receptor a). This protein blocks 
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differentiation of myeloid cells and inhibits apoptosis of the cells. ATRA can 
degrade the fusion protein and restore the normal differentiation of the promyeloid 
progenitor cells and inhibit their replicative capacity (Chen et al,’ 2005). Apart from 
these two examples of "molecularly targeted oncotherapy", cellular therapy with 
haploidentical natural killer cells has been reported to exhibit anti-tumor activity with 
minimal toxicity in patients who have relapsed AML (Rubnitz et al, 2008). 
Our understanding of leukemia continues to expand, leading to more and more 
discoveries of novel targets to leukemia therapy. Nevertheless, most of these targets 
are "locked" thus need to be activated by the "keys". Where can we find such keys? 
Many of natural products, such as green tea catechin and soybean isoflavonoid, have 
been reported to show anti-tumor activities (Kampa et al, 2007). In particular, 
traditional Chinese medicine (TCM), with well-characterized medicinal effects, is an 
important resource for discoveries of drugs against cancer. According to the 
pharmacopeia of TCM, a number of TCM with historical clinical application on 
leukemia treatment can be initially selected. The active component candidates of the 
TCM may be isolated using bioassay-guided fractionation. It is essential to reveal the 
molecular mechanisms of the active component against leukemia cells before 
opening the "locked" target. Arsenic trioxide (ATO), one of the TCM, has been 
approved by the State Drug Administration (SDA) in China and the Food and Drug 
Administration (FDA) of the United States for clinical usage (Zhang and Demain, 
2005). The development and use of ATO, a potent inducer which activates apoptosis 
via down-regulation of the anti-apoptotic Bcl-2 protein and triggers differentiation 
through breakdown of differentiation-inhibitory protein PML-RARa, as an effective 
agent for treatment of APL patients represents a successful example of molecularly 
targeted oncotherapeutic agent derived from TCM (Zhang and Demain, 2005). 
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1.2 Sophoraflavanone G: A Bioactive Compound Isolated 
from Rush en 
As discussed in Section 1.1.2.4，natural products, especially traditional Chinese 
medicine (TCM), as an important resource for discoveries of drugs against cancer 
have extensively caught the sight of scientists. Cumulating evidence demonstrated 
that herb-based TCM could be used for treatment of cancer. It has been reported that 
some Chinese herbs can directly kill cancer cells, such as Qing Dai (青黛){Indigo 
naturalis), Ya Dan Zi 膽子){Brucea Javanica), and She Xiang (窮香){Moschus 
moschiferus). In addition, some can inhibit cancer cell growth, including Jiang 
Huang (薑黃){Curcuma aromatica) and Chang Chun Teng (長春藤){Hedera helix). 
Furthermore, more than 100 kinds of Chinese herbs can stimulate the patient's 
immune system to attack cancer cells (Zhang and Demain, 2005). As mentioned at 
the end of Section 1.1.2.4, many active components can be isolated and characterized 
from the medicinal herbs using bioassay-guided purification. In a previous research 
program in our laboratory, Ku Shen (苦參）�Sophora Radix), or Kushen (this form of 
presentation will be used in this dissertation), which has been clinically applied for 
cancer treatment as recorded in TCM history, was chosen and screened for the 
bioactive components against hepatoma. Among different bioactive compounds 
isolated from Kushen, Sophoraflavanone G had the highest yield of purification and 
it was found to exhibit the most potent anti-proliferative effect on the human 
hepatocellular carcinoma HepG2 cells (Tsang, 2006). Additionally, 
Sophoraflavanone G was also reported to demonstrate high cytotoxic activity against 
the human myeloid leukemia HL-60 cells among different flavonoids isolated from 
Kushen (Ko et al, 2000). Therefore, the modulatory effects of Sophoraflavanone G 
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on human myeloid leukemia cells were further investigated in the present research 
project. In the second part of this chapter, a brief introduction will be given to 
Kushen and Sophoraflavanone G. 
1.2.1 An Overview of Kushen: A Traditional Chinese Medicine 
Kushen is the dried roots of Sophora flavescens Aiton, which is a perennial shrub 
from the leguminous plant family (De Naeyer et al,, 2004). Sophora flavescens Aiton 
is an evergreen shrub reaching approximately 1 to 1.5 meters with leaves of various 
shapes, greenish-yellow flowers and brown seed pods (Figure 1.2 A). The root ranges 
from 10 to 30 centimeters in length and 2 to 3 centimeters in diameter (Figure 1.2 B). 
The plant is widely cultivated in northeast Asia, including China, Japan, and the 
Korean peninsula. Sophora flavescens Aiton can live in light (sandy), medium 
(loamy), or heavy (clay) soils but it requires well-drained soil. It can be cultivated on 
acidic, neutral, and basic (alkaline) soils. However, it cannot grow in the shade (De 
Naeyer et al, 2004; Bagchi and Preuss, 2005). 
The Chinese characters for Kushen, i.e. “苦參"，which literally means "the bitter 
root", point to the fact that although this root may taste bitter, it has superior 
medicinal qualities. Kushen was first described in "Shen Nong Ben Cao Jing"(神農 
本草,經)，a famous Chinese pharmacopeia with more than two thousand years of 
history (Sun et al,, 2007). The roots are prepared for herbal use by bundling and 
cutting them cross-wise into slices which are then dried under sunlight. The 
traditional use of Kushen includes the decoction and the powder of dried plant roots 
(Sun et al, 2007). Kushen has been applied frequently in traditional Chinese 
medicine as a diuretic, stomachic, anti-pyretic, analgesic, anti-helmintic drug 
whereas it also has been used to treat rashes externally (De Naeyer et al, 2004). 
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Recently, using modem phytochemical and biochemical techniques, different 
groups of researchers have tried to elucidate the bioactive compounds leading to the 
medicinal effects of Kushen. Up to now, the major chemical constituents of Kushen 
consist of alkaloids (3.3%) and flavonoids (1.5%) (Sun et al, 2007). Matrine and 
oxymatrine, contributing approximately 20% of the total alkaloids, are the main 
alkaloid components. The reported bioactivities of alkaloids in Kushen include 
anti-arrhythmic, anti-ulcer, anti-asthmatic, and anti-tumor activities (Tang and 
Eisenbrand, 1992). On the other hand, flavonoids, another major component in 
Kushen, also demonstrated pleiotropic bioactivities in vitro (Sun et al, 2007). 
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Fig. 1.2 Photos of Sophora flavescens (A. Sophora flavescens & B. root of 
Sophora flavescens) and chemical structure of Sophoraflavanone G (C). Figure A 
and B were adapted from Volume 4 of Chinese Herbal Medicines (中華本草）（1998)， 
Figure 1 and 2 of Kushen (No.3383) respectively on page 635. Figure C was 
modified from Shirataki et al (1988). 
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1.2.2 An Overview of Lavandulyl Flavanones 
Flavonoids comprise the most common group of plant polyphenols and provide 
much of the flavor and color to the plants. Chemically, flavonoids possess a common 
structure of diphenylpropanes (C6-C3-C6), consisting of two aromatic rings linked 
through three carbons (Figure 1.3). Based on various substitution patterns in the 
heterocyclic C-ring, flavonoids can be further subdivided into six major subclasses 
including flavones, flavonols, flavanones, catechins, anthocyanidins, and isoflavones 
(Ross and Kasum, 2002). 
Among the flavonoids in Kushen，lavandulyl flavanones, a sub-family of 
prenylated flavanones, are attracting more and more attention (Botta et al., 2005). 
Lavandulyl flavanones have a relatively narrow distribution in the plant kingdom and 
they are mainly found in Sophora species (Kim et al, 2004). It has been reported that 
the bioactivities of flavaonoids is correlated with the position, the number of 
hydroxyl groups, and the structure of side chains (Kuntz et al, 1999). The lavandulyl 
side chain, as suggested by accumulating evidences from structure-activity 
relationship (SAR) studies, is essential for the pleiotropic bioactivities of lavandulyl 
flavanones, such as in vitro growth-inhibitory activity on tumor cells, 
tyrosinase-inhibitory and cyclooxygenase-inhibitory activities (Ko et al, 2000; Chi 
e ra / . �2001; Son era/., 2003). 
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Fig. 1.3 Classification of flavonoids. Flavonoids are the largest class of polyphenols, 
with a common structure of diphenylpropanes (C6-C3-C6), consisting of two 
aromatic rings linked through three carbons. Based on various substitution patterns in 
the heterocyclic C-ring, flavonoids can be further subdivided into six major 
subclasses including flavones, flavanois, flavanones, flavonols, isoflavones, and 
flavanonol (Ross and Kasum, 2002). 
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1.2.3 Historical Development and Occurrence of Sophoraflavanone G 
“A new flavanone, named Sophoraflavanone G ..., was isolated from the root of 
Sophora moorcroftiana Benth. Ex Baker (Leguminosae)....“ 
——Yoshiaki Shirataki, 1988. 
Sophoraflavanone G, i.e. 5,7,2',4'-tetrahydroxy-8-lavandulyl-flavanone 
(chemical formula: C25H28O6)，is one of the members of lavandulyl flavanones 
(Figure 1.2 C). Sophoraflavanone G, also known as Vexibinol, was first reported as a 
new member of flavonoids family in 1988 by Shirataki and his colleagues. After its 
initial discovery in the root of Sophora moorcroftiana (Shirataki et al, 1988)， 
Sophoraflavanone G was reported to mainly exist in Sophora species (Leguminosae), 
such as Sophora leachiano (linuma et al, 1990)，Sophora alopecuroides (linuma et 
al., 1995) and Sophora flavescens (Ryu et al, 1996). 
Apart from isolation from the natural plants, Sophoraflavanone G was reported 
to be biosynthesized in cell suspension cultures from callus tissue of Sophora 
flavescens. After this first description of biosynthesis of Sophoraflavanone G in 1991, 
Yamamoto's group also found that the addition of cork tissue increased the 
production of biosynthesized Sophoraflavanone G, three- to five-fold higher than that 
of the cells cultured alone (Zhao et al, 2003; Zhao et al., 2004). Additionally, using 
molecular biology techniques, it was found that the biosynthetic route producing 
Sophoraflavanone G was mainly regulated by three enzymes: naringenin 
8-dimethylallytransferase, 8-dimethylallylnaringenin 2'-hydroxylase, and 
leachianone G 2"-dimethylallytransferase (Zhao et al., 2004). Therefore, it is hoped 
that more in-depth molecular studies on the action mechanisms of these regulatory 
enzymes can enhance the production of Sophoraflavanone G from cell cultures. 
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1.2.4 Biological Activities of Sophoraflavanone G 
After its first isolation by Shirataki in 1988, Sophoraflavanone G has been 
frequently isolated as an active component with different bioactivities from Sophora 
species in various bioassay-guided researches. These biological effects include 
anti-microbial and insecticidal activities, anti-tumor activities and some other 
pharmacodynamics activities, involving multiple inhibitory effects on phospholipase 
Cyl, cyclooxygenases, lipooxygenases, tyrosinases, as well as glycosidases. 
1.2.4.1 Anti -microbial and Insecticidal Activities 
In the nature, Sophoraflavanone G and other members of flavonoids have been 
suggested to play important roles in protecting the host plants from attack by 
parasites such as insect pests, fungi, bacteria and nematodes (Rao, 1990). In the 
laboratories, different researchers have demonstrated the anti-microbial and 
insecticidal activities of Sophoraflavanone G. 
Yamaki et al. (1990) reported that Sophoraflavanone G exhibited anti-bacterial 
effects against Staphylococcus aureus {S. aureus) and Streptococcus mutans. 
Moreover, Sophoraflavanone G showed strong anti-bacterial activity against 
methicillin-resistant S. aureus with minimum inhibitory concentration of 3.13-6.25 
mg/ml (Sohn et al, 2004). These results suggest that Sophoraflavanone G has high 
potential as an anti-bacterial agent. Tsuchiya and linuma (2000) suggested that the 
possible mechanism underlying the anti-bacterial activities of Sophoraflavanone G 
was that this flavanone, with a hydrophobic lavandulyl side chain, can target on the 
bacterial membrane and further reduce the membrane fluidity. 
Besides anti-bacterial effects, Sophoraflavanone G was reported to have in vitro 
anti-malarial activities against Plasmodium falciparum which is the most widespread 
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etiological agent of human malaria (Kim et al., 2004). In addition, Sophoraflavanone 
G, as demonstrated by Zheng et al. (1999), was found to possess strong insecticidal 
and fungicidal activities, and these activities were shown to decrease after 
methylation of the 5-hydroxy 1 group. Moreover, Matsuo et al (2003) suggested that 
Sophoraflavanone G exhibited trypanocidal activity with the minimum lethal 
concentration of 3.7 against Trypanosoma cruzi which is the etiological agent of 
Chagas disease. On the other hand, naringenin, a flavanone without lavandulyl and 
2'-hydroxyl groups, showed only a very weak trypanocidal activity (minimum lethal 
concentration = 370 |iM). These results suggest that the lavandulyl group is essential 
for the trypanocidal activity. 
1.2.4.2 And -tumor Activities 
Earlier studies by Ryu et al (1997)，using a cytotoxicity-guided procedure, 
found that Sophoraflavanone G was one of the most potent anti-tumor flavonoids 
from Kushen and this active compound exhibited high cytotoxic activities against 
various human tumor cell lines, including the lung cancer A549 cells, ovarian cancer 
SK-OV-3 cells, skin cancer SK-MEL-2 cells, central nervous system cancer XF498 
cells, and colon cancer HCT-15 cells. In the same year, 1997, it was also reported 
that Sophoraflavanone G had similar potent anti-tumor activities against human 
cervical cancer HeLa cells and human leukemia K-562 cells, but showed mild 
activity against the mouse leukemia L1210 cells (Kim et al, 1997). In addition, 
similar in vitro anti-tumor effects of Sophoraflavanone G were also shown on the 
human leukemia HL-60 cells and human hepatocarcinoma HepG2 cells (Kang et al.’ 
2000; Ko et al, 2000). 
Apart from screening the in vitro anti-tumor effects of Sophoraflavanone G 
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against various tumor cell lines, some attempts were made to elucidate the possible 
mechanisms leading to its anti-tumor effects. Kang et al. (2000) demonstrated that 
four lavandulyi flavanones isolated from Kushen, including Sophoraflavanone G, 
were able to induce apoptosis in the human leukemia HL-60 cells and human 
hepatocarcinoma HepG2 cells, as judged by detection of DNA fragmentation. 
Nevertheless, this study didn't elucidate the molecular mechanisms leading to the 
apoptosis-inducing effects in the HL-60 cells and HepG2 cells. Recent studies from 
our laboratory showed that Sophoraflavanone G was able to trigger apoptosis in 
HepG2 cells and multidrug resistant RHepG2 cells via death receptor pathway, 
mitochondria pathway and caspase-independent pathway (Tsang, 2006). 
1.2.4.3 Pharmacodynamics of Sophoraflavanone G 
Growing evidences suggested that Sophoraflavanone G was able to interact with 
the key enzymes involved in several important biological processes, such as cellular 
signaling, fatty acid metabolism, lipid metabolism and carbohydrate metabolism. 
Phospholipase C (PLC), an important enzyme in cellular signaling, is able to 
catalyze the hydrolysis of phosphatidylinositol bisphosphate (PIP2) into two 
important second messenger molecules, the inositol triphosphate (IP3) and 
diacylglycerol (DAG). IP3 and DAG will further alter cell responses such as 
proliferation, differentiation, apoptosis, and ion channel conductance. Lee et al. 
(1997) suggested that Sophoraflavanone G, together with other 11 prenylated 
flavonoids from Kushen, had relatively strong inhibitory activity on PLCyl. Analysis 
of structure-activity relationship (SAR) showed that the presence of lavandulyi 
moiety is crucial for the inhibitory effect since hydration of the C4"-C5" double bond 
of the lavandulyi group will lead to complete loss of the inhibitory activity (Lee et al., 
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1997;Botta e t a l ^ i m S ) , 
Cyclooxygenase (COX) and lipooxygenase (LOX) are two key enzymes 
involved in the arachidonic acid metabolism. COX, including COX-1 and COX-2, 
catalyzes the formation of prostaglandins (PG) from arachidonic acid (Kampa et al， 
2007). Three lipooxygenases (5-LOX, 12-LOX, and 15-LOX) have been reported to 
be present in human tissues and all of them can oxidize polyunsaturated fatty acids. 
Their oxidation products were demonstrated to be important in inflammation and 
carcinogenesis (Kampa et al, 2007). Sophoraflavanone G is known to possess 
relatively strong inhibitory effects on COX-1 and 5-LOX, but show weak inhibitory 
effect on 12-LOX (Chi et al, 2001; Kim et al, 2002). In addition, Kim et al. (2002) 
also demonstrated that Sophoraflavanone G was able to alleviate the in vivo 
inflammation in animal models. These findings indicate a high potential for 
Sophoraflavanone G to be used as an anti-inflammatory agent (Chi et al, 2001; Kim 
et al, 2002; Sohn et a/., 2004). 
Melanin formation, due to oxidation of tyrosine, is the most important 
determinant of the color of mammalian skin. Therefore, the inhibition of melanin 
formation may result in a reduction in skin darkness. Since tyrosinase is the 
rate-limiting enzyme catalyzing the oxidation of tyrosine, tyrosinase inhibitors may 
have potential for treating abnormal pigmentation disorders and to be used as a 
skin-whitening agent in the cosmetic industry (Kim et al., 2003). It has been reported 
that Sophoraflavanone G (IC50 = 6.6 |iM) possesses more potent 
tyrosinase-inhibitory activity as compared with kojic acid (IC50 = 20.5 ^iM), a widely 
used skin-whitening agent in Northeast Asia. Moreover, with regard to the 
structure-activity relationship, the presence of A-ring C-8 lavandulyl and B-ring 
2'.4'-dihydroxyl moiety is important for the considerable tyrosinase-inhibitory 
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activity. These findings suggest that Sophoraflavanone G and certain other 
prenylated flavonoids may have potential for use as skin-whitening agents (Kim et 
a/., 2003; Zhao et a/.，2004). 
In recent years, certain flavonoids, such as genistein and luteolin, have been 
reported to show potent inhibitory effects for glycosidases. Since glycosidases 
participate in several important biological processes, such as digestion, biosynthesis 
of glycoproteins and lysosomal catabolism of glycoconjugates, glycosidase inhibitors 
are potential therapeutics for type 2 diabetes, viral infection and cancer (Kim et al., 
2006). In a screening of methanol extract of Kushen, most flavanones with A-ring 
C-8 lavandulyl group, including Sophoraflavanone G, potently inhibited the 
a-glucosidase and p-amylase activities (Kim et al., 2006). 
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1.3 Objectives and Scopes of the Present Study 
Sophoraflavanone G is a lavandulyl flavonoid that mainly exists in Sophora 
species (Leguminosae) and it has been demonstrated to possess multiple biological 
and pharmacological effects as described in Section 1.2.3. Until recently, the 
anti-tumor activities and action mechanisms of Sophoraflavanone G on human 
myeloid leukemia cells remain elusive. Therefore, in our present study, we aimed at 
investigating the anti-tumor activity and possible cellular and molecular mechanisms 
of Sophoraflavanone G against human myeloid leukemia. 
In the present study, the human promyelocytic leukemia HL-60 cells, a 
well-characterized cell line, was chosen as the major leukemia model to investigate 
the anti-tumor effect of Sophoraflavanone G. Three other human myeloid leukemia 
cell lines, including the acute promyelocytic leukemia (NB-4), eosinophilic leukemia 
(EoL-1), chronic myelogenous leukemia (K-562), were used to demonstrate that the 
growth-inhibitory effect of Sophoraflavanone G was not restricted only to one single 
leukemia cell line. The kinetics and reversibility of Sophoraflavanone G with respect 
to its anti-proliferative effect on HL-60 cells were also examined. Apart from 
leukemia cells, the cytotoxic effect on normal cell models, including human 
peripheral blood leukocytes and murine bone marrow cells, was also investigated. 
The anti-proliferative and cytotoxic effects of Sophoraflavanone G were assessed by 
MTT reduction assay, ^H-thymidine incorporation assay and trypan blue exclusion 
assay. Additionally, the cell cycle profile and cell cycle-regulatory proteins of HL-60 
cells after Sophoraflavanone G treatment were assayed by flow cytometry and 
Western blot analysis, respectively. Moreover, the apoptosis-inducing ability of 
Sophoraflavanone G was measured by the DNA fragmentation assay and Annexin 
V-GFP/PI double staining assay. Furthermore, the mitochondrial membrane potential 
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and enzymatic activities of caspase-3, -8，and -9 were monitored to clarify the 
possible apoptotic pathway(s) that might be involved. The expression of 
apoptosis-associated proteins was also analyzed to elucidate the possible action 
mechanism(s) of Sophoraflavanone G by the Western blotting. In addition to in vitro 
studies, the effect of Sophoraflavanone G on the in vivo tumorigenicity of HL-60 
cells was also investigated in BALB/c nude mice. Finally, the 
differentiation-inducing ability of Sophoraflavanone G on HL-60 cells was studied 
by morphological analysis on cytospin preparations and functional assessment of 
superoxide anion production by the NBT reduction assay. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (haplotype H-2'^) mice and inbred female BALB/c nude 
mice aged 6 to 8 weeks old were bred at the University Laboratory Animal Services 
Centre of The Chinese University of Hong Kong under specific pathogen-free 
condition. They were fed with a pelleted standard chow diet (Prolab RMH 2500 
Rodent diet #5P14, PMI Nutrition International) with free access to tap water. 
2.1.2 Cell Lines 
1) EoL-1 
EoL-1 is a human eosinophilic leukemia cell line which was kindly provided by 
Prof. C. K. Wong, Department of Chemical Pathology, The Chinese University of 
Hong Kong. It was established from the peripheral blood of a patient with 
Philadelphia chromosome-negative eosinophilic leukemia (EL) (Saito et al.’ 1985). 
The cells were maintained in plain RPMI 1640 medium supplemented with 10% (v/v) 
fetal bovine serum (Invitrogen) and incubated at 3 7 � C in a humidified incubator 
supplied with 5% CO2. 
2) HL-60 
HL-60 is a human acute promyelocytic leukemia cell line purchased from the 
American Type Culture Collection (ATCC) with the cell line code ATCC number 
CCL-240. It was established from the peripheral blood of a 36-year-old Caucasian 
female with acute promyelocytic leukemia (Collins et al., 1977). The cells were 
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maintained in plain RPMI 1640 medium supplemented with 20% (v/v) fetal bovine 
serum (Invitrogen) and incubated at 37 °C in a humidified incubator supplied with 
5% CO2. 
3) HL-60/MX2 
HL-60/MX2 is a mitoxantrone resistant derivative of the HL-60 cell line 
(Harker et al, 1991) purchased from ATCC (ATCC number CRL-2257). 
Maintenance of HL-60/MX2 cells is the same as HL-60 cells. 
4) K-562 
K-562 is a human chronic myelogenous leukemia cell line purchased from 
ATCC (ATCC number CCL-243). It was originated from the pleural effusion of a 
3 5-year-old female with chronic myelogenous leukemia in terminal blast crises 
(Lozzio and Lozzio, 1975). Maintenance of K-562 cells is the same as EoL-1 cells. 
5) NB-4 
NB-4 is a human acute promyelocytic leukemia cell line purchased from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, 
German Collection of Microorganisms and Cell Cultures) with the cell line code 
DSMZ number ACC 207. It was established from the bone marrow of a 23-year-old 
female with acute promyelocytic leukemia in the second relapse (Lanotte et al., 
1991). Maintenance of NB-4 cells is the same as EoL-1 cells. 
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2.1.3 Cell Culture Medium, Buffers and Other Reagents 
1) RPMI fRoswell Park Memorial Institute) 1640 Medium 
A pack of RPMI 1640 powder (GIBCO BRL Life Technologies Inc.) with 2 mM 
L-glutamine and 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid 
(HEPES) was dissolved in one litre (L) of deionized water. Two grams of sodium 
bicarbonate (NaHCOs) (Sigma Chemical Co.) was added and the pH was adjusted to 
7.2 by either 1 M HCl or 1 M NaOH (Sigma Chemical Co.). The medium was then 
sterilized by membrane filtration with 0.22 \xm bottle-top filter (Millipore). 
Sterilized medium was stored at 4°C until use. 
"Plain RPMI 1640 medium" was prepared by supplementing the sterilized 
RPMI 1640 medium with 1% (v/v) antibiotics (PSF). "Complete RPMI 1640 
medium" was prepared by supplementing plain RPMI 1640 medium with 10% or 
20% (v/v) fetal bovine serum (GIBCO BRL Life Technologies Inc.). Heat inactivated 
fetal bovine serum (HI-FBS) was used to supplement plain RPMI 1640 medium 
when bioassays were performed. 
2) Heat-inactivated fetal bovine serum 
Heat-inactivated fetal bovine serum (HI-FBS) was prepared by heating the fetal 
bovine serum at 56°C for 30 minutes in a water bath and then kept frozen at -20°C 
until use. 
3) Antibiotic mixture solutions 
Antibiotic-Antimycotic or Penicillin-Streptomycin-Fungizone (PSF) stock 
solution (100 ml, lOOx) contains 10,000 units/ml penicillin G (sodium salt), 10,000 
|ig/ml streptomycin sulphate, and 25 |ig/ml amphotericin B as Fungizone in 0.85% 
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(w/v) saline. The stock solution was purchased from Invitrogen Life Technologies 
Inc. and was stored at -20°C as 5 ml aliquots until use. 
4) Phosphate-Buffered Saline (PBS) 
PBS (Sigma Chemical Co.) was prepared by dissolving 8 g NaCl (137 mM), 0.2 
g KCl, 0.2 g KH2PO4 (1.4 mM) and 1.15 g NaaHPCU (4.3 mM) in one litre deionized 
water. The chemicals were purchased from Sigma Chemical Co. The pH of the 
solution was adjusted to 7.2 by either 1 M HCl or 1 M NaOH. It was then sterilized 
by autoclaving at 121�C for 20 minutes. 
5) Ammonium chloride-potassium (ACK) buffer 
ACK buffer consists of 150 mM NH4CI, 1 mM KHCO3 and 0.001 mM EDTA. 
The pH was adjusted to 7.2 - 7.4 by adding either 1 M HCl or 1 M NaOH. After 
being sterilized by filtration, the ACK buffer was kept at 4°C until use. NH4CI and 
KHCO3 were purchased from Sigma Chemical Co. while EDTA was bought from 
USB Corporation. 
6) Methvlthiazoletetrazolium (MTT) 
MTT was purchased from USB Corporation in powdered form. The powder was 
dissolved in sterile PBS to prepare the stock solution at a concentration of 5 mg/ml. 
In each analysis, 30 i^L of MTT solution was applied to each well of 96-well 
flat-bottomed microtiter plate. The stock was stored at 4°C until use. 
7) rMethvl-^H1 Thymidine (F^HI-TdR) 
The stock solution (Amersham Life Science Ltd.) with specific activity of 2 
Ci/mmol was stored as 500 i^l aliquots at 4°C. It was freshly diluted with complete 
RPMI medium to give a working solution of 25 fiCi/ml before use. In each analysis, 
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20 |j.l of working solution was added to each well of the 96-well flat-bottomed 
microtiter plate. 
8) Thioglvcollate (TG) Broth 
Thioglycollate (TG) broth (3% w/v) was prepared by adding 3 g dehydrated 
thioglycollate powder (Difco Lab.) in 100 ml deionized water. The solution was then 
heated until the powder was completely dissolved and was sterilized by autoclaving 
at 121°C for 20 minutes. It was stored in dark for at least one month at room 
temperature before use. 
9) Dye Solutions 
a) Hemacolor® Staining Solutions 
Hemacolor® staining solutions (Merck Biosciences) include three distinct 
solutions were used to stain cells. Hemacolor® Solution 1 is a fixation solution, 
Solution 2 is a buffered red color reagent and Solution 3 is a buffered blue color 
reagent. All solutions were kept in dark, tightly closed glass bottles at room 
temperature. 
b) Trypan Blue Solution 
Trypan blue solution was purchased from Gibco BRL Life Technologies Inc. It 
contains 0.4% (w/v) trypan blue dissolved in a solution of 0.817% (w/v) NaCl and 
0.06% (w/v) KH2PO4. The solution was stored at room temperature. 
c) Nitroblue Tetrazolium (NBT) 
NBT powder was purchased from Sigma-Aldrich Co. NBT-PMA mix solution 
contains 0.02 g NBT powder in 10 ml RPMI with 1 jig/ml phorbol 12-myristate 
13-acetate (PMA) (Sigma Chemical Co.). 
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d) Safranin 
Safranin powder was purchased from South East Chemicals and Instruments 
Ltd. The staining solution contains 0.1 g safranin dissolved in 10 ml of deionized 
water. 
10) Sophoraflavanone G 
Sophoraflavanone G used in the present study was isolated from Kushen (a 
traditional Chinese medicinal herb) by my previous labmate Ms. Tsang Kit Man with 
the collaboration of Institute of Chinese Medicine, The Chinese University of Hong 
Kong. The purification method of Sophoraflavanone G was briefly summarized in 
Section 2.2.1 of this chapter. Before use, Sophoraflavanone G powder was dissolved 
in absolute ethanol to make the final stock solutions with the concentration of 10 
mg/ml and then sterilized by filtration. All stock solutions were stored at - 20°C. The 
concentration of ethanol used as the solvent control in each experiment was 
corresponding to the highest concentration of Sophoraflavanone G used in that 
experiment. 
2.1.4 Reagents and Buffers for Flow Cytometry 
1) Propidium Iodide (PI) DNA Staining Buffer 
The PI DNA staining buffer was freshly prepared by adding 400 |ig/mL 
ribonuclease A (RNase A) (Boehringer Mannheim), 50 |ag/mL propidium iodide 
(Boehringer Mannheim), 10 mM EDTA, pH 7.4 (Sigma Chemical Co.), 0.1% 
trisodium citric acid (Sigma Chemical Co.) and 0.1% Triton X-100 (Sigma Chemical 
Co.). The PBS and PI (stored in dark) stock solution were kept at 4°C while the 
RNase A stock solution was kept at -20°C. 
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2) AnnexinV-GFP 
Annexin V-GFP was kindly supplied by Prof. S.K. Kong, Department of 
Biochemistry, The Chinese University of Hong Kong. The 50x reagent was stored in 
dark at -20°C and was freshly diluted with Annexin V binding buffer before use. 
3) Annexin V Binding Buffer 
Annexin V Binding Buffer was made up of 140 mM NaCl, 2.5 mM CaCb, 10 
mM HEPES (4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid) at pH 7.4. The 
chemicals were purchased from USB Corporation. The buffer was filtered and then 
stored at 4°C until use. 
4) JC-1 Staining Solution 
5,5',6,6'-tetrachloro-l,r,3,3'-tetraethylbenzimidazolyl-carbocyanine iodide 
(JC-1) was purchased from Molecular Probes Inc. The stock solution of JC-1 was 
prepared by dissolving the compound in DMSO to a concentration of 5 mg/ml and 
was stored in dark at -20°C. The dye was stored at -20°C and diluted to 10 ^M in 
warm PBS before use. 
5) Dihvdroethidium (DHE) 
DHE, also known as hydroethidine, was ordered from Molecular Probes Inc. 
The 10 mM DHE stock solution was prepared by dissolving 1 mg DHE powder in 
DMSO and was kept at -20°C in dark. The working concentration of DHE was 10 
I^M. 
6) Fluo-3/AM 
Fluo-3/AM was purchased from Molecular Probes, Inc. The 10 mM Fluo-3/AM 
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Stock solution was prepared by dissolving the powder in DMSO and stored at -20°C 
in dark. The working concentration of Fluo-3/AM was 10 |j.M. 
7) 75% ( v M Ethanol 
The 75% (v/v) ethanol was prepared by adding 75 ml absolute ethanol 
(Analytical grade) (Merck Biosciences) to 25 ml autoclaved deionized water. It was 
stored at 4°C and used for fixing cells in cell cycle analysis. 
8) 1% fw/v) Paraformaldehyde 
Paraformaldehyde was purchased from Sigma Chemical Co. in powdered form. 
One gram paraformaldehyde powder was completely dissolved in 50 ml deionized 
water by heating to 60°C with constant stirring for 1 hour in a fume hood. A few 
drops of 1 M NaOH were added to facilitate the dissolution until a clear solution was 
obtained. After cooling down, 1% paraformaldehyde in Ix PBS was obtained by 
adding 50 ml of 2x PBS. The solution was stored in dark at 4 � C until use. 
2.1.5 Reagents for DNA Extraction 
1) IGEPAL CA-630 Lysis Buffer 
This lysis buffer (Sigma Chemical Co.) was prepared in 50 mM Tris 
[hydroxyImethyl] amino methane (Tris)-HCl, pH 7.5 with 3% non-ionic detergent 
IGEPAL CA-630 ((Octylphenoxy) polyethoxyethanol) and 20 mM EDTA. The lysis 
buffer was stored at room temperature. "IGEPAL" is a registered trademark of 
Phone-Poulenc, Inc. 
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2) TIOEM Buffer 
The buffer was prepared by 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
deionized water. It was stored at room temperature. 
3) Proteinase K 
Proteinase K was purchased from USB Corporation. The stock solution (20 
mg/ml) was prepared by dissolving the powder of proteinase K in autoclaved TioEo.i 
buffer and it was stored as 500 \x\ aliquots at -20°C. 
4) RNase A 
RNase A, a bovine pancreatic RNase A, was purchased from Boehringer 
Mannheim in a powdered form. The stock solution was prepared at a concentration 
of 10 mg/ml by dissolving the RNase powder in 10 mM Tris-HCl (pH 7.5) and 15 
mM NaCl. The solution was then boiled for 15 minutes to denature any contaminated 
DNase. It was stored as 500 \x\ aliquots at -20°C. 
5) Sodium Acetate Solution (NaOAc) 
The 3M NaOAc stock solution was prepared by dissolving 24.61 g sodium 
acetate (Sigma Chemical Co.) in 100 ml deionized water. It was then sterilized by 
autoclaving at 121°C for 20 minutes. The solution was stored at room temperature. 
2.1.6 Reagents for Measuring Caspase Activity 
1) Cell Lysis Buffer 
This lysis buffer contains 1% (v/v) IGEPAL CA-630 (Sigma Chemical Co.), 
150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA and one tablet of protease inhibitor 
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cocktail (Roche Molecular Biochemicals) in 50 ml deionized water. The pH was 
adjusted to 7.5. The buffer was kept at 4°C until use. Each tablet of complete 
protease inhibitor cocktail when dissolved in 50 mL lysis buffer yielded a mixture of 
several protease inhibitors with a broad spectrum of activity on serine-, cysteine- and 
metallo-proteases and calpains. 
2) Reaction Buffer 
The reaction buffer was made up of 10 mM HEPES-KOH, 40 mM P-
glycerophosphate, 50 mM NaCl, 2 mM MgCh, 5 mM EGTA, 0.1% CHAPS, 100 
l_ig/ml BSA (Sigma Chemical Co.) and 10 mM DTT (Invitrogen Life Technologies 
Inc.). The pH was adjusted to 7.0. The buffer was kept at 4°C until use. 
3) Dithiothreitol (DTT) 
DTT was purchased from Invitrogen Life Technologies Inc. It was dissolved in 
deionized water as 1 M stock and kept at -20°C. It was added to the reaction buffer to 
a final concentration of 10 mM and was used to stabilize the enzymes with free 
sulfhydryl groups to give full activity of the enzymes. 
4) Bradford Reagent 
It is a 5x solution purchased from Bio-Rad Laboratories. When use in 
quantification of protein, one volume of Bradford reagent was added to four volumes 
of protein sample. The Bradford solution was stored at 4°C until use. 
5) Bovine Serum Albumin (BSA) 
BSA (Sigma Chemical Co.) powder was dissolved in sterilized deionized water 
and made up to 2 mg/ml stock aliquots. The powder was kept at 4°C while the 
aliquots were stored at -20°C. The BSA standard curve was constructed by using 0 
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Hg/ml, 2 |j.g/ml, 4 jig/ml, 6 |ig/ml, 8 |ig/ml and 10 |ig/ml filtered water diluted-BSA 
solutions. 
6) Substrates, Inhibitors, and Calibrator 
Substrates, inhibitors and calibrator for caspase activities determination are 
listed in Table 2.1. They were dissolved in DMSO as stock solutions and stored at 
-20�C until use. 
Table 2.1 List of caspase substrates, inhibitors and 
calibrator for measuring caspase activities 
Stock 
Item Chemical name Company 
concentration 
Cas ase 3 Acetyl-Asp-Glu-Val-Asp-7-amido-4 g. ^ ^ 
aspase- -methylcoumarin 2 mM r , „ 
rate (Ac-DEVD-AMC) Chemical Co. 
Caspase-3 Acetyl-Asp-Glu-Val-Asp-CHO ALEXIS 
Inhibitor (Ac-DEVD-CHO) 川 mM Biochemicals 
^ o N-Acetyl-Ile-Glu-Thr-Asp-7-amido-4 ^ ^ … t � 
Casp ,e ;8 -methylcoumarin 1 mM 口 严 
Substrate (Ac-IETD-AMC) Biochemicals 
Caspase-8 N-Acetyl-Ile-Glu-Thr-Asp-CHO ALEXIS 
Inhibitor (Ac-IETD-CHO) iUmM Biochemicals 
( ^ a s p 二 -methylcoumarin 5 mM ^ ALEXIS 
她 strate (Ac-LEHD-AMC) Biochemicals 
Caspase-9 N-Acetyl-Leu-Glu-His-Asp-CHO ALEXIS 
Inhibitor (Ac-LEHD-CHO) 川 mM Biochemicals 
AMC 7-Amino-4-methylcoumarin Sigma 
Calibrator (AMC) mM chemical Co. 
All chemicals were dissolved in DMSO as stock solutions and stored at -20°C until 
use. 
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2.1.7 Reagents, Buffers and Materials for Western Blotting 
1) Cell Lysis Buffer for Total Protein Extraction 
The preparation of cell lysis buffer for total protein extraction is the same as that 
of cell lysis buffer for measuring caspase activity (see Section 2.1.6 for details). 
2) Bradford Reagent 
The Bradford reagent, purchased from Bio-Rad Laboratories, is a 450 ml 
ready-to-use solution. It was kept at 4°C until use. 
3) Bovine Serum Albumin (BSA) 
BSA (Sigma Chemical Co.) powder was dissolved in sterilized deionized water 
and made up to 2 mg/ml stock aliquots. The powder was kept at 4°C while the 
aliquots were stored at -20°C. The BSA standard curve was constructed by using 0 
|ig/ml, 2 ^g/ml, 4 |^g/ml, 6 ^ig/ml, 8 |ig/ml and 10 |ag/ml filtered water diluted-BSA 
solutions. 
4) Lower Buffer for Separating Gel 
The lower buffer, a Tris-HCl buffer, was prepared by dissolving 1.5 M Tris 
(Sigma Chemical Co.) in deionized water to prepare the buffer. The pH was adjusted 
to 8.8. The buffer was then kept at 4°C until use. 
5) Upper Buffer for Stacking Gel 
The upper buffer, a Tris-HCl buffer, was prepared by dissolving 0.5 M Tris 
(Sigma Chemical Co.) in deionized water to prepare the buffer (pH had to be 
adjusted to 6.8). It was stored at 4�C. 
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6) 10% Sodium Dodecvl Sulfate (SDS) Solution 
SDS was purchased from Sigma Chemical Co. in a powdered form. 10% SDS 
solution (w/v) was prepared by dissolving 10 g SDS in 100 ml deionized water and 
stored at room temperature. 
7) Acrylamide Stock Solution 
The ready-to-use acrylamide stock solution, also known as 30% (w/v) 
acrylamide/ bis stock solution was purchased from Bio-Rad Laboratories. The 500 
ml solution contains 146.1 g acrylamide and 3.9 g N,N'-methylene-bis-acrylamide 
for a total monomer to cross-linker ratio of 37.5:1. It was kept at 4°C. 
8) 10% Ammonium Persulfate (APS) 
APS was purchased from Bio-Rad Laboratories in powdered form. The 10% 
APS solution (w/v) was prepared by dissolving 0.5 g APS in 5 ml deionized water. 
The solution was stored in 500 |il aliquots at -20°C. 
9) N,N,N,N'-Tetra-Methvl-ethvlenediamine (TEMED) 
The ready-to-use TEMED stock solution was bought from Bio-Rad 
Laboratories and was stored at 4°C until use. 
10) 4x SDS Sample Loading Buffer 
This loading buffer (8 ml) was prepared by mixing 0.4 ml 0.05% bromophenol 
blue, 2 ml upper buffer, 2 ml glycerol, 2 ml 10% SDS, 0.2 ml 2-mercaptoethanol and 
1.4 ml deionized water together. The loading buffer was then kept at 4°C until use. 
All reagents were purchased from Sigma-Aldrich Co. 
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11) SDS Running Buffer (lOx) 
This buffer, also known as Tris-Glycine-SDS Electrophoresis Buffer (lOx), 
contains 0.25 M Tris-HCl (pH 8.6), 1.92 M glycine (USB Corporation) and 1% SDS 
in deionized water. The lOx buffer was stored at 4°C. The working buffer (Ix) was 
freshly diluted 10-fold from the 1 Ox stock solution. 
12) Tris-Glvcine Buffer (IQx) 
This lOx Tris-glycine buffer was prepared by dissolving 0.25 M Tris-HCl (pH 
7.5) and 1.92 M glycine in deionized water. The buffer was stored at 4°C. 
13) Transfer Buffer (Ix) 
This buffer, also known as Tris-Glycine-Methanol Transfer Buffer (Ix), was 
prepared by mixing 100 ml methanol with 50 ml Tris-Glycine Buffer (lOx) and 350 
ml deionized water. The buffer was stored at 4°C. 
14) Washing Buffer (IQx) 
This buffer, also known as TBS-Tween washing buffer (lOx), was made up of 
100 mM Tris (pH 7.5)，1 M NaCl and 1% Tween 20 (Sigma Chemical Co.) in 
deionized water. The buffer was stored at 4°C. The working buffer (Ix) was freshly 
prepared by diluting the stock solution 10-fold. 
15) Kaleidoscope Prestained Standards 
These prestained standards (Bio-Rad Laboratories) are mixtures of 
well-characterized proteins that are used as a reference to determine the molecular 
weight of proteins of interest identified by the antibody probes. They consist of seven 
colored proteins, including myosin (199,000 Da), P-galactosidase (128,000 Da), 
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bovine serum albumin (85,000 Da), carbonic anhydrase (41,700 Da), soybean trypsin 
inhibitor (32,100 Da), lysozyme (18,300 Da) and aprotinin (7,500 Da). These protein 
standards were prepared in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 7), 10 mM 
DTT, 2 mM EDTA and 0.01% NaNa and stored at -20°C. 
16) Polyvinylidene Fluoride fPVDF) Western Blotting Transfer Membrane 
The PVDF membrane with pore size of 0.45 jim was purchased from Roche 
Applied Science. It was cut into 8.5 cm x 5.5 cm sized transfer membranes for 
ready-to-use and stored at room temperature. 
17) Filter Paper 
Chromatography paper (3 mm thick) (Whatman International Ltd.) was used as 
filter paper. It was cut into 8.5 cm x 5.5 cm sized filter paper for ready-to-use. 
18) 5% (w/v) Skimmed Milk Solution (Blocking Solution) 
Blocking solution was prepared by dissolving skimmed milk powder (Nestle 
Company) in washing buffer (1 x) to give a final concentration of 5% (w/v). 
19) Western Blotting Luminol Reagents 
The Western blotting luminol reagents (Santa Cruz Biotechnology Inc.) consist 
of two reagents: reagent A (125 ml) and B (125 ml). An equal volume of reagent A 
and B was mixed freshly before use and a final volume of 0.125 mL/cm^ membrane 
was required. The reagents were stored in dark at 4°C. 
20) Fuji Medical X-ray Film 
The film was bought from Fuji Photo Film Co. Ltd. It was stored in dark at 4°C. 
- 4 6 -
Chapter 2 Materials and Methods 
21) Primary and Secondary Antibodies 
Primary and secondary antibodies for Western blot analysis are listed in Table 
2.2. All the primary antibodies, except anti-p-actin antibody (stored at -20�C)，were 
stored at 4°C. All the secondary antibodies were stored at 4°C. 
Table 2.2 List of the primary and secondary antibodies used for Western 
blotting experiment 
Antibody Name Source Company 
Anti-p-actin Mouse Sigma Chemical Co. 
Anti-CDK-4 Rabbit StressGen Biotechnologies Corp. 
Primary Anti-CDK-6 Rabbit StressGen Biotechnologies Corp. 
antibody Anti-Bax Mouse Santa Cruz Biotechnology 
Anti-Bak Rabbit Santa Cruz Biotechnology 
Anti-Bcl-2 Mouse Santa Cruz Biotechnology 
Anti-mouse-HRP conjugate Goat Amersham Pharmacia Biotech 
Secondary 
antibody ” 
Anti-rabbit-HRP conjugate Donkey Amersham Pharmacia Biotech 
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2.2 Methods 
2.2.1 Extraction and Isolation of Sophoraflavanone G from Kushen 
Sophoraflavanone G used in the present study was isolated from Kushen by my 
previous labmate Ms. Tsang Kit Man with the collaboration of Institute of Chinese 
Medicine, The Chinese University of Hong Kong. No further purification was carried 
out. The purification method of Sophoraflavanone G was described in detail by 
Tsang (2006) and briefly summarized as follows: 
Kushen was purchased from Guangzhou with the specimen voucher number 
2004-2531 and stored in the Institute of Chinese Medicine of The Chinese University 
of Hong Kong. The specimen was morphologically authenticated by Dr. Chak Yin 
Lee, South China Botanical Garden, The Chinese Academy of Sciences. All 
experiments were carried out using this batch of specimen. One kg of sliced and 
air-dried Kushen was refluxed with 8 L of 95% ethanol for 2 hours to prepare 2 kg 
ethanol extract. The ethanol extract was then filtered, and the filtrate was further 
evaporated under reduced pressure to giving syrup. After partition of the syrup 
between 1 L of water (H2O) and 400 ml of ethyl acetate (EtOAc), the ethyl acetate 
extract was collected and the water extract was further extracted with 300 ml fresh 
EtOAc twice. The ethyl acetate extracts collected from three separate extracts were 
combined and washed with 200 ml of 10% hydrochloric acid and H2O to remove the 
alkaloid groups. After adjusted to pH 7, the pH-adjusted ethyl acetate fraction was 
subjected to silica gel column chromatography and eluted with a solvent of hexane 
and EtOAc at the ratio of 1:1. The eluents were further isolated by silica gel column 
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using hexane and EtOAc at the ratio of 2:1 to obtain the Compound 106-1 (190 mg). 
The Compound 106-1 powder was stored in dark at room temperature. 
The chemical structure of Compound 106-1 was identified as Sophoraflavanone 
G by spectral analysis with Mass Spectrometry (MS), Nuclear Magnetic Resonance 
(^H-NMR and ^^C-NMR) and by direct comparison of spectroscopic data with those 
reported in the literature (Shirataki et al, 1988). The purity was measured by High 
Performance Liquid Chromatography (HPLC). 
2.2.2 Culture of Tumor Cell Lines 
In the present study, three human leukemia cell lines (NB-4, EoL-1, K-562) 
were cultured in 10% complete RPMI medium while HL-60 and HL-60/MX2 cells 
were cultured using RPMI medium supplemented with 20% FBS. All cells were 
cultured in tissue culture flasks (25 or 75 cm^) and incubated at 37°C in a humidified 
incubator supplied with 5% carbon dioxide (CO2). According to the doubling time of 
each cell line, cells were sub-cultured every 2 or 3 days to maintain a desirable cell 
population and prevent over-growth. Cells in exponential growth phase were either 
chosen for performing assays or for long-term storage of cell lines by 
cryopreservation in liquid nitrogen (the composition of cryopreservation medium 
was 50% FBS, 40% RPMI medium and 10% DMSO). 
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2.2.3 Isolation, Preparation and Culturing of Human Peripheral Blood 
Leukocytes and Murine Bone Marrow Cells 
1) Human Peripheral blood Leukocytes (PBL) 
A package of human peripheral blood from healthy donors was purchased from 
the Prince of Wales Hospital, Hong Kong. Dead cells and red blood cells were then 
removed by centrifugation on Ficoll-paque gradient. The harvested human PBL cells 
were washed twice with plain RPMI medium and finally resuspended in 10% 
HI-FBS RPMI medium. The human PBL cells were then ready for assays. 
2) Murine Bone Marrow Cells 
To obtain the mouse bone marrow cells, 6 to 8 weeks old BALB/c mice were 
sacrificed by cervical dislocation. The skin of mice was sterilized with 70% ethanol. 
The femurs were removed with aseptic techniques and put into a petri dish 
containing 10% complete RPMI medium. After cutting two ends of the bones, the 
cells inside were flushed out using a 2 ml syringe fitted with a 25-Gauge needle 
containing 10% complete RPMI medium. In order to remove the contaminating red 
blood cells, the flushed-out cells were resuspended in 10 mL ACK buffer and 
co-incubated at room temperature for 5 minutes to lyse the red blood cells. The 
isolated bone marrow cells were then resuspended in complete RPMI medium and 
ready for assays. 
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2.2.4 Assays for Anti-proliferation and Cytotoxicity 
1) Growth-inhibitory Effect as Assayed by MTT Reduction Assay 
To study the growth-inhibitory effect of Sophoraflavanone G on different cancer 
cell lines as well as normal primary cells, MTT reduction assay was performed. In 
this assay, different types of cells, including leukemia cells (1x10^ cells/ml), human 
PBL cells (1x10^ cells/ml) and murine bone marrow cells (1x10^ cells/ml) were first 
incubated with either solvent control (ethanol) or different concentrations of 
Sophoraflavanone G in 96-well flat-bottomed microtiter plates at 37°C for 24, 48 or 
72 hours in a humidified 5% CO2 incubator. Thirty microlitres MTT (5 mg/ml) was 
then added to the drug-treated cells for 4 hours. After centrifuging the plate at 300 x 
g for 10 minutes, the medium was removed and 100 jj,l DMSO was added to dissolve 
the blue crystal formed inside the cells or acted as the blank. The absorbance was 
measured at 540 nm by a microplate reader (Bio-Rad Laboratories). The results were 
expressed as the mean percentage cell viability 士 standard error (S.E.) of 
quadruplicate samples, using solvent-treated cells as a control. The percentage of cell 
viability was calculated as follows: 
Viability (%) = [OD540 of test sample / OD540 of control] x 100% 
2) Determination of Cell Proliferation by [^H1-TdR Incorporation Assay 
Leukemia cells (1x10^ cells/ml) were seeded and incubated with either solvent 
control (ethanol) or different concentrations of Sophoraflavanone G in 96-well 
flat-bottomed microtiter plates at 37�C for 24, 48 or 72 hours in a humidified 5% 
CO2 incubator. The drug-treated cultures were then pulsed with 0.5 ^iCi [^H]-TdR (in 
20 )j.l complete medium) for 6 hours. The cells were subjected to a freeze and thaw 
process before being harvested onto glass microfiber filters using a cell harvester. 
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The radioactivity in the filters was measured by the liquid scintillation analyzer 
[(Microplate Scintillation and Luminescence Counter (Topcount NXT™)]. The 
percentage inhibition of [^H]-TdR incorporation was calculated as follows: 
Inhibition of [^H]-TdR incorporation (%) 
=[(cpm of control - cpm of test sample)/cpm of control] x 100% 
3) Determination of Cell Viability by Trypan Blue Exclusion Assay 
Trypan blue exclusion assay was used to determine cell viability. The viability is 
distinguished by the integrity of plasma membrane and the ability of the viable cells 
to exclude the trypan blue dye. Viable cells with intact membrane are visible as clear 
cell bodies while the dead cells are stained in blue. The leukemia HL-60 cells (1x10^ 
cells/ml) were incubated with either solvent control or different concentrations of 
Sophoraflavanone G at 37°C. The viability of cells was determined after 24, 48 and 
72 hours of incubation. Ten microlitres cell suspension was mixed with 10 |J.1 0.4% 
trypan blue solution, and 10 |j.l mixture was then loaded onto a hemocytometer for 
counting the numbers of viable and dead cells. The results were expressed as the 
mean percentage of cell viability 士 S.E. of triplicate cultures. The percentage 
viability was calculated by the following equation: 
Viability (%) = (number of viable cells/number of total cells counted) x 100% 
2.2.5 Determination of Anti-leukemic Activity In Vivo {In Vivo 
Tumorigenicity Assay) 
Human leukemia HL-60 cells (1x10^ cells/ml) were incubated with either 
solvent control (0.13% ethanol) or 30 |j.M Sophoraflavanone G for 16 hours at 37°C. 
The drug-treated cells were harvested and washed once with PBS. Viable HL-60 
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cells (1x10^ cells in 100 PBS) were injected subcutaneously on the back of each 
BALB/c nude mouse in groups of twenty. The tumor weight was measured at the end 
of the experiment, and the tumor volume was measured twice weekly with a vernier 
caliper. The tumor volume was calculated according to the formula [volume = height 
X length X width x 7c/6]. Maximum tumor dimensions were measured on sagittal 
(vertical height and anterior-posterior length) and coronal (width) views. 
2.2.6 Cell Cycle Analysis by Flow Cytometry 
There were 2 major steps in this assay: 
a) Cell Preparation 
Leukemia HL-60 cells and HL-60/MX2 cells (1x10^ cells/ml) were first 
synchronized in RPMI medium supplemented with 0.5% HI-FBS for 12 hours at 
37°C. After that, the leukemia cells were then resuspended in RPMI medium 
supplemented with 20% HI-FBS and incubated with different concentrations of 
Sophoraflavanone G at 37°C for 24 hours. The cells were harvested and washed once 
with PBS and centrifuged at 400 x g for 5 minutes. Next, cells were fixed with 1 ml 
70% ethanol at 4°C for 30 minutes. 
b) PI Staining and Cell Cycle Analysis 
Before staining the DNA contents within cells, the ethanol had to be removed 
completely. That was achieved by first centrifuging the samples at 400 x g for 10 
minutes to remove most of the ethanol and then washing the cells once again with 
PBS and centrifuging the cells down at the same conditions. Each sample was mixed 
with 1 ml freshly-prepared PI staining solution in dark at 37°C for 30 minutes. The 
stained cells were subjected to fluorescence-activated cell sorter (FACS) analysis 
using the FACSCanto flow cytometer (Becton Dickinson). The excitation wavelength 
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for PI was at 488 nm and the emission wavelength was at 590 nm for measuring red 
fluorescence intensity. Ten thousands events were collected for each sample 
determination. The percentage distribution in GQ/GI, S and G2/M phase of the cell 
cycle was calculated by the MODFIT program (Verity Software House). 
2.2.7 Measurement of Apoptosis-induced Activities 
1) Detection of DN A FraRmentation by Agarose Gel Electrophoresis 
There were 3 major steps in this assay: 
a) Cell Preparation 
HL-60 cells (1x10^ cells/ml) were incubated with various concentrations of 
Sophoraflavanone G for 24 hours at 37°C. The cells were harvested and washed once 
with cold PBS by centrifuging at 400 x g for 5 minutes. Cell counting with 0.4% 
trypan blue solution was performed to determine the cell number and cell viability. 
b) Extraction of DNA Fragments 
DNA fragmentation is the hallmark of apoptosis. By analyzing the genomic 
DNA extracted from apoptotic cells in a 2% agarose gel, the occurrence of "DNA 
ladder" can be observed. HL-60 cells (2x10^ cells) were collected after cell counting 
and treated with 200 [i\ IGEPAL CA-630 lysis buffer for 10 minutes at 37°C. The 
samples were then centrifuged at 6,000 x g for 5 minutes so as to collect the 
supernatants that containing the apoptotic DNA fragments. The supematants were 
transferred to new microcentrifuge tubes and 50 |j.l 5% SDS was added to each 
sample. Ten microlitres DNase-free RNase A (10 mg/ml) was added and incubated 
with the samples at 56°C for 90 minutes to remove the cellular RNA. Afterwards, 
twenty microlitres proteinase K (20 mg/ml) was added and incubated with the 
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samples at 56°C for another 90 minutes to remove all proteins. The DNA fragments 
were precipitated with 0.1 volume (30 |j.l) of 3 M sodium acetate and 2.5 volumes 
(750 1^ 1) of 4°C absolute ethanol. After centrifugation at 20,000 x g at 4°C for 30 
minutes, the DNA pellets were washed with 4°C 70% ethanol by resuspension. The 
pellets were centrifuged down at 20,000 x g at 4°C for 5 minutes and the 
supernatants were discarded to remove ions. In order to remove the remaining water, 
the DNA samples were washed with cold absolute ethanol 4°C) and the DNA 
samples were obtained by centrifugation at 20,000 x g at 4°C for 5 minutes. After 
washing, the DNA pellets were air-dried for about 10 minutes and a milky layer 
should be observed on the walls of microcentrifuge tubes. The milky layer of the 
DNA fragments was dissolved in 20 fj,l TioEo.i buffer, 
c) Detection of the DNA Fragments by Agarose Gel Electrophoresis 
The DNA samples were incubated at 65°C for 5 minutes to denature any DNA 
secondary structures before performing agarose gel electrophoresis. After mixing 
with 5 loading dye, each sample, with a final volume of 25 fj.1, was subjected to 
2% agarose gel electrophoresis at 90 volts. After electrophoresis, the gel was stained 
with ethidium bromide (1 [•xg/ml) for 3 minutes and destained with deionized water 
for 15 minutes. The DNA bands were detected under UV illumination by the Gel 
Doc 2000 UV transilluminator (Bio-Rad Laboratories). 
2) Detection of Early Apoptosis by Annexin V-GFP and PI Double Staining 
HL-60 cells (1x10^ cells/ml) were incubated with either solvent control (0.13% 
ethanol) or various concentrations of Sophoraflavanone G for 12 hours at 37°C. The 
cells (1x10^ cells) were harvested and washed once with PBS by centrifuging at 400 
X g for 5 minutes. Reaction buffer (500 pi/sample) was prepared by mixing 5 i^l 
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Annexin V-GFP and 2 |il PI (50 |ig/ml) with 496 |il Annexin V binding buffer. The 
PBS-washed cells were kept on ice in dark for 15 minutes after resuspending with 
500 |il reaction buffer. The stained cells were subjected to BD FACSCanto flow 
cytometer for measuring green (FL-1 channel) and red (FL-2 channel) fluorescence 
intensities simultaneously. The data, expressed as the percentage of early apoptotic 
cells, were calculated by the WinMDI software (Version 2.8). 
3) Measurement of Caspase Activities 
There were three major steps involved in measuring the caspase activities: 
a) Treatment of Cells and Extraction of Proteins 
HL-60 cells (1x10^ cells/ml) were incubated with either solvent control (0.13% 
ethanol) or various concentrations of Sophoraflavanone G for 24 hours at 37°C. The 
cells were harvested and washed twice with PBS by centrifuging at 400 x g for 5 
minutes at 4°C. After cell counting by trypan blue exclusion test, the cell pellet was 
resuspended in lysis buffer (50 cells) and vortexed vigorously. The cell lysates 
were incubated on ice for 10 minutes to free the cytoplasmic proteins. After 
incubation, the cell lysates were then centrifuged at 20,000 x g for 10 minutes at 4°C. 
The caspases-containing supematants were collected for the next step. 
b) Quantification of Protein 
The protein concentration of the cell lysate was measured by the Bradford 
protein assay. Bovine serum albumin (BSA) standard solutions were prepared by 
diluting BSA stock solution (2 mg/ml) with deionized water to 2, 4，6, 8 and 10 
|ig/ml. Protein samples (3 |j.l) were added to 2400 |j.l of deionized water for dilution. 
The BSA standard solutions (800 |J,1) and the diluted samples (800 pi) were 
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thoroughly mixed with 200 pii Bradford reagent in cuvettes. After thorough mixing, 
the 1 ml mixtures were allowed to stand at room temperature for 3 minutes and the 
absorbance at 595 nm was measured using 200 }il Bradford reagent in 800 [i\ 
deionized water as the blank. A standard curve was constructed by the 
BioPhotometer (Eppendorf) and the protein concentrations of the cell lysates were 
determined by the machine automatically. 
c) Fluorometric Measurement of Caspase Activities 
Fluorescent signal-generating caspase specific substrates were used for the 
detection of caspase activities. Here the measurement of caspase-3 activity was 
chosen as an example to introduce the basic principle. Ac-DEVD-AMC, a caspase-3 
specific fluorescent AMC conjugated substrate, can be cleaved by active caspase-3 in 
the protein extract. The amount of fluorescent AMC released from the substrate by 
the action of caspase-3 is directly proportional to its enzymatic activity. Therefore, 
the activity of caspase-3 can be determined by measuring the fluorescent intensities 
generated by the cleaved substrate. To ensure the signal detected was due to the 
caspase activities, special control was set up with the presence of the specific caspase 
inhibitor. The control was set up by incubating 50 cell lysate and 50 )il reaction 
buffer with 1 of specific caspase inhibitor in a 96-well flat-bottomed microliter 
plate for 30 minutes at 37°C. Meanwhile, 50 [i\ of cell lysate was incubated 50 yd 
reaction buffer without caspase inhibitor. All the samples, with or without caspase 
inhibitor, were incubated with 1 of caspase-specific substrate for 1 hour at 37°C. 
The fluorescence intensity generated by the cleaved products was quantified by the 
Polarizon fluorescent plate reader (Tecan Group). Caspase activity was then 
converted from the fluorescence intensities using a standard curve. The standard 
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curve was made by diluting the AMC solution with lysis buffer to 4 |a.M, 2 foM, 1 |iM, 
0.5 |IM and 0.25 |J.M concentrations. 
4) Detection of Mitochondrial Membrane Potential Changes 
JC-1 staining method is a common method to determine the mitochondrial 
membrane potential (A\|/m) of cells. HL-60 cells (1x10^ cells/ml) were incubated 
with either solvent control (0.13% ethanol) or various concentrations of 
Sophoraflavanone G for 12 and 24 hours at 37�C. The cells (1x10^ cells) were 
harvested and washed once with PBS by centrifuging at 400 x g for 5 minutes. The 
cells were resuspended in 1 ml JC-1 working solution obtained by mixing 1.3 JC-1 
stock solution (5 mg/ml in DMSO) with warm PBS. The mixtures were incubated for 
15 minutes at 37°C. The excitation wavelength of JC-1 dye was at 488 run and the 
emission wavelengths were 525 nm (for green fluorescence) and 590 run (for red 
fluorescence). After staining, the cells were measured for green (FL-1 channel) and 
red (FL-2 channel) fluorescence intensities simultaneously using the BD FACSCanto 
flow cytometer. The percentage cell population of A\|/m dissipation was calculated by 
the WinMDI software (Version 2.8). 
5) Detection of Intracellular Reactive Oxygen Species (ROS) Generation 
The intracellular ROS level was measured by staining the cells with 
dihydroethidium (DHE), an oxygen radical sensor dye specifically converted by 
superoxide anions (O2 ') to highly fluorescent ethidium. After treated with different 
concentrations of Sophoraflavanone G for 24 or 48 hours, the HL-60 cells (1x10^ 
cells) were collected and resuspended in 0.5 ml staining solution containing 10 |j,M 
DHE for 30 minutes at 37°C. After staining, the samples were then subjected to the 
BD FACS Canto flow cytometer to detect the generation of ROS by measuring the 
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change of red fluorescence intensity. The excitation wavelength was 488 nm and the 
emission wavelength was 590 nm. The data from flow cytometry were analyzed by 
the WinMDI software (Version 2.8). 
6) Detection of Intracellular Calcium ion (Ca^ "^ ) Level 
The intracellular Ca^ "^  level was measured by staining the cells with stained with 
Fluo-3/AM (C51H50CI2N2O23). The excitation wavelength of Fluo-3/AM dye was 488 
nm and the emission wavelength was 525 nm (green fluorescence). HL-60 cells 
(1x10^ cells/ml) were either incubated with solvent control (0.17% ethanol) or 
Sophoraflavanone G (20 \iM and 30 [M) for 24 and 48 hours at 37�C. The cells were 
harvested and washed once with PBS by centrifuging at 400 x g for 5 minutes. The 
harvested cells (1x10^ cells) were then stained with Fluo-3/AM and subjected to a 
flow cytometer (BD FACSCanto) to measure the intracellular Ca^^ level by detecting 
the green fluorescence intensity. The data from flow cytometry were analyzed by the 
WinMDI software (Version 2.8). 
2.2.8 Protein Expression Study 
The method of protein expression study involves four major steps: a) treatment 
of cells and extraction of protein, b) quantification of protein, c) Western Blotting 
analysis, and d) ECL detection. The first two steps a) and b) have been described 
previously in Section 2.2.7 "Measurement of Caspase Activities". The last two steps 
c) and d) are briefly described as follows: 
c) Western Blotting Analysis 
Western blotting analysis includes three major steps: 1) SDS-polyacrylamide gel 
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electrophoresis (SDS-PAGE), 2) Protein transfer by electroblotting, 3) 
Immunodetection of target protein using specific antibody. 
To perform SDS-PAGE, a gel was set first. The gel was made up of two parts: 
the separating gel that positioned at the lower region for separating proteins 
according to their molecular size; and the stacking gel that located at the upper 
region for sample loading and for the formation of highly concentrated protein bands. 
The percentage of acrylamide in the separating gel was determined by the size of 
protein being examined. A protein with higher molecular weight needs a lower 
percentage of acrylamide gel and vice versa. The composition of the chemicals for 
setting the separating gels is summarized in Table 2.3. The protein sizes and their 
corresponding percentages of acrylamide used for separation are shown in Table 2.4. 
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Table 2.3 Composition of the SDS-Polyacrylamide Gel 
Stacking Gel (3 ml) Separating Gel (5 ml) 
Gel percentage 5% 7.5% 10% 12% 15% 
Deionized Water 1.65 ml 2.4 ml 2 ml 1.65 ml 1.15 ml 
Lower Buffer — 1.25 ml 1.25 ml 1.25 ml 1.25 ml 
Upper Buffer 0.75 ml … --- … 
Acrylamide Stock 0.5 ml 1.25 ml 1.67 ml 2 ml 2.5 ml 
10% SDS 30 i^l 25 i^l 25 i^l 25 |il 25 p,! 
10% APS 4 0 7 5 75 75 \i\ 75 \i\ 
TEMED 3 2 III 2^1 2 2 \i\ 
Table 2.4 Protein sizes and their corresponding percentages of acrylamide used 
for separation 
Protein Molecular Mass Separating Gel (% Acrylamide) 
(kPa) — 12.5% 15% 
P-actin 42 " 
CDK-4 33 Z 
CDK-6 40 Z 
Bax 25 Z 
Bak 30 / 
Bcl-2 26 / 
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The protein concentration of each sample was adjusted to 1 i^ig/jjl with lysis 
buffer based on the result from the Bradford protein assay. Twenty microlitres of 
protein samples (1 fig/^il) were mixed with 5 (j.1 protein loading dye (4x) to make up 
a total volume of 25 |JJL The mixed samples were boiled for 10 minutes and subjected 
to SDS-poly acrylamide gel with 5% stacking gel. Kaleidoscope prestained protein 
standards (8 jj-l) were loaded and the gel was run under constant voltage of 100 volts 
for about 2 hours. 
Following electrophoresis, the stacking gel was removed by cutting with spacer 
and the protein containing separating gel was immersed into deionized water so as to 
wash away any SDS which might hinder protein transfer. After that, the washed gel 
was soaked in transfer buffer (Ix) for 5 minutes. Before the electroblotting, the 
PVDF membrane was initially activated with 100% methanol and then soaked in 
transfer buffer (Ix) while six pieces of 3 mm filter papers were directly soaked in 
transfer buffer (Ix). Three pieces of filter papers were taken out first and placed on 
the clean surface of a semi-dry electroblotter (Bio-Rad Laboratories). The PVDF 
membrane was then placed on the top of the filter papers. The separating gel was 
carefully placed on the membrane for protein transfer and finally covered by another 
3 pieces of wet filter papers. Air bubbles were excluded by rolling a glass tube on the 
surface of wet filter papers and the surrounding buffer should be dried before 
electroblotting. A voltage of 16 volts was applied for 30 minutes to force the proteins 
to transfer from the gel to the PVDF membrane. After electroblotting, the membrane 
was washed with washing buffer (Ix) for 10 minutes and then incubated with 5% 
skimmed-milk at room temperature for at least 1 hour with rotation to block the 
non-specific sites for probing. Primary antibody for the target protein was added into 
the milk solution at a ratio of 1:1,000. After incubating with the primary antibody at 
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room temperature for an extra 1 hour, the membrane was washed with washing 
buffer (Ix) for 5 minutes for 3 times. Subsequently, the PVDF membrane was 
incubated with the corresponding horseradish peroxidase-linked secondary antibody 
at a 1:1，000 dilution in washing buffer for 1 hour at room temperature with rotation. 
The membrane was then washed 3 times with washing buffer (Ix) and subjected to 
ECL detection. 
d) ECL Detection 
The Western blotting luminol reagents include reagent A and reagent B. An 
equal volume of reagent A and B was mixed freshly before ECL detection and a final 
volume of 0.125 mL/cm^ membrane was required. The mixture of reagent A and B 
was then poured onto the PVDF membrane. After removing the excessive solution, 
the membrane was sandwiched between transparent plastic sheets and an X-ray film 
was placed on top of the membrane in a dark room. The film cassette was closed for 
different exposure time periods, ranging from 15 seconds to 5 minutes. Finally, the 
film was developed and the protein bands were visualized on the film. The protein 
size for the corresponding band w as determined by comparing with the protein 
standards, so as to verify the identity of protein being detected. The intensity of the 
bands was quantified by the ImageQuant software (Molecular Dynamics). After 
normalization with respect to the house-keeping protein p-actin, the relative intensity 
of each protein band was compared with that of the solvent control. 
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2.2.9 Assessment of Differentiation-associated Characteristics 
1) Morphological Detection of Cell Differentiation on Cytospin Preparation 
The effect of Sophoraflavanone G on the differentiation of HL-60 cells was 
assessed by preparing cytospin smears. HL-60 cells (5x10"^ cells/ml) were either 
incubated with solvent control (0.13% ethanol) or different concentrations of 
Sophoraflavanone G at 37°C for 3 days. The solvent-treated cells were harvested and 
washed twice, and finally resuspended in 1 ml cold plain RPMI medium. On the 
other hand, the Sophoraflavanone G-treated cells were allowed to stand at the room 
temperature for a while before harvesting the cells. This procedure gives a short cold 
shock for the differentiated cells to detach from the flask. The harvested cells were 
then washed twice with cold plain RPMI medium and resuspended in 1 ml cold plain 
RPMI medium. Cell morphology was then examined on the preparation of cytospin 
smears. Harvested cells treated with either solvent or Sophoraflavanone were fixed 
onto a clean microscopic glass slide by cyto-centrifugation at 500 rpm for 5 minutes 
using the Shandon Cytospin 3 centrifuge (Shandon Scientific Ltd.). The cells were 
air-dried and subsequently stained with Hemacolor staining solution in the order of 
Solution 1, 2 and 3. Each step involved staining with Hemacolor staining solution for 
15 seconds and followed by destaining with deionized water. Finally, the slides of 
cytospin smears were mounted with a neutral mounting medium, Canada Balsam 
(Sigma Chemical Co.) and the cell morphology was observed and examined under 
the Axioskop Plus II light microscope (Carl Zeiss, Inc). 
2) Functional Assessment of Differentiation by Nitroblue Tetrazolium (NBT) 
Reduction Assay 
When HL-60 cells are induced to differentiate along the granulocytic or 
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monocytic lineage, the conversion of oxygen to superoxide anions will be markedly 
increased upon exposure to phorbol 12-myristate 13-acetate (PMA) due to induction 
of respiratory burst activity (Collins, 1987). The production of superoxide anions can 
be monitored by the reduction of nitroblue tetrazolium (NBT). HL-60 cells (5x10"^ 
cells/ml) were incubated with different concentrations of Sophoraflavanone G at 
37°C for 3 days. Then, NBT-PMA mix solution (100 ^1) was added into the cultures 
and co-incubated at 37°C for 4 hours. The cells were then harvested and washed 
twice with cold plain RPMI medium with vigorous shaking. Afterwards, the cells 
were fixed onto a clean microscopic glass slide by cyto-centrifugation at 500 rpm for 
5 minutes and counter-stained with 1% safranin in methanol for 30 seconds and then 
gently washed with running water. The cells producing superoxide anions will be 
stained with dark blue deposits while the cells which fail to undergo functional 
differentiation will only be stained red (Newburger et al, 1979). 
2.2.10 Statistical Analysis 
Each experiment was performed at least two to three times and the results of 
only one representative experiment were presented in the thesis. The data were 
expressed as arithmetic mean 士 standard error (S.E.). Microsoft Excel program was 
used to analyze the experimental data. The Student's t-test was used for 
determination of the confidence limits in group comparison. Normally, P-value (p) < 
0.05 was regarded as statistical significance. 
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Studies on the Anti-proliferative 
Effect of Sophoraflavanone G on 
Human Myeloid Leukemia Cells 
Chapter 2 A nti-proliferative Effects 
3.1 Introduction 
Sophoraflavanone G was firstly reported by Shirataki and his colleagues in 
1988. Earlier studies by other groups found that it was able to inhibit the growth of a 
variety of human tumor cell lines derived from lung (A549), ovary (SK-OV-3), skin 
(SK-MEL-2), central nervous system (XF498), colorectal region (HCT-15), 
peripheral blood (HL-60) and liver (HepG2) (Ryu et al, 1997; Ko et al., 2000). 
Recent studies from our laboratory showed that Sophoraflavanone G exhibited potent 
anti-tumor effect on human hepatoma HepG2 cells as well as its multidmg-resistant 
variant RHepG2 cells via induction of apoptosis. However, the modulatory effects of 
this compound on human myeloid leukemia cells and its possible anti-leukemic 
mechanisms remain poorly understood. 
In this chapter, Sophoraflavanone G was examined for its modulatory effects on 
the proliferation and survival of human myeloid leukemia cells. Sophoraflavanone G 
is still commercially unavailable so the compound used in the present study was 
isolated from Sophora flavescens by my previous labmate Ms. Tsang Kit Man. At the 
beginning of this study, further characterization of this purified compound was 
carried out by Mass Spectrometry (MS), Nuclear Magnetic Resonance (^H-NMR and 
13C-NMR) and High Performance Liquid Chromatography (HPLC). 
The human promyelocytic leukemia HL-60 cells were selected as the major 
leukemia model in the present study. HL-60 cell line is a well-characterized and 
subcloned leukemia cell model. Previous studies showed that HL-60 cells were able 
to differentiate into granulocytic and monocytic cells in response to different 
inducers, like retinoic acid and vitamin D3 (Collins, 1987). Moreover, HL-60 cells 
can form localized subcutaneous tumors in athymic (nude) mice (Gallagher et al, 
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1979). In addition, Harker et al (1989) established an in vitro multidrug-resistant 
model HL-60/MX2 cell line, which was selectively developed from HL-60 cells. Due 
to these properties, HL-60 cells were chosen in the present study to investigate the 
anti-leukemic effect of Sophoraflavanone G on different aspects, including in vitro 
anti-proliferative activity, differentiation- and apoptosis-inducing properties, in vivo 
effect on tumorigenicity and in vitro multidrug resistant studies. 
Initially, the anti-proliferative effect of Sophoraflavanone G was screened on 
different human myeloid leukemia cell lines, including the acute promyelocytic 
leukemia (HL-60, NB-4), eosinophilic leukemia (EoL-1) and chronic myelogenous 
leukemia (K-562). After the screening, HL-60 cells were chosen for the subsequent 
mechanistic studies. In addition to leukemia cells, the cytotoxic effect of 
Sophoraflavanone G on normal cell models, including human peripheral blood 
leukocytes and murine bone marrow cells, was also investigated. The MTT reduction 
assay, ^H-thymidine incorporation assay and trypan blue exclusion assay were used 
to evaluate the anti-proliferative and cytotoxic effects of Sophoraflavanone G. Apart 
from the in vitro studies, the effect of Sophoraflavanone G on the in vivo 
tumorigenicity of HL-60 cells in xenogeneic inbred female BALB/c nude mice was 
also examined. Moreover, attempts were made to examine the underlying 
mechanisms for the in vitro anti-proliferative effect of Sophoraflavanone G on the 
HL-60 cells. These include the study on cell cycle profile distribution and the 
expression of the cell cycle regulatory proteins, using flow cytometry and Western 
blot analysis respectively. Moreover, the development of multidrug resistance (MDR) 
continues to be a major reason for the failure of chemotherapeutic agents in the 
effective treatment against cancer (Ullah, 2008). Therefore, at the end of this chapter, 
in order to mimic the situation of MDR in vitro, the anti-leukemic effect of 
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Sophoraflavanone G on HL-60/MX2 cells, a well-characterized multidrug resistant 
leukemia cell model, was also investigated. 
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3.2 Results 
3.2.1 Structure Identification of Sophoraflavanone G Isolated from Sophora 
flavescens 
Compound 106-1 was successfully isolated from Sophora flavescens by the 
purification method described in Chapter Two (Section 2.2.1). The purity of the 
Compound 106-1 was measured by High Performance Liquid Chromatography 
(HPLC). The chemical structure of Compound 106-1 was further characterized by 
spectral analysis with Mass Spectrometry (MS) and Nuclear Magnetic Resonance 
(IH-NMR and ^^C-NMR). The NMR measurement was done by Mr. C.C. Lee, 
Department of Chemistry, The Chinese University of Hong Kong. The 
characterization and analysis of Compound 106-1 were done with the help of Mr. 
P.M. Hon, Mr. Franky Choi and Dr. D.M. Zhang, Institute of Chinese Medicine, The 
Chinese University of Hong Kong. 
The purity of Compound 106-1 was estimated to be 93% as measured by HPLC. 
It is a white crystal with melting point ranges from 176 to 178，UV nm: 295; EI MS 
m/z (rel. int): 424(20), 406(18)，301(60)，283(100), 219(20)，165(60), 69(50). 
Spectroscopic data of 'H-NMR and ^^C-NMR spectra are summarized in Table 3.1. 
By direct comparison of our spectral data with the published values (Shirataki et al, 
1988), Compound 106-1 was identified as Sophoraflavanone G, i.e. 
5,7,2',4'-tetrahydroxy-8-lavandulyl-flavanone (chemical formula: C25H28O6). The 
established chemical structure of Compound 106-1 is shown in Figure 3.1. 
(Unpublished data done by Mr. P.M. Hon) 
- 6 9 -
Chapter 2 A nti-proliferative Effects 
Table 3.1 NMR spectral data of Compound 106-1 in DMS0-d6 
Position Compound 106-1 
No. IH-NMR 13C-NMR 
2 5.75，dd (13.5,2.7) 73.80 











3’ 6.52, s 102.34 
4’ 158.35 
5， 6.54, d (7.8) 106.29 
6’ 7.49，d (7.8) 127.61 
1" 2.66, m ; 2 . 1 8 , m 26.56 
2" 2.78，m 46.35 
3" 2.18, m; 1.81, m 30.74 
4" 5.13,m 123.34 
5" 130.66 
6" 1.82, s 17.59 
7" 1.76，s 25.49 
8" 147.78 
9" 1.66，s 110.80 
10" 4.71, d (2.3); 18.56 
4.77，d (2.3) 
Compound 106-1 (10 mg powder) was dissolved in 1 ml DMS0-d6 for ^H-NMR 
measurement. On the other hand, 35 mg powder of Compound 106-1 was dissolved 
in 1 ml DMS0-d6 for ^^C-NMR measurement. NMR measurement was done by Mr. 
C.C. LEE, Department of Chemistry, The Chinese University of Hong Kong. 
Remarks: s repr esents singlet; d represent doublet; dd represents double doublet; 
m represents multilet. 
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10，， 9，， 
6 ” 4” r 5， 
‘ 2， 
5 | 4 
OH C 
Fig. 3.1 Chemical structure of the Compound 106-1 isolated from Sophora 
flavescens. Based on the spectroscopic data obtained from UV, MS and NMR 
spectra, the chemical structure of the Compound 106-1 was established and 
identified as Sophoraflavanone G, i.e. 5,7,2',4'-tetrahydroxy-8-lavandulyl-flavanone 
(chemical formula: C25H28O6； molecular weight: 424). 
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3.2.2 Anti-proliferative Activity of Sophoraflavanone G on Various Myeloid 
Leukemia Cell Lines 
Initially four well-characterized human leukemia cell lines, including the 
eosinophilic leukemia EoL-1 cells, the acute promyelocytic leukemia HL-60 and 
NB-4 cells, and chronic myelogenous leukemia K-562 cells, were chosen for 
examining the in vitro anti-proliferative effect of Sophoraflavanone G on myeloid 
leukemia using the MTT reduction test. The principle of this assay is that the MTT 
salt is metabolized into a colored water-insoluble formazan by the mitochondrial 
dehydrogenases in metabolically active cells. After it is solubilized, the amount of 
formazan formed, which reflects normal cell functioning, and hence cell proliferation 
(Lau et al., 2004)，can be measured and quantified by the ELISA plate reader. The 
percentage of cell viability after treatment with Sophoraflavanone G can be 
calculated by comparing with the control cells. In the present study, EoL-1, HL-60, 
K-562 and NB-4 cells were incubated with various concentrations of 
Sophoraflavanone G for 48 hours. As shown in Figure 3.2, the percentages of cell 
viability in the four leukemia cell lines were decreased with increasing 
concentrations of Sophoraflavanone G. Table 3.2 summarized the estimated 50% 
inhibitory concentration (IC50) of Sophoraflavanone G on four leukemia cell lines. 
As shown in Table 3.2, the IC50 values at 48 hours of incubation for the EoL-1, 
HL-60, K-562 and NB-4 cells were very similar and were estimated to be around 20 
pM. 
Besides using the MTT reduction test, the anti-proliferative effects of 
Sophoraflavanone G on the above four leukemia cell lines were also examined by the 
tritiated thymidine ([^H]-TdR) proliferation assay, which is a sensitive method for 
measuring the incorporation of ^H-labeled thymidine into the DNA of proliferating 
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cells. The mechanism behind this assay is that the uptake rate of ^H-TdR, a 
radioactive labeled DNA precursor, into the DNA of the cells is directly proportional 
to the rate of cell proliferation. By measuring the incorporated radioactivity of the 
cells treated with different concentrations of Sophoraflavanone G, the 
anti-proliferative effect of this compound can be determined. In this study, EoL-1, 
HL-60, K-562 and NB-4 cells were incubated with various concentrations of 
Sophoraflavanone G for 48 hours. Figure 3.3 shows that Sophoraflavanone G 
inhibited the proliferation of four human myeloid leukemia cells in a dose-dependent 
manner. As summarized in Table 3.3, the estimated IC50 values of Sophoraflavanone 
G at 48 hours of incubation on four leukemia cell lines EoL-1, HL-60, K-562 and 
NB-4 cells were 19 jiM，20 |j,M, 14|a,M and 14 p.M respectively, as determined by the 
^H-TdR incorporation test. 
- 7 3 -
Chapter 2 A nti-proliferative Effects 
A. 
I 
？ 。 - � 
H \ 
I 40 - \ 
2 � l 
0 ‘ ‘ ‘ ‘ ‘ " “ I 
0 10 20 30 40 50 




•I 6 � - \ 
I 40 _ 
20 - \ j -
0 L L 1 1 ^ 7 
0 10 20 30 40 50 
Concentration of Sophoraflavanone G (^iM) 
- 7 4 -




f 6 0 . \ 
.2 40 - \ 
0 ‘ ‘ ‘ ‘ ‘ 
0 10 20 30 40 50 
Concentration of Sophoraflavanone G (pM) 
D. 
100 
? � • \ 
| 6 � ’ \ 
.2 40 - \ 
0 ‘ ‘ ‘ ‘ ‘ 
0 10 20 30 40 50 
Concentration of Sophoraflavanone G (|iM) 
Fig. 3.2 Growth-inhibitory effect of Sophoraflavanone G on various myeloid 
leukemia cell lines as assayed by the MTT reduction test. EoL-1 (A), HL-60 (B) 
K-562 (C) and NB-4 (D) cells (1x10^ cells/ml) were either incubated with solvent 
control (0.2% ethanol) or treated with different concentrations of Sophoraflavanone 
G for 48 h at 37°C. After incubation, MTT reduction test was carried out as 
described in Chapter Two. Results were expressed as percentage of viability, using 
solvent-treated cells as a control. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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Table 3.2 The estimat ed I C 5 0 values of Sophoraflavanone G on various types of 
leukemia cell lines at 48 hour incubation as assayed by the MTT reduction test 
Leukemia cell line Estimated I C 5 0 value at 48 h (^iM) 
EoL-1 � 1 9 
HL-60 � 2 0 
K-562 � 1 8 
NB-4 ~ 20 
IC50 value is the estimated concentration of Sophoraflavanone G that causes 50% 
inhibition on the in vitro growth of the leukemia cells under the specified 
experimental conditions. 
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Fig. 3.3 Anti-proliferative effect of Sophoraflavanone G on various myeloid 
leukemia cell lines as assayed by the [^H]-TdR incorporation test. EoL-1 (A), 
HL-60 (B) K-562 (C) and NB-4 (D) cells (1x10^ cells/ml) were either incubated with 
solvent control (0.3% ethanol) or treated with different concentrations of 
Sophoraflavanone G for 48 h at 37°C. After incubation, [^H]-TdR incorporation test 
was carried out as described in Chapter Two. Results were expressed as percentage 
inhibition of ^H-TdR incorporation, using solvent-treated cells as a control. Each 
point represents the mean 士 S.E. of quadruplicate cultures. 
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Table 3.3 The estimated I C 5 0 values of Sophoraflavanone G on various types of 
leukemia cell lines at 48 hour incubation as assayed by the [^H]-TdR 
incorporation test 
Leukemia cell line Estimated I C 5 0 value at 48 h (jiM) 
EoL-1 � 1 9 
HL-60 ~ 20 
K-562 � 1 4 
NB-4 � 1 4 
ICso value is the estimated concentration of Sophoraflavanone G that causes 50% 
inhibition on the in vitro growth of the leukemia cells under the specified 
experimental conditions. 
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3.2.3 Effect of Sophoraflavanone G on the Viability of the Human Promyelocytic 
Leukemia HL-60 Cells 
In order to verify whether the observed anti-proliferative activity of 
Sophoraflavanone G was due to its cytotoxic or cytostatic effect, the trypan blue 
exclusion assay was used to examine for its direct cytotoxicity. After treatment with 
Sophoraflavanone G for 24，48 and 72 hours, viable HL-60 cells were counted by the 
trypan blue exclusion assay in which non-viable cells took up the dye and turned 
blue. Figure 3.4 shows that Sophoraflavanone G exerted minimal, if any, direct 
cytotoxicity on the HL-60 cells at the concentrations tested, and the percentage of 
viable cells remained over 85% after 72 hours of incubation with 23 jiM 
Sophoraflavanone G. On the other hand, Figure 3.5 shows that in the presence of 
Sophoraflavanone G, the actual numbers of viable HL-60 cells declined in a dose-
and time-dependent manner. The results indicate that the growth-inhibitory effect 
Sophoraflavanone G on HL-60 cells could not be attributed to its direct cytotoxicity 
on the leukemia cells. 
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Fig. 3.4 Effect of Sophoraflavanone G on the viability of the human 
promyelocytic leukemia HL-60 cells as assayed by trypan blue exclusion test. 
HL-60 cells (1x10^ cells/ml) were either incubated with solvent control (0.13% 
ethanol) or treated with different concentrations of Sophoraflavanone G for 24 h, 48 
h and 72 h at 37°C. The viable and non-viable cell numbers were counted by trypan 
blue exclusion test using a hemocytometer. The percentage of cell viability was 
calculated as a ratio between the number of viable cells and the number of total cells. 
Results were expressed as mean percentage of viability 士 S.E. of triplicate cultures. 
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Fig. 3.5 Growth-inhibitory effect of Sophoraflavanone G on the human 
promyelocytic leukemia HL-60 cells as assayed by trypan blue exclusion test. 
HL-60 cells (1x10^ cells/ml) were either incubated with solvent control (0.13% 
ethanol) or treated with different concentrations of Sophoraflavanone G for 24 h, 48 
h and 72 h at 37°C. The number of viable cells was counted by trypan blue exclusion 
test using a hemocytometer. Results were expressed as mean percentage of viable 
cells 士 S.E. of triplicate cultures. 
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3.2.4 Cytotoxic Effect of Sophoraflavanone G on Primary Normal Cells In Vitro 
Apart from studying the anti-proliferative effect of Sophoraflavanone G on 
leukemia cells, in vitro cytotoxicity studies on normal hematopoietic cells were also 
conducted to evaluate the potential toxic effect of this compound on normal cells. 
The human peripheral blood leukocytes and murine bone marrow cells, selected as 
the normal cell models in the study, were treated with various concentrations of 
Sophoraflavanone G for 24 hours. The viability of the cells was measured by the 
MTT assay. Figure 3.6 shows that at the concentration of 20 to 30 [iM of 
Sophoraflavanone G which inhibited the growth of HL-60 leukemia cells by over 
50%, only a slight cytotoxic effect (< 20% cytotoxicity) was observed on these two 
normal cell types. However, around 40% cytotoxicity was observed in these normal 
cells when they were incubated with a higher concentration (45 \iM) of 
Sophoraflavanone G. Therefore, Sophoraflavanone G is relatively non-toxic to the 
normal hematopoietic cells at concentrations which effectively inhibit the 
proliferation of myeloid leukemia cells. 
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Fig. 3.6 Effect of Sophoraflavanone G on the viability of normal human 
peripheral blood leukocytes (PBL) and normal murine bone marrow cells as 
assayed by the MTT reduction test. Human peripheral blood leukocytes (PBL) 
were isolated from the peripheral blood of healthy donors. Murine bone marrow cells 
were prepared from female BALB/c mice. The isolation methods of these normal 
cells were described in Chapter Two. (A) Human PBL cells (1x10^ cells/ml) and (B) 
Murine bone marrow cells (2x10^ cells/ml) were either incubated with solvent 
control (0.2% ethanol) or treated with different concentrations of Sophoraflavanone 
G for 24 h at 37°C. After treatment, MTT reduction test was carried out as described 
in Chapter Two. Results were expressed as percentage of relative viability, using 
solvent-treated cells as a control. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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3.2.5 Kinetic and Reversibility Studies of the Anti-proliferative Effect of 
Sophoraflavanone G on the Human Promyelocytic Leukemia HL-60 Cells 
The ^H-TdR incorporation assay was used for studying the kinetics of 
Sophoraflavanone G on the human promyelocytic leukemia HL-60 cells. The HL-60 
cells were cultured with various concentrations of Sophoraflavanone G at 37 °C for 
24, 48 and 72 hours. Figure 3.7 shows the kinetic studies of the anti-proliferative 
effect of Sophoraflavanone G on HL-60 cells. The results indicate that 
Sophoraflavanone G inhibited the in vitro growth of HL-60 cells in a dose- and 
time-dependent manner. 
The above experiments demonstrated the growth-inhibitory effect of 
Sophoraflavanone G on the HL-60 cells. A question was raised: is the inhibitory 
effect reversible? To answer this question, the reversibility study was also performed 
by the ^H-TdR incorporation test. HL-60 cells were firstly treated with either solvent 
control (0.2% ethanol) or Sophoraflavanone G at 12.5 ^iM, 25 |iM and 50 for 12, 
24，or 36 hours. After washing away the drug-containing medium, the cells were then 
further incubated with drug-free fresh complete medium up to a total of 48 hours. As 
a positive control, HL-60 cells were incubated for 48 hours in the presence of 
Sophoraflavanone G. Figure 3.8 indicates that the reversibility of the 
anti-proliferative effect on HL-60 cells was correlated with the duration of drug 
exposure and the concentration of drug used. The results show that the 
growth-inhibitory effect of Sophoraflavanone G was less than 40% after 12 hours 
and 24 hours of drug exposure at lower concentrations (12.5 |iM and 25 jiM), 
whereas more than 50% inhibition was seen at 50 ^iM even after 12 hours of drug 
exposure. It is clear that the growth-inhibitory effect of Sophoraflavanone G was 
partially reversible at lower concentrations (12.5 ^iM and 25 |xM) and became almost 
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irreversible when a higher concentration (50 |xM) of drug was used. 
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Fig. 3.7 Kinetic studies on the anti-proliferative effect of Sophoraflavanone G on 
the human promyelocytic leukemia HL-60 cells as assayed by the [^H]-TdR 
incorporation test. HL-60 cells (1x10^ cells/ml) were either incubated with solvent 
control (0.3% ethanol) or treated with different concentrations of Sophoraflavanone 
G for 24 h, 48 h and 72 h at 37°C. After treatment, ^H-TdR incorporation test was 
carried out as described in Chapter Two. Results were expressed as percentage 
inhibition of ^H-TdR incorporation, using solvent-treated cells as a control. Each 
point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.8 Reversibility study on the growth-inhibitory effect of Sophoraflavanone 
G on the human promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ cells/ml) 
were either incubated with solvent control (0.2% ethanol) or treated with four 
different concentrations of Sophoraflavanone G at 37°C. Drugs were removed and 
replaced by fresh culture medium at different time periods (16 h, 24 h or 36 h after 
drug addition) and all cultures were incubated up to 48 hours after initial drug 
addition. The growth-inhibitory effect was then measured by ^H-TdR incorporation 
test as described in Chapter Two. Results were expressed as percentage inhibition of 
^H-TdR incorporation, using solvent-treated cells as a control. Each point represents 
the mean 士 S.E. of quadruplicate cultures. 
Remarks: * p<0.05, ** p<0.005, *** p<0.001, significantly different from 
corresponding 48h-treatment samples. 
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3.2.6 Effect of Sophoraflavanone G on the In Vivo Tumorigenicity of the HL-60 
Cells 
In addition to the in vitro studies, animal experiments were performed to 
investigate the anti-proliferative effect of Sophoraflavanone G on HL-60 cells in vivo. 
HL-60 cells were incubated with 30 |LIM Sophoraflavanone G for 16 hours at 37°C. 
The cells were harvested, washed and 1x10^ viable cells (in 100 |il PBS) were 
injected subcutaneously into the back of each BALB/c nude mouse in groups of 
twenty. The tumor weight was measured at the end of experiments, and the tumor 
volume was measured twice weekly with a vernier caliper up to one month. As 
shown in Figure 3.9, pretreatment of the leukemia HL-60 cells in vitro with 
Sophoraflavanone G markedly reduced the in vivo tumorigenicity of the HL-60 cells 
in the human tumor xenograft model. 
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Fig. 3.9 Effect of in vitro pretreatment of the human promyelocytic leukemia 
HL-60 cells with Sophoraflavanone G on their tumorigenicity in BALB/c nude 
mice. (A) Size of tumor (expressed as tumor volume); (B) Body weight on Day 36 
(last day for the experiment) after tumor implantation; (C) Percentage of final tumor 
to body weight on Day 36. HL-60 cells (1x10^ cells/ml) were either incubated with 
solvent control (0.13% ethanol) or treated with 30 \iM Sophoraflavanone G for 16 h 
at 37°C. The cells were washed once with PBS. Viable HL-60 cells (1x10^ cells in 
100 |il PBS) were injected subcutaneously on the back of each nude mouse in groups 
of twenty. The tumor weight was measured at the end of the experiment, and the 
tumor volume was measured twice weekly with a vernier caliper. Tumor volume was 
calculated according to the formula [volume = height x length x width x 71/6] • 
Remarks: 1. Sample size for graph B & C (n = 8) is different from graph A (n = 20). 
At the end of the experiment, eight mice were randomly chosen from each of solvent 
control group and drug-pretreated group, sixteen mice in total. Their bearing tumors 
were dissected. The body weight of the mice and the weight of the dissected tumor 
were measured. 
2. * p<0.05, **p<0.005, significantly different from solvent control. 
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3.2.7 Effect of Sophoraflavanone G on the Cell Cycle Profile of the HL-60 cells 
In Vitro 
Previous results as shown in Figure 3.5 indicate that the doubling time of HL-60 
cells was increased with increasing concentrations of Sophoraflavanone G， 
suggesting that Sophoraflavanone G may regulate the cell cycle progression. In the 
present study, the modulatory effect of Sophoraflavanone G on the cell cycle profile 
of the HL-60 cells was examined by propidium iodide (PI) staining followed by flow 
cytometric analysis. 
Cellular division, or cell cycling, is composed of four sequential phases: Gi, S, 
G2 and M phases. After preparation for DNA synthesis in Gi phase, the diploid cells 
enter S phase and start to replicate the DNA content. When the DNA content is 
doubled, the cells reach G2 phase and prepare for entering mitosis (M phase). 
Therefore, measurement of DNA contents in the cells can give a picture of the cell 
cycle. Propidium iodide (PI), a DNA staining fluorescent dye, can bind to DNA by 
intercalating into double-stranded nucleic acids of permeabilized cells without any 
sequence preference. Once the dye is bound to DNA, its fluorescence is enhanced 
20- to 30-fold. The intensity of emitted fluorescence, which represents the DNA 
contents of the cells, can be measured by flow cytometry. 
In the present study, HL-60 cells were treated with Sophoraflavanone G at 20 
p-M and 30 \iM for 24 hours. The results of cell cycle profiles are shown in Figure 
3.10. The percentage distribution of each phase is summarized in the lower panel 
of Figure 3.10, which indicated that Sophoraflavanone G increased the proportion of 
HL-60 cells in the GQ/GI phase while decreased the percentage of treated cells in the 
S phase. It can be seen that in solvent-treated HL-60 cells, - 4 3 % cells were in the S 
phase and -47% cells were in GQ/GI phase. In contrast, the majority (-75%) of 
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Sophoraflavanone G-treated (30 |iM) HL-60 cells were arrested in the GQ/GI phase. 
Therefore, Sophoraflavanone G might exert its anti-proliferative effect on HL-60 
cells through triggering cell cycle arrest at the GQ/GI phase. 
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Concentration of Cell cycle distribution (%) 
Sophoraflavanone G GQ /GI phase S phase G2/M phase 
Control 46.77 % 42.59 % 10.64% 
20 nM 69.05 % 22.19% 8.76 % 
3 0 > I M 7 4 . 4 6 % 1 5 . 0 4 % 1 0 . 4 9 % 
Fig. 3.10 Cell cycle profile of HL-60 cells after the treatment with 
Sophoraflavanone G for 24 hours. HL-60 cells (1x10^ cells/ml) were synchronized 
by starving in RPMI medium containing 0.5% serum for 12 hours and were 
incubated with (A) solvent control (0.13% ethanol); (B) 20 \iM of Sophoraflavanone 
G; and (C) 30 |LIM of Sophoraflavanone G for another 24 hours. The control and 
Sophoraflavanone G-treated cells were fixed by ethanol and stained by PI staining 
solution. The PI stained samples were analyzed by flow cytometry to obtain cell 
cycle profile. Cell cycle distribution was calculated by the MODFIT program. The 
cell cycle profiles are shown in the upper panel. The table in the lower panel shows 
the percentage distribution of GQ/GI, S and G2/M phases of the cell cycle. 
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3.2.8 Effect of Sophoraflavanone G on the Expression of Cell Cycle-regulatory 
Proteins in the HL-60 Cells 
Cell cycle progression is highly regulated by a network of cell cycle regulatory 
protein complexes, which include cyclins and cyclin-dependent kinases (CDK). In 
Section 3.2.7, the results show that Sophoraflavanone G could induce GQ/GI phase 
arrest in the HL-60 cells. It is of interest to find out how Sophoraflavanone G could 
affect the expression of the cell cycle-regulatory proteins that might contribute to 
GQ/GI arrest. The activated cyclin/CDK complex can phosphorylate the 
retinoblastoma protein (Rb). After phosphorylation, Rb will release the 
transcriptional factor E2F which will further promote the progression from G1 to S 
phase. The main cyclin/CDK complexes responsible for Gi/S progression are cyclin 
A/CDK-1 or -2，cyclin D/CDK-4 or -6，and cyclin E/CDK-2 (Shapiro, 2006). In the 
present study, the protein expression of cyclin-dependent kinases CDK-4 and CDK-6 
was studied by Western blot analysis. HL-60 cells (4x10^) were treated with various 
concentrations of Sophoraflavanone G for 24 hours. The cells were then harvested 
and the total cell lysate was isolated and subjected to Western blot analysis. As 
shown in Figure 3.11, Sophoraflavanone G slightly down-regulated the expression of 
CDK-4 and CDK-6 after 24 hours of treatment. 
- 9 3 -
Chapter 2 A nti-proliferative Effects 
C o n c e n t r a t i o n s o f S o p h o r a f l a v a n o n e G 
C D K - 4 _ _ • 書 3 3 k D a 
C D K - 6 m m m ^mmmm 麵 � 峰 4 0 k D a 
- a c t i n ."*^^^H!iiiw*iHPPPP.:*iH|iiiiP�^IBilP^: ^ ^ K u a 
Relative Band Intensity 
Control 10 i^M 20 i^M 40 ]iM 
CDK-4 ^ ^ ^ 
CDK-6 ^ ^ 0.66 
Figure 3.11 Effect of Sophoraflavanone G on the expression of cyclin-dependent 
kinase (CDK) in HL-60 cells. HL-60 cells (2x10^) were serum starved for 24 h and 
then treated with Sophoraflavanone G (0 - 40 ^M) for another 24 h. Proteins were 
extracted from total cell lysate and separated by 12.5% SDS gel. After that, Western 
blot analysis was performed as described in Chapter Two. The relative band 
intensities, shown in the bottom table, were calculated after normalization with 
respect to p-actin, and comparison was made with the corresponding control. 
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3.2.9 Anti-proliferative Effect of Sophoraflavanone G on Multidrug-resistant 
(MDR) Leukemia Cell Line HL-60/MX2 Cells 
Multidrug resistance (MDR) is the defence of tumor cells against many 
chemotherapeutic drugs with different structures and action mechanisms. MDR has 
been recognized as a major cause for the failure of cancer chemotherapy. The 
mechanisms of cellular MDR may be classified as classical (transport-dependent) 
and non-classical (transport-independent) mechanisms (Ullah, 2008). The 
transport-dependent mechanism involves the efflux of different drugs from the cell 
by various energy-dependent membrane transport proteins, such as P-glycoprotein, 
therefore decreasing drug accumulation inside the cell. The mechanisms of 
transport-independent may include a) activation of the enzymes of the glutathione 
detoxification system; b) alteration of drug targets or by enhancement of target repair, 
such as reduction in the activity of topoisomerase II and c) alteration of the genes and 
the proteins in the regulation of apoptosis, such as p53 and Bcl-2 (Ullah, 2008; 
Stavrovskaya, 2000). 
Previous studies in our laboratory on human hepatoma cells showed that the 
resistant RHepG2 cells with P-glycoprotein over-expression were still sensitive to 
Sophoraflavanone G (Tsang, 2005). In the present study, we further compared the 
anti-proliferative effect on the sensitive HL-60 cells with that of the resistant 
HL-60/MX2 cells (in the absence of P-glycoprotein over-expression). 
HL-60/MX2 is a multidrug-resistant variant of HL-60 cells. MX here stands for 
mitoxantrone resistance. Apart from mitoxantrone, it was also found that 
HL-60/MX2 is cross-resistant to several anti-cancer agents, including doxorubicin, 
etoposide, teniposide and amsacrine. The resistance is not due to P-glycoprotein but 
caused by reduced expression of DNA topoisomerase II p isoform. 
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The anti-proliferative effect of Sophoraflavanone G on HL-60/MX2 was 
examined by the MTT reduction test (Figure 3.12) and [^H]-TdR proliferation assay 
(Figure 3.13). Kinetic studies on anti-proliferative effect of Sophoraflavanone G 
were also measured by the [^H]-TdR proliferation assay (Figure 3.14). The results 
clearly show that Sophoraflavanone G exhibited potent anti-proliferative effect on 
this resistant leukemia cell line HL-60/MX2 in a time- and dose-dependent manner. 
The estimated IC50 value is around 8 |iM as determined by the [^H]-TdR proliferation 
assay (Figure 3.13). 
Cell cycle profile analysis on the Sophoraflavanone G-treated HL-60/MX2 cells 
was also performed. The results were similar to those obtained from its parental cell 
line HL-60 cells. As shown in Figure 3.15, Sophoraflavanone G also triggered cell 
cycle arrest in HL-60/MX2 cells at GQ/GI phase. 
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Fig. 3.12 Growth-inhibitory of Sophoraflavanone G on the multidrug-resistant 
human promyelocytic leukemia HL-60/MX2 cells as assayed by the MTT 
reduction test. HL-60/MX2 cells (1x10^ cells/ml) were either incubated with solvent 
control (0.17% ethanol) or treated with different concentrations of Sophoraflavanone 
G for 48 h at 37°C. After incubation, MTT reduction test was carried out as 
described in Chapter Two. Results were expressed as percentage of viability, using 
solvent-treated cells as a control. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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Fig. 3.13 Anti-proliferative effect of Sophoraflavanone G on the 
multidrug-resistant human promyelocytic leukemia HL-60/MX2 cells as assayed 
by the [^H]-TdR incorporation test. HL-60/MX2 cells (1x10^ cells/ml) were either 
incubated with solvent control (0.17% ethanol) or treated with different 
concentrations of Sophoraflavanone G for 48 h at 37°C. The growth-inhibitory effect 
was then measured by ^H-TdR incorporation test as described in Chapter Two. 
Results were expressed as percentage inhibition of ^H-TdR incorporation, using 
solvent-treated cells as a control. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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Fig. 3.14 Kinetic studies on the anti-proliferative effect of Sophoraflavanone G 
on the multidrug-resistant human promyelocytic leukemia HL-60/MX2 cells as 
assayed by the [^H]-TdR incorporation test. HL-60/MX2 cells (1x10^ cells/ml) 
were either incubated with solvent control (0.17% ethanol) or treated with different 
concentrations of Sophoraflavanone G for 24 h, 48 h and 72 h at 37�C. The 
growth-inhibitory effect was then measured by ^H-TdR incorporation test as 
described in Chapter Two. Results were expressed as percentage inhibition of 
^H-TdR incorporation, using solvent-treated cells as a control. Each point represents 
the mean 土 S.E. of quadruplicate cultures. 
- 9 9 -
Chapter 3 A nti-prol iferative Effects 
A A. iC. 
1:; I i:j I N i 
60 100 ISO < SO 1&0 i te 30 、{jo ISO 
Ch«nn®l» (PE-A) Channals (PE-A) “ Ctivirwt* ( P E ^ ) 
Concentration of Cell cycle distribution (%) 
Sophoraflavanone G GQ/GI phase S phase Gj/M phase 
Control 52.25 % 33.62 % 14.13 % 
5jiM 64.58 % 23.56 % 11.86% 
10 nM 71.06% 18.84% 10.10% 
Fig. 3.15 Cell cycle profile of multidrug-resistant human promyelocytic 
leukemia HL-60/MX2 cells after treatment with Sophoraflavanone G for 24 
hours. HL-60/MX2 cells (1x10^ cells/ml) were synchronized by starving in RPMI 
medium containing 0.5% serum for 12 hours and were incubated with (A) solvent 
control (0.04% ethanol); (B) 5 [iM of Sophoraflavanone G; and (C) 10 ^iM of 
Sophoraflavanone G for another 24 hours. The control and Sophoraflavanone 
G-treated cells were fixed by ethanol and stained by PI staining solution. The PI 
stained samples were analyzed by flow cytometry to obtain the cell cycle profile. 
Cell cycle distribution was calculated by the MODFIT program. The cell cycle 
profiles are shown in the upper panel. The table in the lower panel shows the 
percentage distribution of GQ/GI , S and G2/M phases of the cell cycle. 
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3.3 Discussion 
In this Chapter, the chemical structure and purity of Sophoraflavanone G were 
first identified. Subsequently, Sophoraflavanone G was further examined for its 
anti-proliferative effect against various human myeloid leukemia cell lines. 
Sophoraflavanone G used in the present study was isolated from Kushen by our 
previous labmate Ms. Tsang Kit Man with the collaboration of the Institute of 
Chinese Medicine, The Chinese University of Hong Kong. No further purification 
was carried out. By direct comparison of our spectral data (MS, ^H-NMR, and 
^^C-NMR) with the published values (Shirataki et al, 1988), the isolated compound, 
with the purity of 93% as measured by HPLC, was identified as Sophoraflavanone G, 
i.e. 5,7,2',4'-tetrahydroxy-8-lavandulyl-flavanone (chemical formula: C25H28O6). It 
has been reported that many synthetic and naturally occurring flavonoids can exhibit 
anti-proliferative effect in human cancer cell lines and the cytotoxic potency of 
flavonoids is correlated with the position, the number of hydroxyl groups, and the 
structure of side chains (Kuntz et al” 1999). Sophoraflavanone G is a flavanone with 
one lavandulyl side chain and four hydroxyl groups. In particular, the lavandulyl side 
chain, as suggested by accumulating evidences from structure-activity relationship 
(SAR) studies, is essential for the pleiotropic bioactivities of lavandulylflavonoids, 
such as in vitro growth-inhibitory activity on tumor cells, tyrosinase-inhibitory and 
cyclooxygenase-inhibitory activities (Ko et al., 2000; Chi et a/.,2001; Son et al., 
2003). However, the modulatory effects of Sophoraflavanone G on human myeloid 
leukemia cells and its possible anti-leukemic mechanisms remain poorly understood. 
In the present study, the anti-proliferative effect of Sophoraflavanone G on 
human myeloid leukemia cells was investigated. Using the MTT reduction test, 
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Sophoraflavanone G was found to inhibit the growth of human acute promyelocytic 
leukemia HL-60 cells in a dose-dependent manner, with an estimated IC50 value of 
approximately 20 |J.M following 48 hours of treatment. Similar growth-inhibitory 
effect of Sophoraflavanone G was also shown on three other human myeloid 
leukemia cell lines, including the acute promyelocytic leukemia NB-4 cells, 
eosinophilic leukemia EoL-1 cells, and chronic myelogenous leukemia K-562 cells. 
The results from ^H-thymidine incorporation test further confirmed the 
anti-proliferative ability of Sophoraflavanone G on these four human myeloid 
leukemia cell lines. Our results are in line with earlier studies done by other 
researchers. In the study by Ko et al. (2000), the IC50 value of Sophoraflavanone G 
on HL-60 cells after 96 hours of treatment was reported to be 12.5 fiM, which is 
comparable to the results obtained in our present study (20 |JM after 48 hours of 
treatment). Similarly, Sophoraflavanone G was found to exhibit the anti-proliferative 
effect on the human skin melanoma SK-MEL-2 cells, human colorectal carcinoma 
HCT-15 cells, human lung carcinoma A549 cells, and human ovarian cancer 
SK-OV-3 cells with IC50 values of 3.9，5.7, 6.4 and 7.9 |iM respectively (Ryu et al, 
1997). In addition, certain members of lavandulylflavonoids, such as Kurarinone, 
Leachianone A, and 2 ‘ -methoxykurarinone, have been shown to inhibit the growth of 
human hepatoma HepG2 cells and human breast cancer MCF-7/6 cells, with 
estimated IC50 values ranged from 11.3 to 22.2 (Ko et al, 2000; De Naeyer et aL, 
2004). These findings further support the important role of lavandulyl side chain in 
exerting the anti-proliferative activity on human tumor cells. 
Kinetic studies of the anti-proliferative effect showed that Sophoraflavanone G 
was able to inhibit the proliferation of HL-60 cells in a time- and dose-dependent 
manner. The estimated IC50 values after 24，48，and 72 hours of treatment with 
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Sophoraflavanone G on HL-60 cells were found to be 26, 20 and 17 }iM respectively. 
Interestingly, such anti-proliferative effect was partially reversible when the HL-60 
cells were exposed to Sophoraflavanone G at lower concentrations (12.5 and 25 )iM) 
and for shorter incubation periods (12 and 24 hours), although this effect was almost 
irreversible when a higher concentration (50 jiM) of drug was used. These results 
indicate that Sophoraflavanone G may exert its anti-proliferative effect on HL-60 
cells within the first 24 hours and that longer duration of treatment would result in 
irreversible changes. 
In order to distinguish whether the observed growth-inhibitory activity of 
Sophoraflavanone G on the leukemia HL-60 cells was due to its cytotoxic or 
cytostatic effect, the trypan blue exclusion assay was carried out to test for its direct 
cytotoxicity on the leukemia cells. Our results show that Sophoraflavanone G exerted 
no significant cytotoxic effect on HL-60 cells at its growth-inhibitory concentrations, 
suggesting that the anti-proliferative effect of Sophoraflavanone G on HL-60 cells 
could not be solely attributed to its direct cytotoxicity. Moreover, from the results of 
the growth curve of Sophoraflavanone G-treated HL-60 cells, it can be seen that the 
doubling time of drug-treated HL-60 cells was increased with increasing 
concentrations of Sophoraflavanone G, implying that Sophoraflavanone G may 
modulate the cell cycle progression of the treated HL-60 cells. 
This speculation was further confirmed by cell cycle profile analysis. The results 
demonstrated that Sophoraflavanone G could increase the percentage of HL-60 cells 
in the GQ/GI phase dose-dependently which was accompanied by a corresponding 
decrease in the percentage of treated cells in the S phase. The percentage of cell 
population in S phase reflects the proportion of proliferating cells. Figure 3.10 
demonstrated that the cell cycle distribution in S phase at 30 p,M of 
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Sophoraflavanone G was ~ 35% of the solvent-treated cells in S phase. As shown in 
Figure 3.7，kinetic studies illustrated that 30 pM of Sophoraflavanone G can inhibit 
approximate 70% of cell growth following 24 hours of incubation. Therefore, our 
results of cell cycle redistribution are in line with our previous anti-proliferative 
study as measured by the [^H]-TdR incorporation test. Until now, the ability of 
Sophoraflavanone G to induce cell cycle arrest in human myeloid leukemia cells, as 
well as the underlying action mechanisms, have not yet been reported. Progression 
through the cell cycle is governed by a network of cell cycle regulatory protein 
complexes, which include cyclins and cyclin-dependent kinases (CDK). The main 
cyclin/CDK complexes responsible for Gi/S progression are cyclin A/CDK-1 or -2， 
cyclin D/CDK-4 or -6, and cyclin E/CDK-2. The activated cyclin/CDK complexes 
can phosphorylate the retinoblastoma protein (Rb). After phosphorylation, Rb will 
release the transcriptional factor E2F, which will further promote the progression 
from Gi to S phase (Shapiro, 2006). In the present study, our results show that 
Sophoraflavanone G can down-regulate the expression of CDK-6 after 24 hours of 
treatment which may affect the assembling of cyclin D/CDK-6 complex and thus 
activate the Gi checkpoint arrest. Interestingly, Kim et al (2003) reported that the 
aqueous extracts of Sophora flavescens can increase the in vitro proliferation of 
normal human oral mucosal fibroblasts through induction of cyclin E and CDK-2. 
Nonetheless, detailed information regarding the effects of Sophoraflavanone G on 
the cell cycle regulatory proteins are still lacking. Therefore, more intensive 
molecular studies on other cyclin/CDK complexes and their corresponding CDK 
inhibitors should be carried out so as to reveal the underlying mechanisms of cell 
cycle arrest. 
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Since Sophoraflavanone G was found to exhibit anti-proliferative effect and 
triggered cell cycle arrest at GQ/GI phase in the HL-60 cells, the suppressive effect of 
Sophoraflavanone G on the tumorigenicity of the HL-60 cells in xenogeneic BALB/c 
nude mice was also examined. The results show that pretreatment of HL-60 cells 
with Sophoraflavanone G in vitro was able to reduce the in vivo tumorigenicity of the 
subcutaneous-injected leukemia cells in the nude mice. On the other hand, Sun et al 
(2007) reported that KS-Fs, an extract of flavonoid mixture isolated from Kushen, in 
combination with Taxol was able to suppress the tumor growth of human lung cancer 
H460 and esophageal cancer Eca-109 xenograft models in vivo. This flavonoids 
mixture KS-Fs was identified to be rich in lavandulyIflavonoids. Moreover, 
Leachianone A, another lavandulylflavonoid isolated from Kushen, was shown to 
inhibit the tumor growth of HepG2 cells in vivo after intravenous injection (Cheung 
et al,’ 2007). Nevertheless, the in vivo anti-leukemic activity of Sophoraflavanone G, 
which can be administered orally or intravenously into tumor-bearing mice, still 
awaits further investigation using the human HL-60 xenografted tumor model. 
On the other hand, a major problem encountered in conventional cancer 
chemotherapy is the adverse side effects due to lack of selective anti-tumor activity 
and broad-spectrum toxicity to normal tissues (Tsiftsoglou et al, 2003). One of the 
toxic effects of anti-leukemic chemotherapeutic agents is myelosuppression. In the 
present study, Sophoraflavanone G showed minimal, if any, in vitro cytotoxic effect 
on human peripheral leukocytes and murine bone marrow cells at concentrations 
which inhibit the growth of HL-60 leukemia cells by -50%. There is still lack of 
information on the toxicity studies of Sophoraflavanone G in animal models and on 
other types of normal cells, although it has been reported that the extract of Kushen 
could be processed as an injection for clinical usage (Ren and Zhang, 2008). Kim et 
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al (2003) also reported that the aqueous extracts of Sophora flavescens can enhance 
the in vitro proliferation of normal human oral mucosal fibroblasts. In addition, by 
measuring the activities of specific enzymes for heart and liver such as creatine 
kinase, alanine transaminase and aspartate transaminase, Cheung et al (2007) 
showed that Leachianone A, a lavandulylflavonoid also isolated from Kushen, did 
not produce apparent toxicity to the nude mice at dose of 30 mg/kg/day. In contrast, 
Sophoraflavanone G was also observed to demonstrate in vitro growth-inhibitory 
effect on some fast-dividing normal cells, such as human hepatocyte-like WRL-68 
cells (Tsang, 2006) and human foreskin fibroblast Hs-68 cells (data not shown). 
Therefore, more studies should be carried out so as to clarify its possible toxic side 
effects. For example, the in vitro cytotoxicity of Sophoraflavanone G on different 
types of normal cells should also be investigated. In addition, toxicity assessment of 
Sophoraflavanone G on animal models, such as measurement of the serum levels of 
the tissue-specific enzyme activities for heart, liver and kidney etc., should be 
performed to elucidate the toxicity of Sophoraflavanone G on normal tissues in vivo. 
Another major cause for the failure of cancer chemotherapy is development of 
multidrug resistance (MDR). MDR is the self-protection of tumor cells against many 
chemotherapeutic drugs. Over-expression of P-glycoprotein, an energy-dependent 
multidrug efflux pump, is one of the well-characterized mechanisms for MDR 
development (Tsiftsoglou et al, 2003). Previous studies in our laboratory on human 
hepatoma cells had demonstrated that the resistant RHepG2 cells with 
over-expression P-glycoprotein were still sensitive to Sophoraflavanone G, which is 
similar to its parental cell line HepG2 (Tsang, 2006). Apart from over-expression of 
energy-dependent membrane transport proteins, alteration of the biochemical activity 
of drug targets is another mechanism resulting in MDR (Stavrovskaya, 2000). 
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Topoisomerase is an essential nuclear enzyme involved in DNA replication, thus it is 
an important target for many of the clinically used anti-cancer agents, such as 
mitoxantrone, doxorubicin and etoposide (Harker et al, 1995). By reducing the 
expression of DNA topoisomerase II p isoform, multidrug-resistant leukemia 
HL-60/MX2 cells are cross-resistant to the topoisomerase II poisons as shown in 
Table 3.4. In the present study, HL-60/MX2 cells, together with HL-60 cells, were 
used to assess the anti-proliferative effect of Sophoraflavanone G and its modulatory 
effect on the cell cycle progression. Surprisingly, similar to its effects on HL-60 cells, 
Sophoraflavanone G was found to be able to inhibit the growth of HL-60/MX2 cells 
in a dose- and time-dependent manner, as well as triggering cell cycle arrest at the 
GQ/GI phase. The susceptibility of H L - 6 0 / M X 2 to Sophoraflavanone G suggests that 
topoisomerase II may not represent the essential cellular target for Sophoraflavanone 
G. Alternatively, it is also possible that the expression level of topoisomerase II p 
isoform may affect the action(s) of Sophoraflavanone G on leukemia cell lines 
because leukemia cell line HL-60/MX2 with reducd expression of topoisomerase II p 
isoform was found to be more sensitive to Sophoraflavanone G when compared to 
leukemia cell lines with normal expression of topoisomerase II p isoform (e.g. EoL-1, 
HL-60, K-562 and NB-4 cells). 
Our results, when taken together, suggest that Sophoraflavanone G can exhibit 
anti-proliferative effect on various human myeloid leukemia cell lines. Further 
investigation on HL-60 cells demonstrated that induction of cell cycle arrest and 
down-regulation of CDK-6 expression could be one of the possible mechanisms 
contributing to their anti-proliferative activity. Other possible mechanisms, such as 
induction of apoptosis and differentiation of the leukemia cells would be addressed 
in Chapter Four. 
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Table 3.4 Cross-resistant patterns of HL-60/MX2 cells comparing with its 
parental cell line HL-60 cells 
Drug Degree of resistance® 




Sophoraflavanone G 0.4 
a Expressed as a ratio of the drug concentration (HL-60/MX2 : HL-60) inhibiting cell 
growth by 50% (IC50) as measured by the MTT reduction assay, 
b Adapted from Harker et al. (1991)，Table I，p. 9955. 
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Studies on the Apoptosis- and 
Differentiation-inducing Activities 
of Sophoraflavanone G on Human 
Myeloid Leukemia Cells 
Chapter 4 Apoptosis- and Differentiation-inducing Effects 
4.1 Introduction 
In Chapter Three, the anti-proliferative effect of Sophoraflavanone G on various 
human myeloid leukemia cells was examined. The results demonstrated that 
Sophoraflavanone G can inhibit the growth of various human myeloid leukemia cell 
lines in vitro and down-regulate the expression of CDK-6 in the HL-60 cells which 
may further trigger cell cycle progression arrest at GQ/GI phase. These findings are in 
line with a previous report investigating the anti-proliferative effect of 
Sophoraflavanone G on various human tumor cell lines, such as A549, SK-OV-3, and 
SK-MEL-2 (Ryu et al, 1997). 
Apart from proliferating independently of growth signals, tumor cells are also 
characterized as capable of avoiding appropriate cell death (Roderick and Cook, 
2008). Therefore, it is of interest to further investigate whether Sophoraflavanone G 
can lead to cell death in the treated leukemia cells. Cell death is a vital cellular 
process which may include up to 11 proposed pathways occurring in mammals 
(Melino et al., 2005). Among these 11 pathways, necrosis, apoptosis and autophagy 
are three major forms of cell death (Belizario et al, 2007). Accumulating evidence 
has suggested that evasion of apoptosis is a major cause in the development and 
progression of cancer, thus many chemotherapeutic agents nowadays have targeted 
on the apoptotic pathways to induce cancer cell death (Russo et al,, 2006). 
Morphologically, apoptosis is a process characterized by cell shrinkage, membrane 
blebbing and nuclear condensation. In molecular term, apoptosis is triggered by 
"death" signals and is a complex series of events with multiple positive and negative 
feedback loops (Schimmer, 2008). Based on the original source of "death" signals, 
apoptosis can be classified into two pathways: extrinsic pathway, which responds 
mainly to extracellular stimuli, and the other intrinsic pathway, which is activated by 
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modulators within the cell itself (Russo et al, 2006). 
In the extrinsic pathway, also known as receptor-mediated death pathway, death 
ligands such as TRAIL and FasL induce apoptosis by activating the death receptors 
(DR4/TRAILR1 /Apo2 and Fas/Apol, etc) at the cell surface. The activated death 
receptors will oligomerize, which leads to recruitment of the adaptor proteins such as 
FADD (Fas-associated protein with death domain) and further chain activation of the 
caspase-8 and -3 (Russo et al., 2006; Schimmer, 2008; Han et al, 2008). 
The intrinsic pathway, which is also known as mitochondria-mediated death 
pathway, is initiated by damage to the mitochondria which results in the release of a 
series of proteins into cytoplasm, including cytochrome c. When released into 
cytoplasm, cytochrome c complexes with Apaf-1 and this complex further activates 
caspase-9 and ultimately caspase-3. Although, these two pathways are separated 
from each other at least at the beginning, they crosstalk to each other by certain 
proteins (Bid and tBid) and finally converge in a key event which is conversion of 
procaspases into "executioner" caspases, such as caspase-3 and caspase-7 (Russo et 
al., 2006; Belizario et al, 2007; Schimmer, 2008; Han et al., 2008). 
Bcl-2 family of proteins, in particular, play a central role in the regulation of the 
intrinsic pathway (Belizario et al., 2007). Members of the Bcl-2 family can be 
divided into two subfamilies: one includes the pro-apoptotic proteins such as Bak, 
Bax, and Bid; another includes the anti-apoptotic proteins such as Bcl-2 and Bcl-xL 
(Han et al., 2008). Recent studies have reported that induction of pro-apoptotic 
proteins and inhibition of anti-apoptotic proteins, triggered by certain anti-cancer 
agents, will directly alter the permeability of mitochondrial membrane and further 
induce the apoptosis signaling pathway (Jeong et al, 2008). 
In the present study, the apoptosis-inducing ability of Sophoraflavanone G on 
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the human promyelocytic leukemia HL-60 cells was investigated. In the first part of 
this Chapter, the apoptosis-inducing activity of Sophoraflavanone G on the HL-60 
cells was examined by detecting DNA fragmentation in agarose gel electrophoresis 
and quantified by the Annexin V-GFP and PI double staining. The change of 
mitochondrial membrane potential was monitored by the mitochondria-selective 
JC-1 dye staining method. To reveal the possible apoptotic pathway(s) has/have been 
induced by Sophoraflavanone G, the activities of caspase-3, -8 and -9 were measured 
using specific fluorometric substrates. In addition, since Bcl-2 family proteins play 
an active role in the apoptosis signaling pathway (Belizario et al., 2007)，thus the 
expression levels of the Bcl-2 family proteins were investigated by Western blot 
analysis. Moreover, it is known that apoptosis can also be initiated by 
over-generation of reactive oxygen species (ROS) or by alteration of Ca^ "^  
homeostasis (Dirsch et al, 1998; Roderick, 2008). In the present study, using flow 
cytometric analysis, the ROS production and the level of intracellular calcium were 
measured by dihydroethidine staining and Fluo-3/AM staining, respectively. 
In addition to proliferate independently of growth signals and by avoiding 
appropriate cell death, another abnormality of leukemia cells is their inability to 
differentiate into functional mature cells (Tsiftsoglou et al., 2003; Roderick and Cook, 
2008). The degree of differentiation is inversely related to their malignancy and 
terminal differentiation is usually accompanied by the cessation of cell proliferation 
(Tsiftsoglou et al, 2003). The observation of Friend and his colleagues in early 
1970s that MEL leukemia cells can be induced by dimethylsuloxide (DMSO) to 
differentiate into non-dividing mature erythroid cells sparked extensive exploration 
and led to the idea of differentiation therapy of cancer, which is inducing terminal 
differentiation of neoplastic cells by various agents (Friend et al., 1971; Tsiftsoglou 
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et al., 2003). During the last three decades, a wide variety of agents (chemical, 
natural, pharmacological, and biological) have been found and proved to induce 
leukemic cell differentiation (Tsiftsoglou et al., 2003). Some of them have been 
applied in clinical trials for hematologic malignancies, which were summarized and 
listed in Table 4.1. All-trans-rttmoic acid (ATRA), one of the most well-known 
inducers, was demonstrated to induce HL-60 cells differentiate into granulocytic 
cells by Breitman et al in 1980. Nowadays, either alone or in combination with other 
anti-cancer drugs like arsenic trioxide (ATO, AS2O3), ATRA therapy has been 
recognized as the most successful treatment for acute promyelocytic leukemia (APL) 
(Leung et al., 2005; Rubnitz et al., 2008). Apart from ATRA, HL-60 cells can also be 
induced to differentiate in response to different inducers, such as camptothecin and 
vitamin D3 (Tsiftsoglou et al, 2003). Moreover, recent studies reported that some 
members of flavonoids family, such as genistein and apigenin, can trigger HL-60 
cells to undergo differentiation (Takahashi et al., 1998; Kawaii et al., 1999). Thus, it 
is possible that Sophoraflavanone G，a member of the flavonoids family, can also 
induce leukemic cell differentiation. Terminal differentiation of HL-60 cells can be 
monitored by changes in morphological, biochemical and immunological properties 
(Kawaii et al., 1999). In the second part of this Chapter, the differentiation-inducing 
ability of Sophoraflavanone G was evaluated by examining the morphological and 
functional changes in the drug-treated HL-60 cells. 
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Table 4.1 Common differentiation inducers used in 
clinical trials for hematologic malignancies 
• • • • I • • — — ^ ― — — ^ - ‘ • ‘ — — — — • ‘ — — 
Differentiation inducers Examples 
^ — — — ^ ^ ― — — 
Arsenic trioxide (AS2O3) 
,.p . Cytosine arabinoside 
Anti-proliferative agents , , , 
^ Hydroxyurea 
Interferons 
_ , 8-chloro-cyclic adenosine 3', 5' monophosphate 
Cyclic AMP analogs (S-Cl-cAMP) 
Demethylating agents Aza-cytidine 
. Depsipeptide 
i r ^ l ^ L / c ^ S l ^ S i ^ Sodium phenylbutyrate (NaPB) 
Suberoylanilide hydroxamic acid (SAHA) 
Erythropoietin (EPO) 
Granulocyte-colony stimulating factor (G-CSF) 
. . , . Granulocyte-macrophage-colony stimulating 





Short-chain fatty acids 
Sodium butyrate 
PKC agonists and antagonists Tetradecanoylphorbol acetate (TPA) 
Polar-planar compounds Hexamethylene bisacetamide (HMBA) 
Retinoic acid and its derivatives 
Vitamin analogs . ta 
Vitamin D3 and its derivatives 
(Modified from Miller and Waxman, 2002) 
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4.2 Results 
4.2.1 Induction of DNA Fragmentation in the Human Promyelocytic Leukemia 
HL-60 Cells by Sophoraflavanone G 
The induction of apoptosis is accompanied by a number of biochemical changes. 
One of the biochemical changes is DNA fragmentation, which is the hallmark of 
apoptosis. By analyzing the genomic DNA extracted from apoptotic cells in a 2% 
agarose gel, the occurrence of "DNA ladder", which is a characteristic of DNA 
fragments in multiples of 180-200 base pairs, can be observed (Robertson et al., 
2000). 
In this study, HL-60 cells were either incubated with solvent control or treated 
with different concentrations of Sophoraflavanone G for 24 hours. Genomic DNA of 
treated-HL-60 cells were extracted and analyzed by electrophoresis on 2% agarose 
gel stained with ethidium bromide. Figure 4.1 shows that Sophoraflavanone G 
induced DNA fragmentation in HL-60 cells after 24 hours of incubation in a 
dose-dependent response manner. 
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• H i l 
J • 
Lane 1: 100 bp DNA marker 
Lane 2: HL-60 cells treated with solvent control 
Lane 3: HL-60 cells treated with 5 |iM Sophoraflavanone G 
Lane 4: HL-60 cells treated with 10 [xM Sophoraflavanone G 
Lane 5: HL-60 cells treated with 20 |JM Sophoraflavanone G 
Lane 6: HL-60 cells treated with 30 [xM Sophoraflavanone G 
Fig. 4.1 Dose response study for the induction of DNA fragmentation in the 
human promyelocytic leukemia HL-60 cells treated with Sophoraflavanone G. 
HL-60 cells (1x10^ cells/ml) were either incubated with solvent control (0.13% 
ethanol) or treated with different concentrations of Sophoraflavanone G for 24 hours 
at 37°C. Apoptotic DNA fragments were extracted by mild detergent IGEPAL 
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4.2.2 Induction of Phosphatidylserine Externalization in the Human 
Promyelocytic Leukemia HL-60 Cells by Sophoraflavanone G as Detected 
by Annexin V-GFP and PI Double Staining Method 
Apart from DNA fragmentation, apoptosis is also characterized by 
phosphatidylserine (PS) externalization from inner plasma membrane to outer plasma 
membrane. Therefore, PS was exposed to the extracellular environment (van 
Engeland et al., 1998). Annexin V is a calcium-dependent phospholipid-binding 
protein with high affinity for PS. Thus, it is a sensitive marker to detect PS 
externalization (Vermes et al., 1995). Annexin V conjugated with a fluorophore such 
as Green Fluorescence Protein (GFP) can identify apoptotic cells by binding to PS 
when it is exposed to the outer leaflet. However, Annexin V can also bind to necrotic 
cells due to the loss of membrane integrity. Thus, another dye in this assay, 
propidium iodide (PI) was used to differentiate the apoptotic cells from necrotic cells 
because PI can be excluded by viable and early apoptotic cells with intact plasma 
membrane. Therefore, viable cells are Annexin V-GFP and PI double negative. Early 
apoptotic cells are Annexin V-GFP positive and PI negative. Necrotic and/or late 
apoptotic cells are Annexin V-GFP positive and PI positive. The distribution of these 
subpopulations can be measured and quantified by flow cytometry analysis (Figure 
4.2). 
In this study, after incubation with Sophoraflavanone G for 12 hours, HL-60 
cells were harvested and stained with GFP-conjugated Annexin V and propidium 
iodide (PI). By flow cytometric analysis, the early apoptotic cells can be 
distinguished from the late apoptotic and/ or necrotic cells. 
As shown in Figure 4.3, after 12 hours of treatment of HL-60 cells with 
Sophoraflavanone G, there was a dose-dependently increase of cell population in 
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population of early apoptotic cells. The result further confirms that Sophoraflavanone 
G is capable of inducing apoptosis in HL-60 cells with detectable PS translocation 
from the inner to the outer plasma membrane. 
PI+/Ann(3Xin V+ 
o 
“ Dead cells 
(Necrotic cells or 
6 Late apoptotic cells) 
PI 
_ Pl'/Annexin V" Pf/Annexin V^ 
B 
丨 Viable Early apoptotic cells 
cells 
1 0 � 1 0 ' 1 0 : 1 0 ' 
Annexin V-GFP 
Fig. 4.2 Detection of phosphatidylserine extemalization by Annexin V-GFP and 
PI double staining method. The green fluorescence emitted by Annexin V-GFP and 
the red fluorescence emitted by PI are detected by flow cytometry. The lower left 
quadrant (LL) represents viable cells without PS translocation; the lower right 
quadrant (LR) represents early apoptotic cells with PS translocation and the upper 
right quadrant (UR) represents necrotic and/or late apoptotic cells. 
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O ° ° 
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63.4% FITC-A 13.5% 41 6% FITC-A 21.6% 
Green fluorescence (FL-1) 
Concentration of Distribution of subpopulation (%) 
Sophoraflavanone G viable cells Early Late apoptotic cells 
apoptotic cells and/or necrotic cells 
Solvent Control (A) 91.3% 5^ 8% 
10 抖M(B) 83.8% 5.1% 11.0% 
20 fiM (C) 63.4% 13.5% 22.9% 
30 ^M (D) 41.6% 21.6% 36.6% 
Fig. 4.3 Induction of phosphatidylserine externalization in the human 
promyelocytic leukemia HL-60 cells by Sophoraflavanone G as detected by 
Annexin V-GFP and PI double staining method. HL-60 cells (1x10^ cells/ml) 
were incubated with (A) solvent control (0.13% ethanol); (B) 10 |iM of 
Sophoraflavanone G; (C) 20 ^iM of Sophoraflavanone G and (D) 30 |iM of 
Sophoraflavanone G for 12 hours at 37°C. The HL-60 cells were harvested and 
stained with Annexin V-GFP and PI as described in Chapter Two. The stained cells 
were subjected to BD FACSCanto flow cytometer for measuring green (FL-1 
channel) and red (FL-2 channel) fluorescence intensities simultaneously. The 
percentage distribution of three subpopulations, as shown in the Table in the lower 
panel, is calculated by WinMDI software (Version 2.8). 
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4.2.3 Effects of Sophoraflavanone G on the Caspase Activities in the Human 
Promyelocytic Leukemia HL-60 Cells 
As demonstrated in Section 4.2.1 and 4.2.2, DNA fragmentation and 
phosphatidylserine externalization, typical biochemical changes occur in the process 
of apoptosis, were detected in the Sophoraflavanone G-treated HL-60 cells. These 
biochemical changes are mainly caused by an enzyme family, known as caspases 
(cysteinyl-aspartate-specific proteases) (Belizario et al, 2007). At least 14 members 
have been identified in this cysteine protease family. All of them are homologous to 
each other and they cleave their substrate proteins specifically at sites next to 
aspartate residues. They are synthesized constitutively and are normally present as 
inactive proenzymes, also known as procaspases, which have very weak protease 
activity. Cleavage at specific internal aspartate residues, also known as caspase 
activation, is required for inducing full enzymatic activity, which is vital for the 
occurrence of apoptotic characteristic. The simplest way to activate a procaspase is to 
expose it to a previously activated caspase member. This "caspase cascade" strategy 
of caspase activation is extensively used in apoptotic cells (Saraste and Pulkki, 2000). 
Based on their point of entry into the cascade, apoptotic caspases can further 
classified into upstream "initiator" caspases (caspase-2, -8，-9 and -10) and 
downstream "executioner" caspases (caspase-3, -6 and -7) (Belizario et al” 2007). 
For instance, activation of upstream "initiator" caspase-8 or caspase-9 by 
oligomerization and self-cleavage of its monomeric procaspases lead to proteolytic 
activation of the downstream "executioner" caspase-3. Activated caspase-3 will 
further cleave critical intracellular proteins and thereby induce the final stage of cell 
death (Schimmer, 2008). Thus, it is essential to monitor the level of caspase-3 
activation in Sophoraflavanone G-treated HL-60 cells, which may further confirm 
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that Sophoraflavanone G is able to trigger apoptosis in vitro. Apart from caspase-3, 
the activation level of caspase-8 and caspase-9 were be also investigated because 
caspase-8 and caspase-9 are the hallmark "initiator" caspases for the extrinsic and 
intrinsic pathway of apoptosis, respectively (Chowdhury et al, 2006). 
In the present investigation, the levels of caspase-3, -8 and -9 activation were 
monitored by enzymatic activity studies. HL-60 cells were treated with either solvent 
control or different concentrations of Sophoraflavanone G for 24 hours. The protein 
of each sample was extracted and the activities of caspase-3, -8 and -9 were 
measured by fluorometric assay. Specific fluorescent AMC conjugated caspase 
substrates and specific caspase inhibitors were used. For example, for the 
measurement of caspase-3 activity, the protein extract was incubated with caspase-3 
specific fluorescent AMC conjugated substrate Ac-DEVD-AMC for one hour. 
Ac-DEVD-AMC was then cleaved by active caspase-3. The amount of fluorescent 
AMC released from the substrate by the action of caspase-3 is directly proportional 
to its enzymatic activity. To make sure the correlation between the fluorescence 
signal and caspase-3 activity, caspase-3 specific inhibitor Ac-DEVD-CHO was 
incubated with the protein sample before the addition of substrate. The results are 
shown in Figure 4.4 - 4.6. It was observed that the activities of caspase-3 and -9 were 
significantly enhanced in the Sophoraflavanone G-treated HL-60 cells in a 
dose-dependent manner (Figure 4.4 and Figure 4.5). On the other hand, the caspase-8 
activity was markedly elevated when HL-60 cells were incubated with 50 fiM 
Sophoraflavanone G for 24 hours, but no significantly changes were detected at 
lower concentrations (20 \iM and 30 )j.M) of Sophoraflavanone G (Figure 4.6). The 
specificity of the caspase activity assays was supported by the evidence that the three 
caspase-specific inhibitors markedly suppressed the activities of caspases in all cases. 
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Fig. 4.4 Fluorometric detection of caspase-3 activity in the Sophoraflavanone 
G-treated human promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ 
cells/ml) were either incubated with solvent control (0.2% ethanol) or treated with 
different concentrations of Sophoraflavanone G for 24 hours at 37°C. Cytosolic 
extracts were prepared and assayed for caspase-3 activity with caspase-3 specific 
fluorescent AMC conjugated substrate Ac-DEVD-AMC with or without caspase-3 
inhibitor Ac-DEVD-CHO. The samples were excited at 430 nm and the fluorescence 
emitted at 465 nm was measured by the fluorescence plate reader Polarizon (Tecan). 
Results were expressed as fluorescence units of AMC release, which was estimated 
by comparing sample AMC fluorescence units with the standard curve of free AMC 
molecules. Each point represents the mean 士 S.E. of quadruplicate cultures. The 
caspase-3 activity corresponded to the amount of AMC release. 
*** Significantly different compared with the solvent control, p < 0.001 
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Fig. 4.5 Fluorometric detection of caspase-8 activity in the Sophoraflavanone 
G-treated human promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ 
cells/ml) were either incubated with solvent control (0.2% ethanol) or treated with 
different concentrations of Sophoraflavanone G for 24 hours at 37°C. Cytosolic 
extracts were prepared and assayed for caspase-8 activity with caspase-8 specific 
fluorescent AMC conjugated substrate Ac-IEID-AMC with or without caspase-8 
inhibitor Ac-IEID-CHO. The samples were excited at 430 nm and the fluorescence 
emitted at 465 nm was measured by the fluorescence plate reader Polarizon (Tecan). 
Results were expressed as fluorescence units of AMC release, which was estimated 
by comparing sample AMC fluorescence units with the standard curve of free AMC 
molecules. Each point represents the mean 士 S.E. of quadruplicate cultures. The 
caspase-8 activity corresponded to the amount of AMC release. 
*** Significantly different compared with the solvent control, p < 0.00J 
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Fig. 4.6 Fluorometric detection of caspase-9 activity in the Sophoraflavanone 
G-treated human promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ 
cells/ml) were either incubated with solvent control (0.2% ethanol) or treated with 
different concentrations of Sophoraflavanone G for 24 hours at 37°C. Cytosolic 
extracts were prepared and assayed for caspase-9 activity with caspase-9 specific 
fluorescent AMC conjugated substrate Ac-LEHD-AMC with or without caspase-9 
inhibitor Ac-LEHD-CHO. The samples were excited at 430 run and the fluorescence 
emitted at 465 nm was measured by the fluorescence plate reader Polarizon (Tecan). 
Results were expressed as fluorescence units of AMC release, which was estimated 
by comparing sample AMC fluorescence units with the standard curve of free AMC 
molecules. Each point represents the mean 士 S.E. of quadruplicate cultures. The 
caspase-9 activity corresponded to the amount of AMC release. 
*** Significantly different compared with the solvent control, p < 0.001 
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4.2.4 Induction of Mitochondrial Membrane Depolarization in the Human 
Promyelocytic Leukemia HL-60 Cells by Sophoraflavanone G 
As shown in Figure 4.6, the activity of caspases-9 was significantly enhanced in 
Sophoraflavanone G-treated HL-60 cells in a dose-dependent manner. It is known 
that caspase-9, as an "initiator" caspase of the intrinsic pathway, carries an apoptotic 
signal from mitochondrion which leads to the activation of caspase-3 and causing 
apoptosis (Bratton et al, 2001). Therefore, it is of interest to further investigate the 
possible roles of mitochondria in Sophoraflavanone G-induced apoptosis. One of the 
early events of apoptosis is the loss of mitochondrial transmembrane potential (A\};m), 
which can be measured by means of JC-1 staining. JC-1, chemically known as 
5,5',6,6'-tetrachloro-l,r,3,3'- tetraethylbenzimidazolyl-carbocyanine iodide, is a cell 
permeant cationic fluorescent probe which selectively accumulates in the 
mitochondria. It is a sensitive marker for the detection of changes in Ax^ /m. In the 
presence of intact polarized mitochondrial membrane (with high A\}/m), JC-1 
molecules form J-aggregates (dimeric JC-1) with the maximum fluorescence 
emission at 590 run (red fluorescence) after excitation at 488 nm. When the 
mitochondrial membrane is depolarized (with reduced A\|;m), the dyes remain in a 
monomeric form and emits green fluorescence at 525 nm upon the same excitation 
wavelength. Therefore, depolarization of mitochondrial membrane can be indicated 
by a fluorescence emission shift from red to green (Figure 4.7). 
In the present study, HL-60 cells were treated with various concentrations of 
Sophoraflavanone G for 12 or 24 hours. After stained with JC-1 dye, the control and 
treated HL-60 cells were analyzed by flow cytometry. The data were expressed as a 
density plot in Figure 4.8. The X-axis of the plot represents the green fluorescence 
intensity of monomeric JC-1 while the Y-axis represents the red fluorescence 
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intensity of dimeric JC-1. The lower right region R1 indicated the cell population 
with higher green to red fluorescence ratio which reflects break-down of A\|/m. After 
the treatment of Sophoraflavanone G for 12 and 24 hours, the proportion of HL-60 
cells with higher green to red fluorescence ratio was increased time- and 
dose-dependently (Figure 4.8). The results suggest that Sophoraflavanone G may 
induce mitochondrial membrane depolarization in HL-60 cells in a time- and 
dose-dependent manner. 
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Fig. 4.7 Detection of mitochondrial membrane depolarization by JC-1 staining 
method. JC-1 molecules can form aggregates due to the physiological membrane 
potential of mitochondria. This aggregation changes the fluorescence properties of 
JC-1 leading to a shift from green to red fluorescence. Intact living cells stained with 
JC-1 therefore exhibit a distinct red fluorescence of mitochondria, which is 
detectable by flow cytometric analysis (in the FL-2 channel). Apoptosis results in a 
breakdown of the mitochondrial membrane potential and a subsequent decrease of 
the red fluorescence and an increase of the green fluorescence (in the FL-1 channel). 
In this graph, the X-axis represents the intensity of green fluorescence while the 
Y-axis represents the intensity of red fluorescence. Upper left region represents cells 
with normal polarized mitochondrial membrane which emit red fluorescence. Lower 
right region represents cells with depolarized mitochondrial membrane which emit 
green fluorescence. 
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Fig. 4.8 Effect of Sophoraflavanone G on the mitochondrial membrane 
depolarization in the human promyelocytic leukemia HL-60 cells as detected by 
JC-1 staining method. HL-60 cells (1x10^ cells/ml) were incubated with (A & A’） 
solvent control (0.13% ethanol); (B & B’）20 ^iM of Sophoraflavanone G; (C & C,) 
30 |aM of Sophoraflavanone G for 12 and 24 hours. The cells were then stained with 
JC-1 dye as described in Chapter Two. The stained cells were subjected to BD 
FACSCanto flow cytometer for measuring green (FL-1 channel) and red (FL-2 
channel) fluorescence intensities simultaneously. The percentage cell population in 
the lower right region R l , representing cells with higher green to red fluorescence 
ratio which reflects Ai|/m dissipation, was calculated by the WinMDI software 
(Version 2.8). 
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4.2.5 Involvement of Bcl-2 Family Members in Sophoraflavanone G-induced 
Apoptosis in the Human Promyelocytic Leukemia HL-60 Cells 
Results in the previous section show that Sophoraflavanone G can trigger 
mitochondria membrane depolarization in the HL-60 cells. It has been reported that 
the permeability of the mitochondrial outer membrane is modulated by the Bcl-2 
family of proteins, which include at least 17 or more members in mammalian cells 
(Cory and Adams, 2002; Han et al, 2008). Bcl-2 proteins share at least one 
conserved Bcl-2 homology (BH) domain. Based on the BH domains and function, 
Bcl-2 family can be classified into three groups. The anti-apoptotic members, such as 
Bcl-2 and Bcl-xL (Bcl-x protein long form), typically possess four BH domains 
(BHl to BH4). The pro-apoptotic Bcl-2 members, which promote apoptosis, can be 
further divided into two groups, one is BH3-only proteins which include Bid, Bim， 
Bad, Noxa, and PUMA, while the other group members have three BH domains 
(BHl to BH3)，such as Bak and Bax. In healthy cells, Bak anchors at the site of the 
mitochondrial outer membrane, whereas Bax resides in the cytosol. Anti-apoptotic 
members will bind to and antagonize Bak and Bax so as to block the function of Bak 
and Bax. When Bak and Bax are stimulated by death signals, they can form homo-
and/or hetero-oligomers in the mitochondrial outer membrane to permeabilize the 
outer membrane, which leads to the release of mitochondrial intermembrane space 
proteins, such as cytochrome c and AIF, to the cytosol (Belizario et al., 2007; Han et 
fl/.,2008; Jeong era/., 2008). 
To elucidate the possible involvement of Bcl-2 family proteins in 
Sophoraflavanone G-induced apoptosis of HL-60 cells, the expression of several 
proteins of the Bcl-2 family, including Bax, Bak and Bcl-2, was examined by 
Western blotting analysis. HL-60 cells were treated with either solvent control or 
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different concentrations of Sophoraflavanone G for 24 hours. The cells were then 
harvested and the total cell lysate was isolated and further subject to Western blot 
analysis. The levels of pro-apoptotic proteins Bax and Bak were increased while the 
level of anti-apoptotic proteins Bcl-2 was decreased (Figure 4.9). 
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Concentration of Sophoraflavanone G 
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Fig. 4.9 Effect of Sophoraflavanone G on the expression of Bcl-2 family proteins 
in the human promyelocytic leukemia HL-60 cells. HL-60 cells (2x10^) were 
treated with different concentrations of Sophoraflavanone G (0 - 50 |aM) for 24 hours 
at 37°C. Proteins were extracted from total cell lysate and separated by 12.5% SDS 
gel. After that, Western blot analysis was performed as described in Chapter Two. 
Relative band intensities, shown in the bottom Table, were calculated after 
normalization with respect to P-actin, and comparison was made with the 
corresponding control. 
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4.2.6 Effect of Sophoraflavanone G on the Induction of Reactive Oxygen Species 
in the Human Promyelocytic Leukemia HL-60 Cells 
In Section 4.2.4 we demonstrated that Sophoraflavanone G may trigger 
mitochondrial membrane depolarization in HL-60 cells. A recent report shows that 
disruption of the mitochondria transmembrane potential is usually associated with 
increased reactive oxygen species (ROS) production (Ishii et al, 2002). ROS 
includes a variety of molecules and free radicals (chemical species with one unpaired 
electron) derived from molecular oxygen but possessing higher reactivities than 
molecular oxygen, such as superoxide anion (O2,)，hydrogen peroxide (H2O2) and 
hydroxyl radical (0H") (Martindale et al.’ 2002; Turrens, 2003). At the physiological 
level, ROS, whether generated intracellularly or derived from exogenous sources, 
can act as second messengers in various signal transduction pathways or as 
byproducts of normal aerobic metabolism. Transient fluctuations in ROS serve 
important regulatory functions, but when present above a threshold and/or sustained 
levels, ROS can randomly attack DNA, proteins and lipids, and interfere with vital 
pathways to cause cell death either by apoptosis or necrosis (Martindale et al, 2002; 
Belizario et al, 2007). 
To investigate the accumulation of ROS in Sophoraflavanone G-treated HL-60 
cells, dihydroethidine, an oxygen radical sensor dye while can be specifically 
converted by superoxide anion (O2,) to highly fluorescent ethidium, was used to 
measure the intracellular ROS level by flow cytometric analysis. After treatement 
with different concentrations of Sophoraflavanone G for 24 or 48 hours, the HL-60 
cells were stained with dihydroethidium and further analyzed by flow cytometry. The 
data were expressed as a histogram graph as shown in Figure 4.10. The X-axis of the 
graph represents the red fluorescence intensity. The right region Ml represents the 
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cell population with higher red fluorescence which reflects higher intracellular 
superoxide anion (O2') production level. The results in Figure 4.10 show that 
superoxide anion (O2') production was markedly enhanced in Sophoraflavanone 
G-treated HL-60 cells at a higher concentration (40 fiM) of the drug and a longer 
incubation time (48 hours). 
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24hr-treatment 2.98% 5.24% 15.06% 
48hr-treatment 2.12% 3.23% 39.07% 
Fig. 4.10 Effect of Sophoraflavanone G on the production of superoxide anions 
in the human promyelocytic leukemia HL-60 Cells. HL-60 cells (1x10^ cells/ml) 
were incubated with solvent control (0.17% ethanol) (red line), 20 pM of 
Sophoraflavanone G (black line) or 40 |iM of Sophoraflavanone G (green line) for 
24 and 48 hours. The cells were then stained with oxygen radical sensor dye 
dihydroethidium as described in Chapter Two. The stained cells were subjected to 
BD FACSCanto flow cytometer for measuring red fluorescence intensity (FL-2 
channel). The percentage distribution of the right region M l , as shown in the Table 
of the lower panel, represents cells with higher red fluorescence intensity which 
reflects higher intracellular superoxide anion (O2') production level. The results of 
percentage distribution of Ml are calculated by WinMDI software (Version 2.8). 
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4.2.7 Effect of Sophoraflavanone G on the Intracellular Ca^^ Level in the 
Human Promyelocytic Leukemia HL-60 Cells 
The maintenance of cellular and intraorganelle ionic homeostasis, particularly 
for Ca2+，plays a pivotal role in the cell survival and death (Belizario et al., 2007). 
Cytosolic free calcium [Ca ]i increases have been observed during apoptotic cell 
death and have been shown to be required for apoptosis to take place (Szado et al, 
2008; Roderick and Cook, 2008). The results in previous sections show that several 
biochemical changes related to apoptosis, such as DNA fragmentation, caspase 
activation and mitochondrial membrane depolarization, can be observed in 
Sophoraflavanone G-treated HL-60 cells. Therefore, it is of interest to examine 
whether the intracellular Ca^^ level is increased in Sophoraflavanone G-treated 
HL-60 cells. In this study, HL-60 cells were incubated with different concentrations 
of Sophoraflavanone G for 24 or 48 hours. The harvested cells were then stained 
with Fluo-3/AM (C51H50CI2N2O23) and further analyzed by flow cytometry. The data 
were expressed as a histogram graph as shown in Figure 4.11. The X-axis of the 
graph represents the green fluorescence intensity. The right region Ml represents 
indicated the cell population with higher green fluorescence which reflects higher 
intracellular Ca^^ level. The results in Figure 4.11 show that the intracellular Ca^^ 
level of Sophoraflavanone G-treated HL-60 cells was increased dose-dependently 
after 24 hours of treatment. In addition, it was also found that the intracellular Ca^^ 
level was higher in the 24hr-treatment than in the 48hr-treatment. 
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Fig. 4.11 Effect of Sophoraflavanone G on the intracellular Ca^^ level in the 
human promyelocytic leukemia HL-60 Cells. HL-60 cells (1x10^ cells/ml) were 
incubated with solvent control (0.17% ethanol) (red line), 20 jiM of 
Sophoraflavanone G (black line) or 40 |iM of Sophoraflavanone G (green line) for 
24 and 48 hours. The cells were then stained with Fluo-3/AM as described in Chapter 
Two. The stained cells were subjected to BD FACSCanto flow cytometer for 
measuring green fluorescence intensity (FL-1 channel). The percentage distribution 
of the right region Ml , as shown in the Table of the lower panel, represents cells 
with higher green fluorescence intensity which reflects higher intracellular Ca^^ level. 
The percentage distribution of Ml was calculated by the WinMDI software (Version 
2.8). 
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4.2.8 Morphological Studies on the Sophoraflavanone G-treated Human 
Promyelocytic Leukemia HL-60 Cells 
Human promyelocytic leukemia HL-60 cells can be induced to differentiate into 
four general types of cells: granulocytes, monocytes, macrophage-like cells and 
eosinophils by various agents (Collins, 1987). These differentiations are usually 
accompanied by morphological changes including general enlargement of the cells, 
decrease in the ratio of nucleus to cytoplasm and/or increase in vacuolation and 
cellular granularity. To investigate the differentiation-inducing potential of 
Sophoraflavanone G on the human promyelocytic leukemia HL-60 cells, HL-60 cells 
were incubated with different concentrations of Sophoraflavanone G (10 - 30 |_LM) at 
37°C for 72 hours. Cytospin preparations of harvested HL-60 cells were made on 
microscopic slides and were further stained with Hemacolor 1，2 and 3 solutions as 
described in Chapter Two. The cell morphology was observed by light microscopy. 
The morphological changes of Sophoraflavanone G-treated HL-60 cells are shown in 
Figure 4.12. It was observed that Sophoraflavanone G-treated HL-60 cells did not 
have the typical morphologies of terminally differentiated cells, like cell enlargement 
and increases in cytoplasm to nucleus ratio and vacuolation. The Sophoraflavanone 
G-treated cells (Figure 4.12 B - D) only showed similar morphology to the solvent 
control-treated cells (Figure 4.12 A). These results indicate that Sophoraflavanone G 
failed to induce the terminal differentiation of the HL-60 cells under the given 
experimental conditions. 
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Fig. 4.12 Cellular morphology of the Sophoraflavanone G-treated human 
promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ cells/ml) were treated 
with (A) solvent control (0.13% ethanol); (B) 10 ^M of Sophoraflavanone G; (C) 20 
fiM of Sophoraflavanone G; (D) 30 ^M of Sophoraflavanone G for 72 hours at ITC. 
The treated cells were harvested and further cytocentrifuged onto microscopic glass 
slides and stained with Hemacolor solutions as described in Chapter Two. The cell 
morphology was observed by light microscopy. The scale bars represent 20 jim and 
the magnification is 400x. 
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4.2.9 Effect of Sophoraflavanone G on the NBT-Reducing Activity of the Human 
Promyelocytic Leukemia HL-60 Cells 
Apart from examining the differentiation-inducing effect by morphological 
criteria, functional characteristics assessment, like the NBT-reducing activity, is also 
a widely used method. When HL-60 cells undergo differentiation into granulocytes 
or monocytes, the conversion of oxygen to superoxide anions will enhance upon 
exposure to phorbol myristate acetate (PMA), due to induction of respiratory burst 
activity (Collins, 1987; Ishii et al, 2002). Nitroblue tetrazolium (NBT), an electron 
acceptor, can be used to monitor the production of superoxide anions. NBT can be 
reduced by superoxide anions from the water-soluble form into water-insoluble, dark 
blue nitroblue diformazan deposits. Therefore, the cells producing superoxide anions 
will be stained with these dark blue deposits (Newburger et al, 1979). 
In the present study, HL-60 cells were incubated with different concentrations of 
Sophoraflavanone G at 37°C for 72 hours. The treated cells were then incubated with 
NBT-PMA solution. The cells were then cytocentrifuged onto microscopic slides and 
counter-stained with 1% safranin in methanol as described in Chapter Two. As shown 
in Figure 4.11，Sophoraflavanone G-treated HL-60 cells were stained red, which 
were similar to the solvent-treated control cells. Therefore, Sophoraflavanone G 
failed to enhance the NBT reduction activity of HL-60 cells under the prescribed 
experimental conditions. 
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Fig. 4.13 Effect of Sophoraflavanone G on the NBT-reducing activity of the 
human promyelocytic leukemia HL-60 cells. HL-60 cells (1x10^ cells/ml) were 
treated with (A) solvent control (0.04% ethanol); (B) 5 [iM of Sophoraflavanone G; 
(C) 10 ^iM of Sophoraflavanone G for 72 hours at 37^C. The 1:1 (v/v) mixture of cell 
suspension (2x10^ cells/lOOp,!) was incubated with freshly prepared NBT-PMA 
solution for 4 hours at 37°C in the dark. The cells were then cytocentrifuged onto 
microscopic slides and counter-stained with 1% safranin in methanol as described in 
Chapter Two. The cells were examined by light microscopy (400x magnification). 
Differentiated cells will be stained in dark brown color, due to formation of 
intracellular dark blue diformazan, instead of red color. 
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4.3 Discussion 
In addition to proliferating independently of growth signals, leukemia cells are 
characterized as capable of avoiding appropriate cell death and fail to differentiate 
into functional and mature cells. Most of the strategies for cancer therapy are 
targeting on these three aberrant characteristics. In Chapter Three, Sophoraflavanone 
G was shown to exhibit potent anti-proliferative effect on human promyelocytic 
leukemia HL-60 cells via cell cycle arrest at GQ/GI phase. Previous studies in our 
laboratories had found that Sophoraflavanone G could inhibit the growth as well as 
inducing apoptosis in the human hepatocellular carcinoma HepG2 cells (Tsang, 
2006). In addition, both cell cycle arrest and apoptosis are known to occur in a 
simultaneous or sequential manner (Shapiro, 2006; Blagosklonny, 2007). Moreover, 
it has been reported that genistein, also a member of flavonoids, could trigger HL-60 
cells differentiation (Takahashi et al, 1998). Therefore, investigation on whether 
Sophoraflavanone G could induce apoptosis and/or cell differentiation of human 
myeloid leukemia HL-60 cells was performed. 
The induction of apoptosis is accompanied by a number of biochemical changes, 
such as DNA fragmentation and phosphatidylserine (PS) extemalization. In order to 
examine the hypothesis that Sophoraflavanone G could induce apoptosis, DNA 
fragmentation assay and phosphatidylserine extemalization analysis were initially 
carried out. In DNA fragmentation assay, as detected by agarose gel electrophoresis, 
it was observed that 24 hour treatment of HL-60 cells with 10 to 30 |iM of 
Sophoraflavanone G triggered the formation of "DNA ladder" in a dose-dependent 
manner, which is a characteristic of DNA fragments in multiples of 180-200 base 
pairs. The apoptosis-inducing ability of Sophoraflavanone G was further confirmed 
by PS extemalization analysis, which was performed by Annexin V-GFP and PI 
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double staining. The co-staining method helps to differentiate and quantify the early 
apoptotic cells from total cell population. The data showed that the proportion of 
HL-60 cells in early apoptotic stage was increased from 3% in solvent-treated cells to 
22% in cells treated with 30 |_LM of Sophoraflavanone G for 12 hours. This finding is 
in line with a previous report showing that four lavandulylflavonoids isolated from 
Kushen, including Sophoraflavanone G, could induce DNA fragmentation in the 
HL-60 cells as detected by gel electrophoresis and sandwich enzyme immunoassay 
(Ko et al, 2000). Nevertheless, the underlying action mechanisms for the 
apoptosis-inducing activity of Sophoraflavanone G have not been studied. 
To further confirm the apoptosis-inducing ability of Sophoraflavanone G in 
HL-60 cells, the activities of caspases were measured. It has been well documented 
that apoptosis triggered by "death" signals will culminate in the activation of 
caspases which will further cleave apoptotic proteins and hence induce the final 
stages of cell death (Schimmer, 2008). Multiple pathways are known to lead to 
caspase activation. These pathways can be divided into two main pathways: extrinsic 
pathway, which responds mainly to extracellular stimuli and is mediated by 
caspase-8, and the other intrinsic pathway, which is mainly initiated by modulators 
within the cell itself and subsequently mediated by caspase-9 (Russo et al., 2006). 
Activation of upstream "initiator" caspase-8 or -9 lead to further activation of the 
downstream "executioner" caspase-3 (Schimmer, 2008). Therefore, in the present 
study, the activities of caspase-3, -8 and -9 were measured using specific 
fluorometric substrates. The results demonstrated that, after 24 hours of incubation 
with Sophoraflavanone G，the activities of caspase-3 and -9 were significantly 
increased in the HL-60 cells in a dose-dependent manner, whereas the caspase-8 
activity was only significantly induced at a higher concentration of 
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Sophoraflavanone G (i.e. 50 \iM). These findings suggest that Sophoraflavanone G at 
lower concentrations may trigger caspase-dependent apoptosis in the HL-60 cells 
mainly through the intrinsic pathway, although activation of caspase-8, mediator of 
extrinsic pathway, was also observed when HL-60 cells were treated with higher 
concentrations of Sophoraflavanone G. 
In the intrinsic pathway, the activation of caspase-9 is triggered by upstream 
apoptotic proteins released from damaged mitochondria and the release of such 
mitochondrial intermembrane space proteins results from collapse of the 
mitochondrial membrane potential (Bratton et al, 2001). Therefore, the change of 
mitochondrial transmembrane potential (A\|/m) was monitored by JC-1 staining in the 
present study. The results suggest that Sophoraflavanone G may induce 
mitochondrial membrane depolarization in HL-60 cells in a time- and 
dose-dependent manner. These findings confirmed our speculation that 
Sophoraflavanone G may activate the intrinsic apoptotic pathway in HL-60 cells. 
The intrinsic pathway, also known as mitochondria-mediated death pathway, is 
initiated by damage to the mitochondria which results in the release of mitochondrial 
intermembrane space proteins into cytoplasm, including cytochrome c, apoptosis 
inducing factor (AIF), and endonuclease G. When released into cytoplasm, 
cytochrome c binds to an adaptor protein Apaf-1 and this complex further recruits 
procaspase-9 to form an apoptosome. The formation of apoptosome leads to 
autocatalytic activation of procaspase-9 to caspase-9 and subsequently activates the 
downstream "executioner" caspase-3. During apoptotic execution, activated 
caspase-3 is able to cleave a number of critical proteins to inhibit survival pathways 
as well as promote death activities. Poly(ADP-ribose) polymerase (PARP), one of the 
caspase-3 substrates, is responsible for DNA repair, transcription and chromosomal 
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Stability, which are important for cell survival. However, cleavage of PARP caused 
by caspase-3 during apoptosis leads to stop any pro-survival functions of PARP. 
Moreover, caspase-activated DNase (CAD), also known as caspase-activated 
nuclease, is one of the death-promoting factors. CAD resides in cytosol and is 
normally inactivated by binding to its inhibitor iCAD. During apoptosis, activated 
caspase-3 cleaves the iCAD to release active CAD which then enters the nucleus to 
degrade chromosomal DNA into fragments (Enari et al., 1998; Tang and Kidd, 1998). 
To get a more complete picture on the downstream intrinsic pathway, more studies 
should be carried out to investigate the differential expression of apoptotic regulatory 
proteins. 
When look back to the upstream pathway, it has been reported that the 
disruptions leading to mitochondrial membrane depolarization involve the 
mitochondrial membrane permeability transition pore (PTP). This mitochondrial PTP 
is regulated by Bcl-2 family proteins, such as Bcl-2, Bcl-xL, Bax and Bak, through 
the interaction of the voltage-dependent anion channel (VDAC) and adenine 
nucleotide translocator (ANT) (Jeong et al, 2008). Bax and Bak, the pro-apoptotic 
members, will physically interact with one another and form the homo- and/or 
hetero-oligomers which can move onto the mitochondrial outer membrane and cause 
its permeabilization. Anti-apoptotic members Bcl-2 and Bcl-xL can block the 
function of Bax and Bak by binding to and antagonizing Bax and Bak (Belizario et 
al, 2007; Han et al.’ 2008). The interaction between anti-apoptotic members and 
Bax/Bak is reported to be associated with "BH3 (Bcl-2 homology 3)-only proteins", 
another subgroup of Bcl-2 family pro-apoptotic members. The BIB-only proteins, 
such as Bim, Bid, Bad, Noxa, and PUMA, respond to different forms of cellular 
stress, resulting in activation of Bax and Bak. BH3-only proteins can bind to Bcl-2 
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anti-apoptotic proteins, releasing Bax and Bak to promote cell death. Additionally, it 
is suggested that certain BH3-only proteins can also bind and activate Bax and Bak 
after their dissociation from anti-apoptotic proteins (Roderick and Cook, 2008). 
Therefore, in order to elucidate the possible involvement of Bcl-2 family in 
Sophoraflavanone G-induced apoptosis, the expression level of several proteins in 
Bcl-2 family, including Bax, Bak and Bcl-2, was first examined. It was found that the 
levels of pro-apoptotic proteins Bax and Bak were up-regulated while the level of 
anti-apoptotic protein Bcl-2 was down-regulated. However, more studies should be 
performed on other Bcl-2 family proteins so as to elucidate the detailed mechanisms 
modulated by the Bcl-2 family proteins in Sophoraflavanone G-induced apoptosis of 
HL-60 cells. 
The disruption of mitochondria transmembrane potential, modulated by Bcl-2 
family proteins, is usually associated with reactive oxygen species (ROS) 
overproduction and the onset of oxidative stress (Giovannini et al., 2007). ROS is a 
collective term for a variety of molecules and free radicals (chemical species with 
one unpaired electron) such as superoxide anion (O2,), hydrogen peroxide (H2O2) 
and hydroxy 1 radical (OH"). Among these free radicals, superoxide anion (O2 ') is the 
precursor of most ROS (Martindale et al, 2002; Turrens, 2003). On the other hand, 
Sophoraflavanone G, as a member of flavonoids, was reported to be a potent 
antioxidant which is able to scavenge the ROS (Piao et al., 2006; Jung et al,, 2008). 
It seems to be paradoxical that some of flavonoids can act as an antioxidant releasing 
the intracellular oxidative stress and show potent pro-apoptotic effect at the same 
time. Giovannini et al (2007) suggested that the actions of flavonoids exerting in the 
cancer cells depend on the concentration of flavonoids and the stage of the 
degenerative progress (such as oxidative stress). Under certain experimental 
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conditions, flavonoids can paradoxically have pro-oxidant effects and generate ROS. 
It has been observed that low or high concentration of the same flavonoid compound 
is responsible for antioxidant and pro-oxidant activity, respectively (Giovannini et al., 
2007; Vailo et al, 2007). Apart from having the role of antioxidants, it is known that 
flavonoids, even in low concentration, can directly interact with specific proteins 
responsible for the regulation of apoptotic signaling and thus lead to the apoptotic 
cascade in the cancer cells (Giovannini et al, 2007). In agreement with these 
speculations, our study found that the intracellular level of superoxide anion (O2,) in 
the HL-60 cells was markedly enhanced only at a higher concentration of 
Sophoraflavanone G (i.e. 40 |IM) after 24 hours and 48 hours of incubation. However, 
whether the loss of membrane integrity is a direct result of mitochondrial membrane 
permeability transition pore (PTP) formed by pro-apoptotic Bcl-2 family members or 
due to ROS destroying membrane components remains to be determined. 
Growing evidence has shown that, apart from the oxidative stress, Ca^ "^  as an 
initiator or mediator in various apoptotic signaling pathways, plays an important role 
in the activation and execution of cell death (Belizario et al., 2007; Roderick and 
Cook, 2008). Ca2+ is mainly stored in the endoplasmic reticulum (ER). Increase of 
intracellular Ca^^ level has been observed as one of the important events during 
apoptotic cell death (Roderick and Cook, 2008). Furthermore, it has been 
demonstrated that the flow of Ca^^ released through inositol-1,4,5-triphosphate 
receptor (IP3R) of ER can cause mitochondrial permeability transition and further 
activate the apoptotic cascade (Hanson et al., 2004). Interestingly, our results show 
that the intracellular Ca^ "^  level in Sophoraflavanone G-treated HL-60 cells is higher 
in the 24 hour treatment than in the 48 hour treatment, which may indicate that Ca^ "^  
release into cytosol is an early event during apoptosis induced by Sophoraflavanone 
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G. However, more extensive studies, such as monitoring the intracellular Ca^^ level at 
different time points and investigating the activities of InsPs receptor, should be 
carried out so as to elucidate the possible role of Ca^ "^  in the apoptotic process 
induced by Sophoraflavanone G. 
Apart from induction of apoptosis as a strategy of leukemia therapy, 
differentiation therapy has become another novel and targeted approach to leukemia 
treatment (Leung et al., 2005). Normally, hematopoietic stem cells (HSC) are 
programmed to differentiate into restricted cell lineage pathways of blood cell 
development through regulation of certain external growth factors that keep 
balancing cell growth, differentiation and apoptosis in the bone marrow (Tsifsoglou 
et al., 2003). In leukemia cells, early hematopoietic progenitors fail to differentiate, 
leading to an accumulation of immature blast cells in the bone marrow and in 
peripheral blood (Tsifsoglou et al., 2003; Leung et al, 2005). With the treatment of 
different biological or chemical inducing agents, differentiation therapy induces 
terminal differentiation of neoplastic cells with reduced malignancy (Leung et al., 
2005). Previous studies demonstrated that the human promyelocytic leukemia HL-60 
cell line was able to be induced to differentiate along the monocytic and granulocytic 
lineages by various inducers, such as vitamin D3 and ATRA. Therefore, in the present 
study, the HL-60 cell line was chosen as an in vitro model for examining the 
differentiation-inducing effect of Sophoraflavanone G. 
Our preliminary results indicate that Sophoraflavanone G is unable to trigger 
terminal differentiation of HL-60 cells under the prescribed experimental conditions, 
as judged by morphological analysis on cytospin preparations of Sophoraflavanone 
G-treated HL-60 cells and functional assessment of differentiation by the nitroblue 
tetrazolium (NBT) reduction assay. Morphological studies showed that 
-146 -
Chapter 4 Apoptosis- and Differentiation-inducing Effects 
Sophoraflavanone G did not increase the vacuolation and ratio of cytoplasm to 
nucleus in the HL-60 cells even after 72 hours of treatment. This morphological 
finding suggests that the treated leukemia cells fail to differentiate into the more 
mature monocytic or granulocytic lineage cells. In addition, when HL-60 cells 
undergo mature differentiation along the granulocytic or monocytic linages, the 
conversion of oxygen to superoxide anions will markedly increase upon exposure to 
phorbol myristate acetate (PMA), owing to induction of respiratory burst activity 
(Collins, 1987)，and the production of superoxide anions can be monitored by 
Nitroblue tetrazolium (NBT). In our study, it was observed that, Sophoraflavanone G 
failed to enhance the NBT-reducing activity of HL-60 cells under the prescribed 
experimental conditions. It has been reported that with lower concentrations and 
longer treatment periods, some members of the flavonoids family, such as genistein, 
quercetin，and apigenin, can trigger differentiation in HL-60 cells (Takahashi et al., 
1998; Kawaii et al, 1999). Therefore, further studies of the possible 
differentiation-inducing effect of Sophoraflavanone G should be performed by using 
lower concentrations of the compound and longer incubation periods so as to clarify 
whether Sophoraflavanone G can trigger leukemic cell differentiation. 
In conclusion, our results in Chapter Four suggest that Sophoraflavanone G can 
trigger apoptosis mainly through the intrinsic pathway in the human promyelocytic 
leukemia HL-60 cells. Ca^^ and ROS may also act as an apoptotic initiator and/or 
mediator in the Sophoraflavanone G-induced apoptosis in the HL-60 cells. On the 
other hand, induction of myeloid leukemic cell differentiation is unlikely to be 






Chapter 5 Conclusions and Future Perspectives 
Sophoraflavanone G, also known as 5,7,2',4'-tetrahydroxy-8-lavandulyl-
flavanone, was firstly reported by Shirataki and his colleagues in 1988. This 
compound belongs to the lavandulylflavonoids family which is found to be enriched 
in Sophorae Radix {Kushen). In nature, members of this family mainly function as 
phytoalexins which protect the host plants from attack by parasites such as insect 
pests, fungi, bacteria and nematodes (Rao, 1990). Laboratory studies have provided 
growing evidence that certain members of this lavandulylflavonoids family exert 
pleiotropic bioactivities including anti-inflammatory, antioxidant, anti-tumor and 
tyrosinase-inhibitory activities (Ko et al., 2000; Chi et al, 2001; Son et al, 2003; 
Jung et al, 2008). Among all these bioactivities, the anti-tumor activities have 
received much attention. Previous studies on bioassay-guided isolation of bioactive 
compounds from Kushen against human hepatocellular carcinoma showed that 
Sophoraflavanone G exhibited the most potent anti-proliferative effect on human 
hepatoma HepG2 cells with the highest yield among the six bioactive flavonoid 
compounds purified from Kushen (Tsang, 2006). Apart from human hepatoma 
HepG2 cells, Sophoraflavanone G was also reported to have potent in vitro 
growth-inhibitory effects on a variety of human tumor cell lines such as human skin 
melanoma SK-MEL-2 cells, human colorectal carcinoma HCT-15 cells, human lung 
carcinoma A549 cells, human ovarian cancer SK-OV-3 cells, and human acute 
leukemia HL-60 cells (Ryu et al, 1997; Ko et al, 2000). Nevertheless, the 
modulatory effects of Sophoraflavanone G on human myeloid leukemia cells and its 
possible anti-leukemic mechanisms are still unclear. 
Sophoraflavanone G was successfully purified from Sophora flavescens by our 
previous labmate Ms. Tsang Kit Man (Tsang, 2006). In the beginning of this study, 
further characterization of this purified compound was carried out by Mass 
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Spectrometry (MS), Nuclear Magnetic Resonance (^H-NMR and ^^C-NMR) and 
High Performance Liquid Chromatography (HPLC). By direct comparison of our 
spectral data (MS, ^H-NMR, and ^^C-NMR) with the published values (Shirataki et 
al, 1988), the isolated compound, with an estimated purity of 93% as measured by 
HPLC, was identified as Sophoraflavanone G, i.e. 5,7,2',4'-tetrahydroxy-8-1 avanduly 1 
-flavanone (chemical formula: C25H28O6). The modulatory effects of 
Sophoraflavanone G on human myeloid leukemia cells and the possible underlying 
anti-leukemic mechanisms were the major focus of the present study. 
As shown in Chapter Three, Sophoraflavanone G could inhibit the proliferation 
of human acute promyelocytic leukemia HL-60 cells in a dose- and time-dependent 
manner. The observed growth-inhibitory effect of Sophoraflavanone G was not 
tumor cell line specific, as similar anti-proliferative effect of Sophoraflavanone G 
was also demonstrated in other human myeloid leukemia cell lines, including EoL-1, 
K-562 and NB-4. On the other hand, our results also indicated that Sophoraflavanone 
G exhibited minimal, if any, in vitro cytotoxicity on human peripheral leukocytes and 
murine bone marrow cells at its growth-inhibitory concentrations for the leukemia 
HL-60 cells. Moreover, the observed anti-proliferative activity of Sophoraflavanone 
G was most likely to be caused by its cytostatic rather than direct cytotoxic effect on 
HL-60 cells as suggested by the trypan blue exclusion assay. 
In order to elucidate the mechanisms by which Sophoraflavanone G could 
inhibit the in vitro proliferation of HL-60 cells, the effects of Sophoraflavanone G on 
the cell cycle progression, the induction of apoptosis and differentiation in the HL-60 
cells were investigated. Our findings revealed that Sophoraflavanone G could arrest 
the cell cycle progression at the GQ/GI phase. Cell cycle is tightly regulated by a 
network of cell cycle regulatory protein complexes, which include cyclins and 
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cydin-dependent kinases (CDK). The main cyclin/CDK complexes responsible for 
Gi/S checkpoint are cyclin A/CDK-1 or -2，cyclin D/CDK-4 or -6, and cyclin 
E/CDK-2 (Quereda et al, 2007). Using the technique of Western blotting analysis, 
Sophoraflavanone G was found to decrease the expression level of CDK-6, which 
may affect the assembly of the cyclin D/CDk-6 complex and thus results in the Gi 
arrest. Furthermore, the activities of CDK are also regulated by various 
cyclin-dependent kinase inhibitors (CKI), which are grouped into two families: the 
INK4 inhibitors (pl5腿朴，pis�脳a, pigiNMc ^ ^ pi9腿4d) ^ ^ the Cip/Kip 
inhibitors and pST^^ '^ )^ (Quereda et al.’ 2007). Therefore, more 
detailed molecular studies on other cyclin/CDK complexes and their corresponding 
CDK inhibitors should be carried out so as to provide deeper insights on the 
underlying mechanisms of cell cycle arrest induced by Sophoraflavanone G. 
Since Sophoraflavanone G has shown to exhibit anti-proliferative effect and 
modulate the cell cycle profile in the HL-60 cells in vitro, therefore, the suppressive 
effect of Sophoraflavanone G on the tumorigenicity of the HL-60 cells in BALB/c 
nude mice was also examined. The results show that pretreatment of HL-60 cells 
with Sophoraflavanone G in vitro could significantly inhibit the in vivo growth of 
leukemia cells in nude mice. Nonetheless, more studies should be performed to 
evaluate the in vivo potency of Sophoraflavanone G on prevention of tumor 
formation and/or inhibition of established tumor growth in leukemia-bearing mice. 
Moreover, development of multidrug resistance (MDR) remains to be a major 
problem encountered in the chemotherapeutic therapy against cancer (Stavrovskaya, 
2000; Ullah, 2008). The applications of natural products as potential anti-MDR 
molecules have received growing attention since many of these are expected to have 
fewer side effects and may possibly represent a new generation of MDR modulators 
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(Ullah, 2008). In order to mimic the situation of MDR in vitro, the anti-leukemic 
effect of Sophoraflavanone G on HL-60/MX2 cells, a well-characterized multidrug 
resistant leukemia cell model (Harker et al., 1991)，was also investigated in Chapter 
Three. Interestingly, Sophoraflavanone G was found to inhibit the growth of the 
HL-60/MX2 cells in a dose- and time-dependent manner, as well as triggering cell 
cycle arrest at the GQ/GI phase, which are similar to its parental cell line HL-60 cells. 
In addition, since the resistance of HL-60/MX2 cells is caused by reduced expression 
of DNA topoisomerase II (3 isoform (Harker et al, 1991)，the susceptibility of 
HL-60/MX2 to Sophoraflavanone G suggests that topoisomerase II may not be the 
cellular target for the action of Sophoraflavanone G. However, whether 
Sophoraflavanone G could be a potential MDR modulator still requires further 
studies and pinpointing the cellular target of Sophoraflavanone G in the HL-60/MX2 
cells is an intriguing aspect that is worthy of further investigation. 
The induction of cell cycle arrest could be one of the possible mechanisms 
responsible for the observed anti-proliferative activity of Sophoraflavanone G on 
human myeloid leukemia cells. Apart from proliferating independently of growth 
signals, tumor cells are also characterized as being capable of avoiding apoptosis 
which leads to cancer cell death. Consequently, induction of apoptosis in tumor cells 
has become an attractive strategy and further leads to the recent success stories in 
cancer therapy (Roderick and Cook, 2008). In this regard, a series of bioassays which 
measure different aspects of apoptosis were carried out to investigate the 
apoptosis-inducing activity of Sophoraflavanone G and the possible underlying 
action mechanisms. Our results clearly demonstrated that Sophoraflavanone G was 
able to induce apoptosis in the HL-60 cells mainly through mitochondria-mediated 
death pathway (i.e. intrinsic pathway) in a dose-response maimer, as evidenced by (1) 
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induction of DNA fragmentation; (2) phosphatidylserine (PS) externalization; (3) 
activation of caspase-9; (4) mitochondrial membrane depolarization; and (5) 
induction of imbalance in the expression of Bcl-2 family members between the 
anti-apoptotic and pro-apoptotic proteins. 
Based on the results so far obtained, a hypothetical model can be proposed to 
illustrate how Sophoraflavanone G may exert its apoptotic activity on the HL-60 
cells. As shown in Figure 5.1, Sophoraflavanone G can activate the apoptosis 
intrinsic pathway by up-regulating the pro-apoptotic Bcl-2 family members Bax and 
Bak proteins, and down-regulating the anti-apoptotic member Bcl-2 protein. Leaning 
to the apoptosis-promoting signal, the imbalance between the pro-apoptotic and the 
anti-apoptotic Bcl-2 family of proteins further induces the formation of 
mitochondrial membrane permeability transition pore (FTP). The formation of PTP 
leads to the mitochondrial membrane depolarization which triggers the release of 
cytochrome c from the mitochondrial intermembrane space into the cytoplasm. 
Nevertheless, whether Sophoraflavanone G can induce the release of cytochrome c 
awaits further investigation. Cytochrome c binds to an adaptor protein Apaf-1 and 
this complex further recruits procaspase-9 to form an apoptosome. The formation of 
apoptosome triggers autocatalytic activation of procaspase-9 to caspase-9 and then 
further activates the downstream "executioner" caspase-3. Subsequently, activated 
caspase-3 signals the downstream apoptotic pathways by cleaving a number of 
critical proteins and ultimately leads to the final stages of cell death. Moreover, Ca^ "^  
may also play a role as an apoptotic initiator and/or mediator in the 
Sophoraflavanone G-induced apoptosis. On the other hand, high concentration of 
Sophoraflavanone G can activate the extrinsic pathway "initiator" caspase-8 and 
enhance the level of intracellular ROS. However, the effect of Sophoraflavanone G 
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on upstream signaling molecules of caspase-8, such as the death receptor Fas and 
adaptor molecule FADD，should be investigated so as to delineate the role of 
Sophoraflavanone G in the activation of the extrinsic apoptotic pathway. 
Apart from induction of apoptosis, stimulation of differentiation has become 
another novel and targeted strategy for leukemia therapy. With the availability of a 
wide variety of differentiation-inducing agents, differentiation therapy will lead to 
the terminal differentiation of neoplastic cells resulting in reduced malignancy 
(Leung et al., 2005). Our preliminary results demonstrated that Sophoraflavanone G 
is unable to trigger terminal differentiation of HL-60 cells under the prescribed 
experimental conditions, as judged by morphological analysis on cytospin 
preparations of Sophoraflavanone G-treated HL-60 cells and functional assessment 
of differentiation by the nitroblue tetrazolium (NBT) reduction assay. Further 
confirmation of our results should be carried out by studying the expression of 
differentiation antigens on the surface of Sophoraflavanone G-treated HL-60 cells 
using immunophenotyping and flow cytometry. 
In conclusion, our results show that Sophoraflavanone G can inhibit the growth 
of human myeloid leukemia HL-60 cells in vitro, possibly through triggering cell 
cycle arrest at the GQ/GI phase and by inducing mitochondria-mediated apoptosis. 
Therefore, Sophoraflavanone G, as a naturally occurring compound, might have the 
potential to be exploited as a therapeutic agent against certain forms of human 
leukemia. However, it is a long way to go and many problems need to be solved in 
the therapeutic development of Sophoraflavanone G as an effective anti-leukemic 
agent. It is obvious that more in-depth investigations are required to reveal the 
molecular mechanisms and signaling pathways by which Sophoraflavanone G can 
modulate the proliferation and apoptosis of human myeloid leukemia cells. 
-153 -
Chapter 5 Conclusions and Future Perspectives 
Additionally, more in vivo evidences should be provided on the safety and efficacy of 
using Sophoraflavanone G as an anti-leukemic agent in animal models, which is 
essential before Sophoraflavanone G can be used for the clinical trials in leukemia 
therapy. 
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